var title_f13_36_13888="Contents: Thyroid disease";
var content_f13_36_13888=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/56/1934\">",
"       Endocrinology and Diabetes",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Thyroid disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Thyroid disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Congenital thyroid disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2682\">",
"           Clinical features and detection of congenital hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/6/97\">",
"           Evaluation and management of neonatal Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/47/40696\">",
"           Thyroid physiology and screening in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/46/15081\">",
"           Treatment and prognosis of congenital hypothyroidism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperthyroidism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25065\">",
"           Amiodarone and thyroid dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/17/275\">",
"           Beta blockers in the treatment of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17593\">",
"           Bone disease with hyperthyroidism and thyroid hormone therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/33/23062\">",
"           Cardiovascular effects of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/29/7641\">",
"           Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/57/26520\">",
"           Diagnosis of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4103\">",
"           Disorders that cause hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/6/97\">",
"           Evaluation and management of neonatal Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/4/4165\">",
"           Exogenous hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/36/12871\">",
"           Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42760\">",
"           Hyperthyroidism during pregnancy: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/47/14073\">",
"           Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37779\">",
"           Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/59/39864\">",
"           Iodine deficiency disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10852\">",
"           Iodine in the treatment of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/5/20568\">",
"           Iodine-induced thyroid dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28550\">",
"           Lipid abnormalities in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42453\">",
"           Lithium and the thyroid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42584\">",
"           Management of tissue wasting in patients with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/22/30057\">",
"           Neurologic manifestations of hyperthyroidism and Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/2/4137\">",
"           Nonthyroid surgery in the patient with thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/60/14279\">",
"           Overview of the clinical manifestations of hyperthyroidism in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16186\">",
"           Overview of thyroid disease in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/22/3432\">",
"           Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/30/40425\">",
"           Pathogenesis of Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/21/41303\">",
"           Pharmacology and toxicity of thionamides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/50/1828\">",
"           Pretibial myxedema in autoimmune thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/7/12410\">",
"           Radioiodine in the treatment of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23701\">",
"           Respiratory function in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13799\">",
"           Struma ovarii",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23913\">",
"           Subclinical hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/8/12424\">",
"           Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/25/12696\">",
"           Thionamides in the treatment of Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/18/18726\">",
"           Thyroid disorders and connective tissue disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33655\">",
"           Thyroid storm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/20/327\">",
"           Thyrotropin (TSH)-secreting pituitary adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21143\">",
"           Treatment of Graves' hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/26/35239\">",
"           Treatment of Graves' orbitopathy (ophthalmopathy)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/30/41448\">",
"           Treatment of toxic adenoma and toxic multinodular goiter",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypothyroidism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21865\">",
"           Acquired hypothyroidism in childhood and adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25065\">",
"           Amiodarone and thyroid dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/62/3046\">",
"           Cardiovascular effects of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/6/18536\">",
"           Central hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2682\">",
"           Clinical features and detection of congenital hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14503\">",
"           Clinical manifestations of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/7/26744\">",
"           Diagnosis of and screening for hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/47/42744\">",
"           Disorders that cause hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29093\">",
"           Hypothyroid myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/47/14073\">",
"           Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/59/39864\">",
"           Iodine deficiency disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28550\">",
"           Lipid abnormalities in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42453\">",
"           Lithium and the thyroid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/23/8566\">",
"           Myxedema coma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/46/36585\">",
"           Neurologic manifestations of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/2/4137\">",
"           Nonthyroid surgery in the patient with thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16186\">",
"           Overview of thyroid disease in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/11/27833\">",
"           Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/8/16518\">",
"           Resistance to thyrotropin and thyrotropin-releasing hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23701\">",
"           Respiratory function in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/48/3850\">",
"           Subclinical hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/18/18726\">",
"           Thyroid disorders and connective tissue disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/46/15081\">",
"           Treatment and prognosis of congenital hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/53/43865\">",
"           Treatment of hypothyroidism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23721\">",
"           Anaplastic thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8872\">",
"           Approach to therapy in multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24452\">",
"           Atlas of thyroid cytopathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/33/41495\">",
"           Classification and genetics of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22794\">",
"           Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/16/14599\">",
"           Clinicopathologic staging of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/45/24280\">",
"           Congenital and acquired goiter in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/17/39191\">",
"           External beam radiotherapy in the treatment of thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/21/9560\">",
"           Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/23/38263\">",
"           Medullary thyroid cancer: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/20/43337\">",
"           Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/11/21688\">",
"           Overview of follicular thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/15/8440\">",
"           Overview of papillary thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/62/21482\">",
"           Overview of the clinical utility of ultrasonography in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/17/44313\">",
"           Overview of the management of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/49/1818\">",
"           Radiation-induced thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34010\">",
"           Radioiodine treatment of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23701\">",
"           Respiratory function in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/39/37496\">",
"           Serum thyroglobulin in the management of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/6/41064\">",
"           Surgical treatment of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/24/2437\">",
"           Technical aspects of thyroid ultrasound",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/25/28056\">",
"           Thyroid biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35974\">",
"           Thyroid lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/4/31814\">",
"           Ultrasound-guided thyroid biopsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid hormones and physiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/40/42632\">",
"           Drug interactions with thyroid hormones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43829\">",
"           Endocrine dysfunction in the nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/856\">",
"           Euthyroid hyperthyroxinemia and hypothyroxinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/5/20568\">",
"           Iodine-induced thyroid dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/33/3608\">",
"           Laboratory assessment of thyroid function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/8/16518\">",
"           Resistance to thyrotropin and thyrotropin-releasing hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23701\">",
"           Respiratory function in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/25/2453\">",
"           Thyroid function in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44663\">",
"           Thyroid function in nonthyroidal illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10200\">",
"           Thyroid hormone action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33320\">",
"           Thyroid hormone synthesis and physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/47/40696\">",
"           Thyroid physiology and screening in preterm infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid nodules or goiter",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24452\">",
"           Atlas of thyroid cytopathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/2/46\">",
"           Clinical manifestations and evaluation of obstructive or substernal goiter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/45/24280\">",
"           Congenital and acquired goiter in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/15/37111\">",
"           Cystic thyroid nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/27/32185\">",
"           Diagnostic approach to and treatment of goiter in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28506\">",
"           Diagnostic approach to and treatment of thyroid nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/47/14073\">",
"           Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/15/43257\">",
"           Infiltrative thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42453\">",
"           Lithium and the thyroid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/20/43337\">",
"           Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/62/21482\">",
"           Overview of the clinical utility of ultrasonography in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16186\">",
"           Overview of thyroid disease in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/60/1990\">",
"           Overview of thyroid nodule formation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23701\">",
"           Respiratory function in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/24/2437\">",
"           Technical aspects of thyroid ultrasound",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/16/25864\">",
"           Thyroglossal duct cysts and ectopic thyroid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/25/28056\">",
"           Thyroid biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/0/22535\">",
"           Thyroid hormone suppressive therapy for thyroid nodules and benign goiter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32742\">",
"           Treatment of obstructive or substernal goiter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/4/31814\">",
"           Ultrasound-guided thyroid biopsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroiditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/47/33527\">",
"           Hashimoto's encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/15/43257\">",
"           Infiltrative thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43830\">",
"           Overview of thyroiditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/7/24694\">",
"           Painless thyroiditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/11/27833\">",
"           Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/248\">",
"           Postpartum thyroiditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/23/1399\">",
"           Subacute thyroiditis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-FF643247C3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f13_36_13888=[""].join("\n");
var outline_f13_36_13888=null;
var title_f13_36_13889="Annular elastolytic giant cell granuloma - arm";
var content_f13_36_13889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Annular elastolytic giant cell granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAUUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC5bR8DvV6NPao7ZMCrqLXio9EYq+n51Kqk8CnqnQ9hUqKAM0xjAnFOC561KFpwXuOaQEIUg0Yx7VNt9abjFAERGRx+lAHWnsPTFN9aYhR6dKXNNUjrQWwDmhjQpOBWXqbgg4/OrU0wXPT8TWDqd7wQnU1hVmkrGsI3ZlX12iB9xCkcn6VxureILXSZ986far4jdHbA/cB6Fz2+nWrGtS6nqMjWfhu3kurnP76ZMeXD7Fz8uf5VBpvwtuJzv1fVliJ+Zo7VN7575c9azoQpx/eVnbyLnKb92mvmcRrPiDVtVYi7u3ji7QQkogH9fxrGKr6j869zsvhv4YgGJbe4unPVp5yf0GKvJ4C8LABf7Fg/F3z/ADrsWY0YaRTt6HO8FUlrJ/mfPpX6GkI9uvavdrv4Y+GJ1xHBdWrEcNFMf5HNcvq/wmuogW0fU4px2iuV2E+24cfyrWGY0JdbepnPA1VtqeX9j7Vb0rVdQ0m487TL24tZPWJ8A/UdD+VWNZ0XU9Fl2avYTW3o5GUb6MOKz9oxlDke1dqcZq61RyuLg7PRnpfhz4qyxgQ+JLQ3C9rm1AVvxTofqCK9S0XVNO16yNzpF0lzEpw23gofRgeRXy/gd+tWdM1C90q9S80y6ltblfuyRnBx6EdCPY1xVsBTnrDR/gdFLFzhpLVH1GYRkY/lVe6tQycLk4wRjqK4/wACfEm11gx2GtiKz1E4WOXOIZj9T9xvbp6V6IyArjOO3AryZ0p0XaR6dOrGorxMCdRBHNI6bkIB9Snqw/QY9KryR+aFVSrKw6jofofStq7j+XOORzWDhba4EMjhIJCTGx6Ie6E9h3FVCTBq2xztzCYrvy+g7Z/lSrlGwcZz1HetLV7TzEZ1H7xcnNZMMm6MkDnHT3rpTLTJmCnPAz29KjCuHIPQ9Ae1Jv4DKMkfpUpOQCx3D0qwZCqkKRySOpqs+1VzjO0kcVdumVEORj3rE1PUY7C2dzh5tpMafh1PtVJNvQiclFczZl6pOkF2wdtueSB1rp9L8PXsqI95JHBAwDBUO52H8hXnitJcyRNKxaSRl3H1JNe6Mu2NU9FA/SlXXs7WOOnXdRvsZphSGIRxLtUdBVObrWjP05qhL1rhk+pvHYrlfSmFcipyOaaRgVJRXKc0U8ryaKLjPRIFOBmraL7cVHAvHSriL9Pxr0DjGqn86lVcc9Kcq8VIE45FAyMJkg4/E07bxUm31FKBgUAQ4prCpSvNMOOvegCBqjJNPcjFV3YA80xMdnueKilk2rn09aa0mBmsjVb3ZuQHHrUTlyq5UVd2K+o3peQImTk4AHU0yDTQ4Jux5hbjYTwPr60tnCsYMkoPnsP++R6D3pbi43EQqcZ6gVwNuTO+ELFlWSJVghVVjTgLGMKv4DinwoXyAx3deOKggCtGVVQ2BzmrUcbtgFgoHXA/rUSaRsrIXaY0yr/L3yetPgYcttYk9iaVLWJgerkd2qwiYjKhEOemBgAfWs5SHdDRzHuPyr700jr86jnGRU52Iv7w8Z7VIsJIU+WAPTFZtgUZoFmiaGZEmicfNFIoZT9RXB+Ifhfpd+Xk0kvpV11wMvC34dR+H5V6gluQTkcjn8KURbk7E469cfWtKOIqUXeDsZ1KcaitJXPlzxJ4a1bw5IF1W2KwscJcx/NE/wCPY+xxWO6+gwPrX1pc2MU1vJDcRpNBKuJIpF3K49xXhnxJ8BN4e3apoyvJoxOZYidzWhP80PY9uh9a9vCY9VXyT0Z5eIwfIuaGx50V+XBxj07GvUfhz8Sm09Y9L8TSvJY8LDet8zQYGArdyvv1HuK8zIBGV6etMI68V3VKcaseWRxQnKnK8T63lQMqg4KsNysO4PIP0rDvraKeF42G5ScfQ15b8L/iAdFkh0jXJC+lMdsMzcm2Yn+I90/lXtFzBls/Lk8hhyGHbnv9a8SrRlQlZ/I9ejVVZXW5zEYdM2twBvXhHx98f41z+r2z27yTQKzD+OPufce9dvNbRzRskyn+RB9qyry32R4uA0kadLhBlgPRx3A9RzRGdvQ1Rw41OE4dHBUj8vwqCXVwq4jUk9uwrR1zw88aG4s1DoxLDYchh7VzEg25BzuHBr0KMITVzgxFerB2WxJeapdT8FwB6LWLfMTBMxJLFeSauSGqN/zbkdyQP1roUVHY4ZVJT+J3LOjxCXWLCLH3pkH617dPXj3hCPzfFWnLjpJu/IV7BOe9cGMfvI6sNsyhOOtUnHzVcnPWqjck1wSZ3RIyOwphHBqXFJjNSUQFcmipCOaKdgsek26jHTiraL+lRQLgDNWkHNeizjYKntUqrQB/9anUhDCtIfepD9Kaw/OkxkT96hcZ4qZ6ryHGRQmVYrysB6ZqjPKKluZNueaxb256jIxVXE0SXl6saMwI49axbdjcSmZ+VB+XPr61Svrh7i6S2ibBPXHatMIsccapnao4rjrTvoddCFldlgs28Y/P0qCGAnDcp/WpiOuQPxqRc8EkHAyawvY6EyWMKi9VAHUdqtrJvVRxjvVYEbQMbiTzU0SksSeAehx0pWC5YBUFSG5PcjpT4LiJ3kSNSSvUtwuarrw7HewLcZ/oKsorCLbCF356kZA+tQ4D5i9CBJHuUqVPpzViJCSWGMepP8qgjfy8A4zjPyjircTqI13DPqDWTjYV2PQENsO3jnPXb9aUKqlmVcMw64+9+FPfEhZmORxSZO9cLhQeDQoDuQvlmICgAfpVK5jAV1aJJUZSjIwyHUjkEHqDWk6EMcZI69aruoKkheD2qkmiT53+JfgdvDc39paUrSaJO2CvU2zn+Fv9n0P4GuFIBwRyD+NfWF5aqTNHLEk1ncRlJI3GQ4PUEe9eB/EbwRP4VuvtVmHm0Sd8Ruckwsf4G/oe/wBa97BYv2i5J7/mebi8Ly/vKexxePbj0NenfC3x4LBYND16Y/YSwW1upG4tv+mbf7BPQ9vpXmWehByD0IHWkYA544798121acaseWRxQm6cuaJ9WXKBs/KVYHHIqm8AYbWyu054OOa4D4TeM/tiReH9YlP2lRiyuJGz5gHSIk9x/D69PSvSZIwD83Bz2rwqlOVGfLI9qlUjVjzRMu4tvKLGJANx+eMnCt/gfcVwvjXSUgjj1G1H7qU7ZB/db39D2NelHBBBweOmKwtesftFheW//LK4Xnj7jjpJ9OMEfjWtGo4STRNalzwcTx+UkmqV7ysY9ZBWjewyW07wzrtkQ4PcfUeorMuj+9gH+0T+lesnfVHi8rTszpfh9Hv8VwkD7kbt+lepTnmvNvhkm7XblyPuQfzNejTH3ry8W/fO3Dr3SlOeDVX1qeY81ABk1xPc7FsIKDS4pMY4pDExRRge9FMD1CBeB6VZAzUUI6GrA/SvSZxi4GKXHSjFAoAQjrTSOKcaY5qGMifv7VSunCjmrMz7Rxisq9lAB5ovYtGZqM55wa5vULry0ZyRgDNaWoynnnPqa5PWpHlaO3jPzzOFFZudtTRQuXvDkZkSW9kPLkqh9u/+FbgwAW5yOtQ28SW8EUKf6uNdowOtWVGByRzXK9TrSsrC7jwQRkjp0p6kbgSflz696jHzPwevA/8ArVKFBA44zjOM0JAKSw9Sxzk+lWEl2EKA2W6c9BVNGDOrDIO7AGOtWYw+4c4B5xinyhcugFuTyg4x61ICq52knHXb2qFAoGMlmB7Gpozt2Bjglug5otcVyzAxySB8w756ir0bHaCGG3r65qmg7AfKTj3NTtGMqVPPp6U/Zici2CQwMbKAecUM5VMyEJg1GrBc7m+b3qO8kSNS74bP8NL2Qk9bC3JLrI3mCM4yMHOaZp9yk0Q5w6nHHP8AkVTijkuZCXJEfQAjoKnaxECblOx+o96PY3Rs5Rtys0JI8hgx4YdegqnPaW17ZTafqMST206lCj9HB/r6Gp4rkXMb4bEgHzKRxmmoyzny2BWRMMB/hWdnF3M9dmfMvxA8J3Hg/WzA26TTp8tbTt3HdT/tDv8AnXNAZ6dPavq7xDoVn4n0W50m/IwwzHLjJRx0ZfcV8wa7pF3oGr3Gl6mm24gbGezA9CPYjkV7uExHtY2lujycXh/ZyvHZlAEoysjFGByrA4ZSDwR6Gvffhr4uXxLpptb+Rf7atV/eBjzcJ/z0A/Q/nXgfUcdO4qzpWoXek6hBfafM0F3C25HB/MH1BHBFaYigq0bPfoY0Kzoy5j6ZIdX2tgqeUb09qil5bI/Oo/CuvWfinRI7+yURyAhbm3B5gkx936HqD3FWpoiM9CteHrCVpbnuJqorrY8+8faG0kJvrSFcx/fWNcHb9B6dc/WvNpQXuoFXliDgetfQODvYAbh0I9vevMPE3httL1eC8tk36ezEjjmM46f4V30K6S5WcGJw7b54kvwujxcalIRyoRP1NdxMeTXJfDaEx2mouRjfMBn14rqZTnPpXNiXebCirRRVlOaj6U9zyaZjiuU6UIaDS44pKAE+lFBGaKAPVoBU2KZEOOtSjnjp616ZxgOlHajGKQ8D2oAaSBUMh4PrUrdKgk47fjSGtytcHCk5HSsTUJMA+ta105ANc5qUnJ5+tZTkbQRjX75J6CsbSo/tOtyS4yluuB/vGrl9IUDZPQE5NP8ADUGyzErKd0hLH+lc0mdcY6XNYKcc4zTnXg5PvipNmMHIPtQQT15qChqJuORw38qkSPGQensetLApXj5j9acWbaTjdg4HbNUiWxoG+QgqVIPUdanQbSAxbJGeBmmwkhfuED61ZhQuflJ2k81SQm7E2AiFl2kjt0zSCe3WVIw/73PApXiB2qwULnOetQx6bFDN5gY/MPTr9DWsYhHl6mjA/mAbcr/d7fjV1CCuSce/rWXbXscYCHcT04XqavxyKJERg+09COlWkZyTJyB5i/xY6grUF/ieJDuUNz19Kt+Yqx5Y7e3TilaJSu4gErgcU7ERlZ3M+BwhUSIVIHGe49a0If3wxw4zyc8VFfwmSMiNcMBn2pibrKNGCnafvDPOfWg0clJX6kNzAbe5iuFGCGw4B7VLKhZ1njHIfB9xUzyCZChUEEdR3qpZs8LmIn5M4H1FZzh1Hd2L32dSAygjLBjtOPrXD/GbwW/iPRjqNhEDqlgpIK9ZoupX6jqK9Ft8FAMDB7VYQqHO3r3BqYTdOSkuhnNc65ZHxKuWGQDuHBzRjKmvTfjh4K/4R/VxrenJ/wASy+c+YqjiGU8kfQ9R715mPUYINe7TqKpFSR49SDpy5Wb3gbxPP4W1pbuIGW2kHl3MGSBInr/vL1B/xr6NtprTULKC90+ZLizuE8yKQDG5fXHY+1fKZBPzc16T8HfF39laiuh6jKBpl4/7qR24t5T29lY4z74NceNw/OvaR3R1YTEezlyy2Z63NEYmyThG6mqlxDFKkkE6hoJV2kdP/wBVbstuSHQqeDg7qoXVnvQ7Tg4zXjxnc9hnIaNpraNFJZsdyeYWVz3HarDsSzDuK2PszXCGJlwy/dJ7H0+lZU4Klo2XawHRu3/1quTcndnNKnyvQqt1PNN7Uc854pO1Z3AKQ0tIaQxO5ooopAetxjjpUgx2pi8ccZp/X2r1ThQZ7Gmt+lKfamsetAyNjzwahkI5qU/jUE3Q5NIqJmXzYByRXNag+Sa3dRfhgDXNXrkk4Fc82dFNGHqvzx+WvLSMFH4muhtIgkaqv3VAH5VhRAzanAh+6mXI/QVvxBzHJswD0UnoTXOzq2iWAoAzkk9aQcbc4pwT5FTJ45Yj+VD4IJ4GegoSJFGNzZ68ZpsgdFOxQT2z60/C8DuaVFO4cZA5GasQW4ZUUuMuVyR2Bq4hO1QFOSc49KhjXa5yT0yRmpgGUj5iCeh7CrRLZchBY5xgD17VIgXhSB9KYqhFQ8Z6H1NTzMEXJBOOy1qkTciRoTIQChlHPNRXc8qAqpGRzkfWmXMQ3tJHlVZBn0zTY7Z3TG/LAY5rWMXuWklqy1pl8XDrOp3ds8H2rTjnzITg9BnnrWBLBLE3Xk5w3rir2nGXepAUKQF49cdfehoU4J6o2HbKbieOpBrO1GQpDlgTGT823qKlfUNkwilXOeCRTrxQISwUyoQMqO9SZRTi1cyrSZlR2Vt6ddoPb1FWbJ5HlVGQFHOSR2NTppca4dTgbcHHXJqWwie3d/MGRuGCPf1qZGkqiexoQrg46jH41OR3A4xxTFUg8cAnmlZS0u5GITHQfzrBozTK2s6Taa3o93pmoIGt7lChHcHsw9wea+RPE+h3XhnX7vSNQH72FvkfoHU/dYexH9a+yRz37V5p8cPCJ8QeHV1OyTOp6aCRtHMkXUr7kdR+NdGDreznyvZmOIpe0jdbo+buvbNNIByM8U9WDoGBPofrTeD16j0r2Tyz6H+Dvi8+ItJOmahMW1exTl5GG65jzww9So4b8D6129xbuc4AD18m6Pql3ourWepaa4S7tZBJGzDIPqD6gjINfWPhrV7TxPoNpq9hlIbheUJ+aJxwyH3B/MYNeFjsN7KXtI7P8z1sHiOdckt0Z0sYMiSBSp6Nnt71R1ewN2AsXEwBIPr7V0t1DhGbBIPeqLN5QVyASM7W7Y71xxkdsldHCsNqAcYHTHao/etPVIStw7RReZFI24BTja3pWZzzuBXHYjofSm0YgRSUuST70hpAJiijrRRYD11BgcUuec8UYoJ+n416hwjTz7UxjjnrTieDTCeOaBjWNVrk4U54qdj3qleNhaTKiYeovya567bJOa1tQkyWOawrtuSc1zPVnVDYraXl9RuHA+6Nua6SBAFQenU+tc/4c/eCZz/ExP61uxMzTlV/1adfr6VlY6G+haY4TH8uaawyuAM+hp3I7jk9M04KFGTkHPXsaEiGMxlgSMEClRDhuDzTiDvJZuCeB60+MfN1AzwfrVIAxtKlhnjAqeM4Cqy5ycg+n1ppXKEtwo7mnQHYgOSST1P9K0S7mbZeDrhAW6c5x/nmpUEzuwH3Ooz1NVLe4jnO1TuKHn2rVQgwjy+SeenStkkS247ox7i3lUO7jcehweM5/wAKvWX+pRtvQY9eaS5jcQscjuTiobSUlQhI3d+MDNaRsaX5olqZgyosmGGODWcJnhmUAMCTgAflVmZCsbBwADyR3qG0QyKViClgfmLduKbHFJK5qNBFLEsyoC3UAnFWnKom5+EUZ+lZ17Iwt1AlWSNhtYp2HrWgkKPaeXnchUDJ+nWs2jCWlrgs8LlcOG3fdA7mpUQq7OSfm/Ss7TtPaNv3+Mo25MVsouGIc/Q1EkJ2T90kjBEY5/8ArUr4IC4wcjr6UA/LnacE0pDMeDis+W4riE4AAJahVG8bxkEdDz+FOXBzxinmP5Rgkdz3zUyiVFnyx8YvCQ8K+LHktEK6XqIM8PYIc/Mn4E/kRXDEY4Oa+svir4YXxZ4QuLONA17ADcWjd/MUcr9GGR+VfJSEkAMMMpwQeMEV62Eq+0hZ7o8/FU+SV1swPXIr0P4LeLx4a8RNYX0m3SdSZUkJGfLm6I/sOcH2Oe1eedM9cmmkAjByAfzrepTVSLhLZmEJODUkfbckWAyMORkEH1rm7iDZKyknAfKnOPwrM+DHiw+J/CMcF24Op6dttrjJyzrj5JD9RwT6j3rfnhE0sobkFsEdq+aq05UpOL6Hu0J+0V0c3qOEEgRVIfODng+/1FYE4YAkjYo7DlR9K6nV9M+020ypkTxHcVzyfcVzF+qxpHIzht37uT+lNaoJxsytxjgmkbtSnjp0pOtQSFFJ3op3GevAYFBP/wCqjJ9/pSMa9U4BrE80w96c+c+lMbrQCGMcZJrK1CTg81pzH5SawdUfhuamWiNIbmFevknmsLUZNsbEdv0rWuWyxOa5/VZMKecCsYRvI3vZF/wic6cjHnP+JrcjU7nPfOcVzvgyQtpxA/hZl49jXRwNuGW/HFZSVmzbmuWEGSAxGP5mpztZMHGAQCaYmVPy4OfamzWryPEN2EVssPekg9Qnm8oZ4J7VnKWvbwne4AOFHTA9frV+6fylyq+vJ6VSsIx5jM3GQCSPfnitaaRpDRNmiI2hiEe9nUCiW8jiKK4zkdR0pRIdm1W4Hf1qlOfMBjiUuc5HFbNGcVzPU27BI0UyQqFEnJPXNacY2nYCGY8fhXPW0j2dqvm/MI8sRnoPpXQW7GRFZRww3fMOaaVtDKorO5JNKka8DPYBu9VWt5UuUkDYjbll649h6VIxV1LNgYPJB6GoIZ5JMqxLgEjIFXEI7GlJAs0Yyo6fjUE1iPKyhCt29MU+GWRlwSfy64pl1MIVZhymapoUb3sU7mFo412/Kpx09O9W9Juy6BZWwM7UJ7+1ZdzctM6BeFJBB9KeLcpJBuc+WGBOT0NQ1fY1cbq0jpUyXHA46e1TKQFJ4NVFmC3DIzDcQCnqfWrKjcepz6GoaOQcN5zwanhByQQeKTOMnqRRC3ABPJ54pW6AkTIMkrxu9KGAHqTjIoZhtG3BNJgnBPBPPXpUtFohUFXyGIA/SvmD43+Gx4d8cS3ECBbLVAbmPAwFYn51/Bufxr6hf5SMk4z3Fed/HzQxrPgGW8hUfatKcXI/65nhx/I/hVYaXs6i7PQmvH2kGj5icZ69cUwjpz9acWDKOpzTfpk969k8k6/4U+JX8MeMba4Z2Wyux9luVXnKsflJ/wB1sGvqdYAsWBjeg6+46818TkbgQelfWXwl8Qf8JL4GsbiZk+2Wg+xXAB53IAFY+m5cH8DXlZlRvaaPQwNW14GxfKy3MbhGKOu1sDkGuO8S2hjeT5AYJP4sdD/SvQMF0ZHADpxuHpWH4hgaexdCAW/hx615a0Z6LfMjzqEgpgNuxxnrin545qpb/u7hkCkKT+Iq0WGOn405KzIEPJopCTRWeoz2Ec46005pc0meK9c88YcdqYelPY1G5xn0pgiC4bCnmuc1R+uTW/dNheK5nVGy3tWc9jaBi3LcE5rndTOSeeK3bpsgiufveST706S1NJOyJvBc+J7637q6yAexH/1q7C15344O4159oc/2bxLDk4W4jaL/AIEPmH9a9AsTuQseRuI4rLER5ZGlJ80UzQt2ViSpyp6VMuSWxg9qrwKQOMAdKsKdu3GMk96xRbKEi+bvSRtrfpVGTZFMoiIKg87atX5LXB8snzW6Y7D1qe3slSL5x82OD3NbQXU0TUFcprO7ybEUkkHAx+tOs4JklaUgtjtnrVy2sZY4SFbkAnI459Kq+ZJZ+Ys+9kOCCOorZ6gpJ3UTRtbb/SPPYbS4+6e1akEpOUGMg4OP0qlp7+ZAjMS/HXGPwq4ki4O7jHOT29qFoc87t6jbmPdvdGxjBYf/AFqfpjIV8oKQo6ZPI71l31zK90gUkWzDhgep7/8A6607RoVtx5RXgc5Oc+9XEpq0bE8rZwBtHfHtVG6naR8nBi/i+n+NRX13J5uIiShPTvzRp6XMk7FWUdj6ZobKjHlV2StYmOIyKxZiflA7fWrEcok00k8Sdx707VlmS0b5V8vq5Xjms92kjQZViWTJ9xUpiT5ldm9bBZo7eV0LSIMA59a04eSTj8Kw9Nlke4XBZYo1weOGB6GtzeegAHuaRzSVmOY4b8KjWTHXIGajkkIXnGfaq00oAAOCcetAI0Y34GaeJGYgevSsyK4G3rk/Wp4pf5UWuGxb3e2MdKS4tY9Rs7m0nCtHdQtCwx/eBH9arGbPU9+9OFz5br8xJFRKNx3PiiaBra4mtpCQ8MjRHPqDj+lRt+OOua3viBCLbx34giUYX7W7AD0Jz/WsHtXsxd0meTJWbQEnPHT0r0/9n3xEdJ8aHTJn22mrJ5WD085clD+PK/jXmA57H6Zp9tPLa3MVxauUnhdZY2HUMpyD+lTUgpxcX1HCTjJNH25IjBCTjI/lWXfgBthK9O/G4elR6NrSa5oem6tbnMN7CsrJn7rY+YfgwIouZFdQjICRyrY5r5+ULOzPbhK6ujznVIvK1e4jGdpPmLuH8J7fnVY8fd4FbHiqJU1K3kyNxUqSOhGeP51jNwSOw6VjUGKevrRTc0VFxnsR9qa3PAPFOJ+lMbpzivXPPGN3PaozTiRUZPHJpjRTvWwp6VzGpHk9Pwror5iFJNcvqDZJrKojWGxj3jdaxbrvWvdnOayLkcHFaU0aSMDV5zaLFdJw0EyOPwNenaTIJbOORMFHJIPqDXlviRd2mTdcjH867zwDcGfwnaO3OCVqcWtEwoPdHUq3HynHepIBgL1HHQ1VjY7gAMkjk1MzFQGBOfTPX8a5UjYpsTFcu2MkHr2x65qytwrbmLD5DgjNQ6oQIQ4G5uw6cVQSG5edY4o9qMATn/Gt4vQ3UYzV2dFHOMZDAK1Vb23FxGGAwi8hicVXS1ljKqJAFHIUnJqQTzhWVowwPp0/CtE1cy5LO8WNs5543VN6rhtrAjgVupsAGSHJ4yOaw7K286ZxLv8ALI57ZrbtkVRtQZUdCOaGTVsPmtIrj5GUKgGRjig2OWdjMxbgBjgfyqV2IUlCc4xipIyXwGx2zikZKTSKE2lSBoyJNx6nPBNS2FpGWEglyYzhxzxWimditwcZGPSpIwmSdoAPX60A6rtYc4DArgEEd6Y6bnCKFEQGGyP0qVgNhI78cU4e5zSMUxVVUIAA2jGAKcffvTAcLxwaBnJGaYiO5OM89KwL++/0lY14yMn6VtXj4j+oNcKtx51zLLkEO559AOKiV72NYLTU6a3lOc9u1XVnGBkgVgR3IQDPA7VajE84PVF9T1q0Jmhc6gsWOct2UdTWZe3OpG2ea2iA4yN/UD1xWlBZqnIGf9o9TVvb8hDY9OvarS1IlfofKnj+3e38TzvKzM86iUs3JYnrXPqeeteifGrTpbXVradwoUs8alf7vBGffrXnG7BPP6V6VN80UefVVpscc5bikJ5/Wgc8456/WkY8nP61Zme9fALWmn8O3mlO3zWE/mx7jwI3GcD/AIED+dejBwQ5wcbj8w7GvnP4R6z/AGT4vVW5jvIWt2Hv1X9RXuNtqjvK0bc/0NeTi6dp37nr4JOdP0MzxfKHmtQmOC/T6c1jZJHJrpbq1S/1eSEAFEiJIHXJx/hXP31s9nctDLnjlT/eHrXm1NGbohzRTD1orK7GeyEY/OmtTzUbHH0r2DzURsc1ETge1SN+tQkjPtQWZ1+2FNctftlzXS6kcKa5a9PzHrWcldmsDLuj1rMue9aNx1NZtx3rWCLexha4hbTrgf7NdN8LHDeFuRny7h14PbisDUk3W0y+qH+VaPwhlzpepQk58qdXA9iv/wBajEK8CaL949AiA3YzgdcCqt3fpbP5Srk9xU0TFtpxjPQYrJuX8m8cypuJOeOa5Kauztpxu9Tet3W5jVlwcnkNVpFBPHJbg+grF0gySSu5Pyt+WO341tQRrHnauN3UZ61ezIno7ISSxVowiswyc56mmwKgjeHHKnJLdCOtXN+eGHHbB61WuQ5ViqjYy/ezzn0xVRdiVK+jIFv42kj2wb3PCla0raaOWV1j3Bh1HasSyuFiJ3gq+cru/wAauaZI8txvXPl9M9vpWrStcucd9LG2ickEkYHBHYVNHgt8p4xjp1qAuVUk7j83IUZNTFmC7wpx3PoKg5rFjco+Ugk9zTsfOQM4FNgVdgyDxyCe5qcFTjnAPH40EMRQoJYZOetAYAFV7Gk5BYkdTgU1w2AFwcn5s9vpSuKzZEhm+1TM7KbcABEC/MG7knuDxipAx35yMZ5x1od1AOMZPGKhkfapPHI4NMdinrdyY7KYoMttIUDrmuV07S5yq+YVjXHQcmt27ffKFZSY8nJ9DVqBfkBOB2Hv70cqepeqViraWUdu/Iyx/ibk1qRBQ3P0+lNUDHHI9alUENyM1RLJVzkbec/pTyuRyKZyOlP5zwM/jTJbPK/j7pgl8MpeqvzQyKSQOg6f1r5/7YOORX1n8QbBdS8IapbkBmMBYAeoGa+Sl+4Otd2Hd42OLELVC5x2560Pw+e9N78E8Up7EV0GBYsblrO+trqJtrwyK4P0NfR2lTfao4ZvLMYiGSe756V8zvyCPUda+idHvP7Q8N6MlphTJbRlmX6YP8jXDjUrJnfgqjjzR7nQ6KPME94wOXkwpA6DtTvEth9qtcgZni5BzyR/hW7oljELHy2xsZMY/unpTr+z2220Eny+MnnI/wAK8SWrPRVuU8qzknPUUVP4gt/sWoyKMFH+ZcdqKycXfQLHsBqM9aeT+X1qJuhz1r2DzBr8VXPWpieMVDJ1p7lmXqR4auUvTlmGe9dTqXCnJrk70/OahrU0gzNn71nzn0q9MetUZj6VrFFyM+5G4MPUGo/hNJt1bVrY/wAUSv17hsf1qSb+tUPh6/keOpIicCSKVSPXHI/lTrK8GRSdpHqw6E4OR79aGRZWUugPPpSoeWxnHUY6mnEgDgnJ6H0rz4nZqTxgR55wBgVYLLgZOP61TLF+MYU9zzU6BAnOSf51aYmiy0gMblVx7GliSQ43ru7de1RwlTGpYE44yRzxU65yuCQhPX1+tUtSbDY7aElmZSck9R0rRhVY1AG1F/u96g2jcCMDjGKmCkNhwGH19K0FJjipCFskn9RU8cgPuvftUKEiVtuCMfePapYMKe5zxx2oIZM5Cp3zjirCYULuxnpUMTcckAnoaUsN3zDrwMUmQx7Dgd8+vSoZSVII5Ipy4V27ZGarTNuzjIUelQNIld1AOQT3JqncuQc54I/KmyuTgHg5z+FVZXy2315zVjsMiy7PjBDH1q7BGSAckgHoeo9qbbqu0AggDoKthRtyev8AOqQrgBkgqcGpEyTk8qBxg1GQQQRnFTZA5xximJgdxYhe3c1KAdoJ9OTUaSY+709aCwGPmODzQKwy6jSa3niYZUqVI9eK+O9dtfsOtX9rgDyZ3UD2zX2FLMqq3Bx718r/ABIi2eLbuQDCzfP/AErqwz1sc2IjdXOY69xRuxx+dJjHtQSQeuDXacYGvf8A4KoLzwZA52kwTSQtk+4I/Q14AcjA9fWvb/2cboNZa7ZN1ikiuBj3BU/yFcmNjek2dGGdqiPatPt1SJUJ5X9atTqrKVbOcdqZaHIKkZqW5DBcxn5xzz/KvCaPVTOC1vT7eW7MdztUpnaScZB/wora1aCK4lR3Tggkb1zj1FFMo1yRnNRseeKcxph5zXoo80Y/6moHqZz2zxUDtz2zVofoZupcqa5G/wCJSO1dbqP3K5HUeJTzUNamsDLmJNUZ+lXpu9UZe5/StEU2UZ+T1rF8PSG3+INkxOA8+w/RlIram9a5+5YWfibTrs52iVCSPY4rSSvFozg7TR7IGyRjIHQVIGDE8EcenWqdnMWCgj5g2M+tWonyxGcsOua8q1j0dtCwnyIRjINSkggYzj0zUCvtHJ54xzUsYxgHOemRVolllcKw4GGGM9KvIANoGQFFZ0ZG8DIwTn5u9WY5cylR2G6tESy18oYkjA/2TTnfDZdjs24Un69MU3O4EYGTTlViwK4JPfrVIVhY2RMb87j81Sg5TKFlA5HrVSRlL4A+dhyPQ+mfSpg0yqMBSxPPpQDRZEigAZXOOOO9PLKNp6Yqk3XOBgjoD0pRKNpGN2B17mk2ZuJZkO47h0xioDJ5cTO33VXJyajjmwCDlVySc/zqOdt6MnDKRhh6iouVEq2uoR3yO0e4bTgg9qkjGRwRu96qafaR2aOictIevr7VoxoSAGGPpWkdWKfLf3diSHIHzOScdTVhOTyTioo9oyNvFTjaOT1NWZsf1xg07/PNR7gOxpPMB+919qQEpxt6kCo8DB9aZ5uAcDgdqhdmIOBye9AmQalMYoJmDD5VJzXzl8RFL3NtcDJJLIT+te+6+rDS7gng7DXiPjeAS6RIwGTGwYEV00XaSMausWcBz0/+tSZyRzzQeg96T6dK7zgHA8YBNen/ALPF55Pjq4tSflu7Nxg9yhDD+Rry/PoK6v4UXw074keH53bbG1yIWPs4K/1rKtHmpyXkXTdppn1xakKMkcfyp8vzAlj8oqaNCqP3xwQarTgshBIOOMV891PZMTUGMdwdgaRW5wo6UU6VpUbaW24/WiixVy4enFMannPtUbHA616KPOI3PUmq8h4PHFTsc49arSHBqwKN/wDcPNcjqZ/eV11/9w4rkdW+/wBaTNKb1MqY81Rl5q7KfX86py9TVIuRQl6mue8TITbRuvGxsZ9K6KUc1ja4pfT5cdsGtTLqeh6BdG40axugdzSxKzEeuMH9RWtE5YhumeOK4/4c3Jk8LxoTzDK8f4dR/OumLFUG47M9x6V5k42k0elF80Uy9uVgcZHHfsatQT7FyWGTwPT8apBCyAkH3NSCMlkwwUA9qcNGDsXEmVzzjBHftVlJEADEHgdcVSjGJD0+Yc571KhO4spyB6elNvUk0AwAUknp0/kaElKZ+bGTgdhUMbyJlweMA8/4Uea7DLkEDk4HTvmquIn88Iwzt44BHp706Oc7iobgc4Ixmqsd2s3luhBjPT3qfzAzfOu1g+FwfalzDaLbN8vbFQElWJXB9ar3t0LOANIQoHLH2oMokgR1bjGceoqXIXK9yR5OPp0qNnOSecnkj0qmJS8zqwIbH6VJ5p2kZNQ2CjYngUSXHOQFGc1ox4zyQKzLVgFyWIJP51bWTBJxit4bGUty9hfTB9aQMADjp71BGxP3icVJxgcVZA8nPTg9s0qxAjtgUzaGGSpIFSbuAMfXvigA2BSAv5UjNkdQAOvFKWAAx1qMszAk/j7UITM3V0MtnOp6FDXj+tWvn2dzH/eUgCvaZoS6MD9015jq9oYL6WNx91jWkHqZ2urHhhzyCeRwaB096uazB9l1a7g6bZCR9Kp5OTXpLVHntWdg98/hUttcG0ure5QfNDIso+qkH+lRZHqKQ4KketMR92RXMd3BHcxkGOdFlXHPDAH+tQTE4JUA59O9c78NtQOpfD3w9dBtzmzWNz7plP8A2WtqZgQxyc+nTFfOyhyyaPZhLmSZlXBYyHGDz0I6UUswbOSCAemKKVjUuscg5qMnC9qeehxUTcde9dyVzzhjk49P61XlPr9amkOT6VA/Y1aApXn+rJFcnrHWusueYzXK6wOpoZUNzEl61Tmq3L0qnLnmmi2U5qz75d9vIp7qRWhNVKbk/pWpmyb4XXOI9RtWONrJKPx+U/0r0BWwgyMc9cdK8s8BzG28WSwngSxuuPccj+Vemg4bByQ3brmuCurTud+Hd4FwSSFgYySffj86sxqP4uoPOKoQSc4Zvnz0bvV5DlsHALHmsypD1GJDgE5OQPepVJiI+QYz97NQpLiU87t3Bz61KrjcR95fcUxFhGJkUEE4XOKcs2X2sg244HSq4fDgBuCpHHXPpUkhwnJGe57gUId7AiRgNGkf3hlQvYnvmrUaZ6/eXvnOfrUKPlsOSPoOPpTPMwvy5AbOPcUXDclv0FxbmOSNXGc/UVmwI8UqrZSboQcSITnb7Cr6SnYBlhjpmqd9FNHBMbUKkp5OO59PrWctDSL+yXSwcNwNqjriq+Wy+BxnHrxWfpb3EsLC7TEqHLc8Zq80gMg5+UEH3NJauxMly6F+KJ1Ayv61ajOOoqutyNpx09aesv0rsVkrHIy0OMdOfenGQgfKB9TVdZAeOtPHzHigCykoH3vyp4JbHFV4vlHABYnqatIzEdyP0pAPjjGewpfLyDnBNPQHqRj2FPHzMQQRnvQBTkj2k9Mdq4zxnYYxcoOvyt/Su7kAPUDA61marbLdWk0LDG4Y59a0iyHpqfMPj238nXFkxhZkB+pHFc2a9A+J1k0cMEzLhopCh9s158eD1FehSleJwVVabF69v0puOc9KdnvSHrzWhmfSv7O+ofafh9NaFvmsr10x6K4DD/2avQ5TlTt5GeMmvDP2bNQEeo67p7NgSQx3Cj3Vtp/Rq9wkfOeMj2rx8TG1RnqYeV4IqSRgtlwTRSySMD159xRXLym5ZY1E54981Ix7moXIyfWu5HCMfrVdzUrk7vrUD8VSArznMZrmNYX5Tiuol+6a5vVhkGhhHc5qXpVSQ1al7iqkvSmjRlOY4JxVKX9Kuzd6pTZ5rQhmNYyGz8Y2MuRhpVz/AMC4r1WCXIyOp5JPY9K8f1/dHNBMmdy8j6g5r1XT5hPbQyr92VA498jPFc2JWzOrCSumjUgIA+YrvBxknmriszrg49M4rKjZfMCqRnGQvr71p2sg2APwW/P61znRMkX5iA2FB4YetPWQLlFyCoxg1FMu5cyZIB+Ugd6avyxkuGGRx7UiEWEBJ/eHcwGd3rUqcMxZgS3frn2qrHIxOCwB6ggVNGT5mAAVI4JFBRbdgcYAUkZB7ZpsR3hgV24OKYMDCqMkc5z0pY2YgFDkA5IP9aTBD/u7kUkkc/X2qN5H2HOPMIzz60gY8hucelNOChBxnFSx+pVIQBzkl2+8elJIzKuY1LNkZHtRKu1MR7d2OM84NPsQTuzTgrySCb0Fhml/jQrV+Ik4z09+9NUc4IH1qdY+ByceldSRzMmjUkg5FWUG3O7oaijIGMdasqQw6d+KZI+MjpjpVuLAPB4681VB4Gf1qwg4BY/40mh3JtoJz1qTsDmo0G4nnAqRc7iBj8aVxDcE8H88VBLHkEDp3z3qyy7VO3JPpTSmQOKE7BuePfGHSQ2nXciLkOnmD2Za8G6ge9fXXjHS11LR7iIDcwU4/LmvkiaIwzywtwUcofwNd+HldNHFXWzGMSSSeT3NFJ2IorpOc7v4I332L4h2SlgFuYpbc+5K5H6ivpTfhemCeor5F8J3h0/xVo92DjyruNifbcAf519ZysBI47ZxXnYyPvJndhHo0NkkAP3tv9aKz7u68pgCnXn8KK4js1NwnI/pULnnFPJqNjn611I4iNzxgVA54qVjnioXPWrAhfv9KwdVHynFbjnmsjUxlWoYk9TkJ+HYVUk/Wrt2AJT71Sk5BNCNXsU5upz0qjL3q/N3qjN1rRGTMHxAmbRWx91q7fwbdCfw5Y7j9xDGfqCR/hXIauu6zlHtmtn4dzCTSLmAn5optw+jD/61Z11eFzbCytOx3MaIcZPIOV9qt5cthPl78HPHeqcbgQrjBZTjgVetXJXdtGR1riPQkyzFL5kYznOe/FByVYtyD2pgL9cfKcg8c0qtiMlG+YdCTx7c0jP0FjRXlVgSAuMY9KsxvjaScY6g1VUkKCxGSefx9Kng5wxOSe+etAxzZZFI6bs5UY6VJHtYARjC5pCpCYRuvQGpRkKpJAJwSB0qWx2I1OVJJ6daiIALdBnofWrLRDa68kk5O2qrqpckHtipKSK0jKqtkkg8U+34UHPvUDsHbYARk4z61aRBnp24rakupnVdtCykmOam80jueelVkHzDAFWlTgHv6VsjBj1lOBg1bjl6cj6mquzPIGKeBg4JqhF6N+Tk85qdGA3Zbr0HpVBXORxg1YDDuM/hUgXYpsNjknHHFSDL7d2dwOc+tUWKvx0AP0qbzsEHj6ChgXwQTxy1KG7ueOlVVlA4p3mAg98dqiwiVyp3KQMHivkz4maYNJ8c6rbquI2k81PYNzX1W0gGSe9eA/tDWYj8R6beqMC4tyh+qn/69dWFlaVjDEK8bnlOaDSUduOa9A4RVcxurjqhDD8Dmvri1u472xt542WRJolbcjBgcgZ5FfIjZKMfbFfUXhIxHwppH2WJI43tY22xrgZ2jJx65rjxi0TOrCv3mbLYc9c444FFIgYL+7IA9qK4LM7TVJwuKjfpTicjntTHPFdBykb96hboakY9faoX7+tUJkLntWdqK/KTV+SqV79w8fnVNaEo4/UOJM+tZ8laeqL81ZkmOalG19CpN0NUZzgVel6cVRuOtaIzZmX/ADDJ/umpfh1Li5v4vWNX/I4/rUd4P3Tr6g1D4DO3XGHPMD5x+FKr8DKou1RHo8Ujp8suMNxkHg+hFacDbkIHDDkEjtWAZCsgJwAPy/KrNlqBeQLzsBzgda4uVvVHp2ujd84qQrYzjjnvTZD5zhMkYOSvqagO1pFK8sOQCf1qhLd+VcK5/hGfx/rUpXdkSot7G3FgnC+nJHalEji2Gxlj+bHyjis22v1kLeYpbJ5KjFTJIZpVUgEEjAPG4d6rkaGotPU2INxKb33gHk461aCom4LwMZzXO6fdSRufl/dnIB7j61uxCR4eFAdxknP3fWs6sHFlNWJJHxtwST6iq07jLHG3AqeTaI9rAHAxnFV5QfLbODz2rIZms480nGTVmOXj1HUmqAy0jelWYs4Azjvx2rrirKxzz1dy7G7At90r2x1q3FJ8oHSs/wCYDII4qeNyq5B/SqINJCMgdT29qcV3DoQPSqsUoPWp0k7Dp3oFYlXGODgUjPlRg5x2pVOB6+mKeFGM+vpQII3baN3B9qfvydp/nUKg8cYPoTTkXknPWgC1G525ByKf5nIyearg4AGOPSjcoyec+lICUuRyf515T+0HEJNF0ucD5op2Un2K/wD1q9PdupNecfHAeZ4TTI+7MrVpRdpozqq8GeDE0h9KM8cUma9Q80D6V9JfDmQTeAtEJJJFvt4PPDEV83ds17/8Hpd/gG0ABLRyyp1/2s/1rlxa9xHRhvjOxHAHaipt2Tg7SRRXnnoGnkYzTGP50uePWmMeOvFdCOQY9QMakc81C9NEtkMhqpecoasuTmq1xyhrR7EnLaoOvrWM5rc1YfeNYUneoRrcry96oznrV2WqM/U+tWiHsUZRnI61U8Hv5XiVEBwCsi/jj/61W5eBxWTZebb+JLVoB87SjaPXPUflTkrxaFTlaaZ6TKvA81d3rjv9aW0VCdwzxyDxgmlhkEmQSMAkEdx7UizIkuwsgye/BrgV9j199i48xJUjGO56YqvcwZnEkQJUDp7UrSxqgZM889asQy8AqMDBySO9JOz0HF2InCySDaoUcDdjGPergmlCqYyDtbl8dBjGB7GljhRpEyQBjgjvmrMNsV27wJFHAXoMd8Hsa0VRXsUrE8doHEcsMhG0chu5rTiYIDtY5/vAevpWKEdZM/NHHsIBzww7f4VPBdwxuYYZAWRcYJz6dPepqRctQaNcKqKQwJzzn/Cqt5xuyCAB6dKmtpi6CST5fT0qO9YBeTjjH1rmtqJmREBnv7e9XFTngYzzio1AIGzpn9asIox7V2HKx0Ywc+nrUnyheSc0qLuABJ4qVYzjjANAhgU5HGR61ZTKgYH/ANejYcDA+tSKCOnyjrzQK4/LcYFSodqZxiok7jpTwedp+tIRIOcf5xS45+Wmq7FsGmO7LIoRMqfvHOMUAStxnBND4z160HH50AdMd6AGECuL+LNobjwlcnjKYbj0rttmfXFZ/iKyW90S9gYZMkTAfXFODtJMia0Pk/OQMU2nOCjsp4KkgimmvXPMCvdPga5l8I3EWf8AV3jcH3C14VXs/wAAZlOm6zAw+7NG4PoSpH9K58Uv3bN8O7VEer4bJHyqO2aKSQLx375zRXmXPQLWeB6Uxm7UL0701uO9dKOUYxqCQ+tSs2DUDtk00QyJ+lQS8oalc1C/T8K0Ec5qozmufkPWuk1Vcg+lc5LwSKgu5Vk6VSm6nFXJapS9KtEyKcozWdejC+an+siIdSPUHNaUvXFU5O9WjNuzO3iiE8Ud1CBLDMvmBo2weR/jThCJpQFkJyMNvXmuT8C6lc6frQ0/eGsp97CN+QGxnj0zXoVzHbzqH8vjGMrwy/UVxzg4SsepSqKpG5i3sTQRjYeBzxTdOvm3bJHwMcZ71oSW3mR7Y5t4H8Lc5rn7qGSIuuxlP8GRxSSTVjZHW2TCZQhO3oV9D/8AWrbWWJ8Rlcc8gH9feuGstQKBVd8bcZIPWuksLxXhYSzDj7rY6Dt+VZuBXmPvEAiOz5RjGM9QTUESpFeRtGNw3jLHtxU0hjWFC43fNnrjJ9AaSKPzJyZFMSZyxPPHoK1TtHUtyNezIMe7cSSMLnoKjmJkOwEsRwT6CpIgCwCA7AOuKmYLGp9DyxriluIoopwMHJ9PSpSCGyEJ7VWWbybghjkScnHStFMZwfyrqjLmVzlnHldgQMpyDkelSox2gj8qYVA6GnKpB7VRBMv69alVs8571Dk/Qe9ODg9ucdaAZJtG4kMSR0zS7sZBNMBB2kE59KcSOeoPekIerEdT15xTlPBIzzUYx09acrbfvDB7YoAlJ7UDI4HT2qLOR1704Njhsn3pCJt2Oc9KjL7yy9V7mmdSQ1L8vYc0J2YM+VfFNp9h8S6nbAYEdw4A9s5rLrr/AIsW4g8d6gVBCyhZB+IrjzXrwd4pnmTVpNATXqnwCmI1HWodxCtDG+PXDEf1ryuvQvgnK0fiW9AzhrU5wf8AaFRX1psqj8aPcmkAPA3ex7UVkCdxnznBYkn5RgAdhRXjnqHSBuOtITTQeOlIe9dZxjJDULGpHPWoXOapEsiY1ETUjGoGI9asTMnUhkGuZuv9Ziuq1AcHjmuYvhiTikUtjPmHWqU3vV2U9apzVQmU5R3qjOeauznArPmPNWjNlK5lkt3iuIDiaFw6H3Feq+HtRt9Vs0urZhiQYaP+63cH6V5Ref6lyegFdF4LQ6fcQRyFkM6c4OPm6is60bxv1RthqnLLlfU7a7jMUyhlOEGeOGx9aR4o54j8xYHgFuMn6VLvXarRuxbuevHpUMsvlhgUHPQdB9c1zxs9D1FqYd6PIumVfnUAbTjnFT2l08GOd5zwD6Vbv18/LcbxjJPUiqAV45RyApH5H2qpKzCKNqELcyBkKgqudueg71rxYER2DIGMnJ3Y+p7/AErlxcIsa4BbvV6C9mAHmEGM9AvQDHA+lKSujTludRa3DAnqu44FL9pV541Kn5dwPp+P41z8VxNKmwcFjncvJHtV6x/0Y75EMjs3rWE6fUpRL10oyEIwU4zUljMHj7bxwwNZs94Z2LMcBSdwH86ZYTiK6jG/5JlVlJ71MLp2ZlWjdXOkGFNK6qxDYBYdO1RRyZxginrhTkkBjwOetbHKSAn1BHpSk57HFMVl6EjHtTmbuD160AScYLdaTcf7ufamAhQBnmk38cnFBJKOee/8qVmIU8jpwaiLZ5GCPSjdnHNK4EoYHG7OfWgsQOATURY9AcU4twMHNICYNuxt496Td8uQMjvUIY84I+uajkcFuD9aQHi/xzgEfiaznAGJbfn6gkV5v2zXqPxzTFzpDgYBSQZ/EV5bXq0NaaPPrfGwr0H4PqyX2p3AHCxJHnPHLZx+lefdq9B8O3LeGvCbzLGxv7r995bqRtX+E4PtyPWpxD9y3cdBe/d9Dr/EHiGy0u4SO7lIkZc7U7D3orxq+upby5e4uJGeWQ7mZuaKyWEjbVmrxbvoj6wTvStUcZ4609jWIEbN+lQuaklOPpULdMVQiNz1qAnFSyHmoHOTTQFS9HBPeuZ1IAV1F0MrXOaivWmnqNbGJIfeq02KtSjHB61Vm71RLKE56ms+Tvmr9xyCBVZVC7pX4VRmqTsQyvcQfPaQfKXmfc3qFXk1ryTK6RXdvjYhBB+hrF08td6yZXyGRMj/AGfQVv2EaOskKj5HJkTPv1GPYg1oo3VieazujrLeRXVHThSA2c/eBpt2oKMzHZGx4GeorK0mQi1MEhw8RwPp2q/LJugKkbumCK863JKx7NOfMkxqsHjCrnJ7txVaRVEuxsYHXjNSqxJwxAOe/GKZK4IGGUE8DHrWzdzTqQs6qRtAxnqDwatQOChBXntVJ2U7m2AgHac9PrTowSithiFOQ3TGaQ07GzY3AWchGUt6k9T6VKLlmuCU65OR15+tZUJZpSSSEHTIx+VW4kCzLgkqRkjsMVLRaZpFS8Zx0bOQf5Uy8x5UUkagLGRgeg9KSGXzJVXjnv7Ut82yCRBnAGQa5r2ZMtUattcbkBJ5Iq2kvGWxntmue0i4DxFSSCvFayHPIrp3RxNGgsmATjPtT/MBHXI/lVAEg/ezUglbsfwqBFsNyeaFbJOcVVMh/h60hlOeBQBe3DsaTzABx1ql5jH6U4Njk4+lJgXA47ce9BkPGCMGqXmkZGMDrUbTnt2pAXXkPIB5NQs6rxu/GqrXPXkVja/qb2OnXE0XMoU7QPWhK7A8++MeoJc6xaWySbvs8ZLDPQk/4VyGi6Lf6zOI7GEsv8Urnaij3P8AhT7DVp1uLqVLK1vbybLebNCZnj5zuUZxn3INekWD3r2KreKfs/lkAQTbnZmXIYvjHBxlQB3Fd85OjBJHEkqs2zCsNF0vRJl3Y1PUk5Lsv7iE+w/iP1/KptSuJ72V5rt3nkfhmc5JH+FPmi8pQpXbjsKqSOcEZFcEpOcrs6ElFWRxl9GkN3LHG4ZVPGO3tRS6zF5GoS4+6/zj8aK9eDvFM4ZLVn1PGcVKSKrRtwKkLV550hIcntULdKcxzUT880xDHOagY4qRzUD+3WqQDJuUPesC/XrW63KH1rI1BevFUhHNzdTVOar10MEms6U5PFMGVSNzHPAHX2qjqcmB5K9sFvY9h/WrtxIIkOD82cKPVv8AAVi3BOeTknnJ7046u5L0RY0Dia7fqQo4rXsWSNdyE7EPU9lbH8j/ADrF0QqJLjdxyK3IfkG5Qp5IIPQg9QfbFdHRGPU0rl1tp4rmMZjkKpL32+jVpgK6HJAII+72rnbWb7Ows5yTaTgi2mb/ANFt7j9RWpasywhurKMMP61xYmnZqSO7CVNOUsSB/tDtu8wk5ZicbqVvKKsM4J5BHY1C8m/DDBJ5pjYbnI3DP3jj8KlHencehTBCHIK44pN20DYd67cbT/Km5HAyob+ZqSIvJNwp3nkg8f5+tMtO5LAx4Lc98dyPrVmMk8lVDfex2OPanxRtFh2XCn+EVNahCDIB8w69se1Zzb2RaZLGpiAdwCxG4Y6Z9Khu5DJETnqcZx1p006KAeWx/CO9QFvNwpyr9P1rGKXUA019t1IgXg4bBrchYgdD9Kw2IS8V41Zsny8KO/0rYE4QfvUliP8AtIQP5VtC7icdRpPUuLKMYqQMD1K1nC8hx94GpUuIsZBHNNxfYjQtgBj1FKRgdRVJ7y3B5YAiojqUROEEj+yxs2fyFLlfYV0upoNwfwqJpOcBhn0qi1xeuP8ARtM1GXPTbbt/WoHsPEFwDjTo7JW6teXCxn645NVGlKXQl1YR3ZbubtIQTJKAB6mub1bxfp9iCPMaV/RasS+DNQvMteeINPgj64t43lOPY8A0/TvA/h+3TzjZ3OryZyJ9Qm8qIn2RecfU10U8I95GFTFJfCc9pfiXWvEd0bfw9pjy7fvynlUHuelaOoafZWRz4k1VdUvlXf8AYIpRDAp9HPVvpkZroNU1SbTdLmij8lIlXEdpYwiOI5HTjlmrlbmyTSPCgvJYopNTmlTzGcBtryN05/urxXVGhGGpzSrSno2dX4Ytwmgm5jtdPtBcqzM0EKq8gJIEeOygD8aHijWNUVQiDgKBgD6VabHkW7qoUPCjFffH/wBamhOOvNebiKnNNrsdNKFomJqGmpKhIwHI5zXG6jE0ErK1elyKpBBFcX4liBmOAA3r7VhpuanC66ImkiMoIbB6UVR12TdfsnUIMUV6lKD5Eck5+89D6bjbj3p5bjk1WjbjHapd3SuJG48nrUbH1pCSKYTx71SJGuTmq7mpXbrUDYzVIncT2rMvxnOa0CRmqd4AVNUg6HMXw5OKzJflXqAT3Pb3rbvI87ifujkk1gXzEFlHfqPQdh/WiWuiGu5m3L73zyFAwB6Cs+fmrkp7mqcntWkVYze5LouPOnVvQGtq0fO9ffP4Vz+ntsvlGPvgpz61t248m4A9a3jsZvculY5YJEnjEtu42uucdMkEehHY06xmltrhILiQyCQfuZzx5mB91h2fHbv1FC5BAzimlfKdgUDxsQzAnqR0OexHY1NSHNGxdOfLJMvMuAxXp146iozLgkIudw6mljmWQsAcHO0g0x/kfIA9j/jXAlbc9SMr6omEhblcbuwI4HvViykMcpIdt/Rcf56VUG88YHJ4G3ir0CO0BYbd69MDNO5smads0kqL86ZPXjOKdJEyYK7d2ej5wfWs7fNGm2NCW/2ePwqyJJRHulJwvJLdfoB60vNF20L0VudofaAnPHUimSFEc5OSOfrUEE7fvPm3R54APX2NJI+5vnICkk4Pr6fSsnGxSRHLCd1wFJ+bDgjsa2tM1K/ktRtuJiFwGUOSV98VlrJmLdn72Bio9Oup7W8wkj7N+MKm7K/zrqwU7TcWtzz8wp3ipI6S51G5iQMbqTBONzrnn8qhOp3/AJiCSWQRkcGNep9OlQXbTyXUJWa6igB5HldTSM14bxXinvDCBlojEv8AU161o9jxuaXc03vb+KVWSW6mDYORgfnkdac15qIdg9zKAfmB83aB+VZkVvLdX5udsrJgKkbTADd6nGcVJHpkyzSySxxxtJzuclto9PmP9KXu9h69yXU9Skity8l8PMJ2oYizlj6elU3dWuoIGWWWZvnMjPjy+/Qfyq49pZho1lmeWRc7Y4x8oPrjgVatbbgiGPygwyNw3H6e1NPogMbX/ET6chh0+GO4nZtuABhTjJLfh2qew+03mnW02oh98q5KEbAwz6dgateDFgure+s7xYZLzT5jKxUZDqx+99QePpWjqlnbyTLI9zMY16RrwPoaysuZ3Zd9NEYfifSn1bRpLezcQTRsHiVOADjoTWH4xRnk0TTZTukLLNJjlY9ij88kHJrvYthAKoFAzwP61zLaez+Ibu+mO6JyECuMcKOAvtnk1FSpFay2Q4wb0XUtMqpFBHgYjjVTj6Z/rTF3ZwQcAZBNSlMnJcbvpUbKAT2H6V4kpczbPRjHlVhkjBt23nFcV4ikAllZskKCa7NlynydM9+lcD8QA9tZzOP4wBwfU04rmaiNuyueZzuZp5JGPLMTRTTwTRXtbHnXufTsT9qnDe9UYGHUVYDcV5p2D2fJxTWbOPSo2b8KYXzmmSxzNnionPPuKC3Xn6VEWGRVpCsKW4qCZdy+tOZs8VJkRpvbvwM+tN6aha5g6ovlpgj/AOuew/Dqa5a8XknOc109+3mkknI6D/H8a56+TBNUo21ZLfYw5utVJKuzjBNVH9QKpElZ8ghl4YHIrcMu+OOYdcbunWsUjI9BWpYRubXYeCDkD2PStIPWxMlpc2V5RXBOTznrTgQVBOCCcD2qpYSYjMZPCcZPpU+Nv3W49BWpASkROHJIXocHp6GpyfMAOV5GDnpUQw4w35HvUQk8shW6jvXLWh9pHXhqn2WXoo5QhIfIB4DGrts4+62Fb+dZsb/KwQnJ6Lmp4LkKhUERt39a50egpGojGNSseCCcAGrCoJVU5+dT972rKgusMBt35569atfa9isjKNzDnJ7f40NXLTJlcmRdgOegAwBVrbCYFdgORk+/rWWHaZiCgReTuZvu1KZAAobLhQAAehFTJaFLcsuwZCeQq9Oex6VVjLQ3UbwhGYHo65APapXLzB3CqBncEAxtHaq8hG1mVjv4Azx0qKcuSSbJqw9pBxOtX7ayq/l28owDu8sEg464q/5V0xRwyKARvYIAzAetZ+h6g0sbFgAwGSfXtWnJdFNpzjnoBXuKSkro+ecWtGNMcjo4Z5kQ9gQo9/xqN7SOORCxbCnOM5zQ1y/zMAD9TjjPX2pqsGk3s+e+MZNCdhWFUIZFYKA/baOtVPEWrHS7CYxlUfYTknpWh9qhgheR2WNB1LfLzXBeJbd9UiknvJWt9JGWZyNrz4/hjB7ernj0zTj3kD00RD8ItVebxJrjzS586yZpHIyMhhwD+Nd7ZSiWNtzZOc9M15f8JpRL4m1Ty1EVumnSBEHQDI/zmvRtNUwxqUJAwOR3qVrdj7I2EwiMVABIxWVIS5JD5wenoPSr24lCT1UZNUigLF0+Vuhx0rycfLVI7cOt2RuCjZ4JqLD4JYAj1BqSQfINzHg5+tNcrtXGDg4HPFcSZ0DGACgZBBrkPiHZibRJSByOR+FdcxX5TWfq8C3VjMhUZIIHvVxlyu4mrqx4AVz35oq3qlo9nfSwsCu08Z9KK9tPmV0ee1bQ+goX7g1YD47is6F+lThuOK887CwZKbuwKi3HPtTS1NIlkjP0ApjNTC+KZuJOM1ohXJoxubrVS9uBIcJkLjCj0X/E/wAqnnZVjKN93G6Q46L2H4nisxnLszMRljk4qYrml5ITdl5kdwBjnrWLer1JrYlPFZd2M59K2aMznrleT6VScc1qXS1my8Z6UhjLeLzJgD90cmtPBPI69Khto/LjGR8zcmrCVDbWo0riQkR3CsxO1uD9D/8AXq8uNxwMgcZqjNhQCR97g1YtXLxjPLDg5NdNOakrmUouLsWByAw5znp1FMkUOMpyRzQCcrkcg4NPX29f85qmroSdndFfggjofSnLNzucbuxzSTxkElBg9SKqu3zZBPPXmuKcOV2PSpVeZXNaMlMbRtz+n41aWdldw8WUOMexrFt7yT7hAbJ4zWhAjkHcAQfyzU+p0KTNOzlV9iuCwydwz0qYAtJuRNin1OfyqqlwqmNETcw6jHQ/1q3l4lLSsT/IH1qJXsWmFzIkcRjDc9Scdarjb+5zyDy2PSoXnSbfK5OScAdqfDK+TsAz2J79s/Ss2tC+ZFmyv5rSeTyl3LjIzIEUfUmugnuL2WNhHp8QOCAftKMCT75ri7+3E6yRZPXK47Ct7w6Iv7MihtNzeSx8suAMn64yBmvQwtWVuXsePjKSjLm7j0XVcETSWMALfMTch8D6LkmtCHCLma+lfjkxRhAR6bm5/SoV0m9l/wBY0SLksVUdM+5+taEOmCBhukcgHOeBmumUpPqciSGNNbpumSMBj/y0k/eH824H4CuH+IF60tmxLHBbBJYkn/61dlqjxqNq4OFPJ5xXn1z/AMT3WVWGPzLeFwiqP+WknoPWnFKK5paibbdkXPhhYvZx6pdyggzW3lc+rnhfrgE16LZ7hAgxkqoArHtoI7ONNPhIZkO6Vx/HKR29hjArYRT5QRWwcfMc9KFotR21JZHCQkDkN1z3qvuygJ6n/OaHbLqFGQvTIzUYBJCttJ9fSvExcuaq12PQoq0ELICPvEYPFM2hcnr7/wD1qV25JJ5HYVETyVIOemf6Vzo1BgCcscgjkVHKCY2U8jaTikkC9QCcenFI5OwhlwpByQfarQjmtc8K2mqzxzsTE+3krj5qK2d7Kq4UyHHJHaito1JpWTI5E9RsMhqysnqay4JM4q0r10WIuW/M4zSF+Krh+aTfz1qkiWTs/anIyxoZH5A4AHUnsKrqdzYxUN3cfNtU4CcDH97u34dB70NvZdRJdWLcybmxkM2cuwPBb/AdBUJbA9qiDADims/FaRjyqxLd2Eje9U7nlanZqrznjr1qiTIuxxms+OMyTZP3V5rSuu9VynlIFPU8mpY0JnmnqeKhzUityKzlsWhZ+i+nvUikIytk4brUc/3BSJ33cgdTW+H1izKto0XdxHPbFCsCGKkDPoaYgHlj36j1oK9Npxzk8VtujMmJ3Lhh8w4zVC4QhunTkj2q8cnHIzUNypMbOuSxA4UZOBznFZzhzI0pzcHcoNweOvXNWraaZmA2kr/dqkrF4lc4G7OMHg/SpEYp8p79z2rla5XZnoQmpK6N61kGQwYqw9qmaWW5fygAAe2evvmsm0mXKhyemCAe/tWzEY1GMlUPr1FS0bKSEht2kYhiFUdCec/QVOyeUu0ZwPmJ7k+9K91Gq5BUv0Bz0qot1uJTJO7np1qGjRaahGCcsSTkZJ9a2PCN+I5XgkUHB4yKy5WJjK7PmJ2DnoO+Kr2Trb3u9lyin5s9h61VOTjI58RFTgejyXQXJ6A+tYOra5HbRl5JAEA65rMn1KS8Bg0uCW8nJ6RKSoH16CqDeFJL2dT4g1MIB0s7I+ZK3sW6LXoqyPIZiy6rf+J74WGmo6QE7ZJFXLEeg+tdnpemR6FaiKFlN6qFBs5FuD1we7n17VahSLTrJbTR4ILG3x2Pzkf7TdSaTzYwmEHmP3xwAatRbd5fcK/Ydp8QiIig5Yj77ex61pSPk7F4B545JqnbhpPmBwSe/YVayqx8EM54yaVR2XMxxWth+QpIBO0U0tnhgRgVUaUICArgnr/FSmZWY5bj3r56cnOTZ6kVypIlfL4GAF+tQs4YBdrY6c/zprtuDLkcngkcYph3MFy3TjpwaENi7gD83bjHqajkkyrhsbSOAOuKa+I1YnGCetRswkQ4AI+uKoQkZHloSCvA5B60Ulq2IFAcY9MdKKCT/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular erythematous patches and plaques are present on sun-exposed skin. A biopsy revealed findings consistent with annular elastolytic giant cell granuloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Benjamin Ehst, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13889=[""].join("\n");
var outline_f13_36_13889=null;
var title_f13_36_13890="Approach to pallor algo";
var content_f13_36_13890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    The diagnostic approach to pallor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 787px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Initial hemoglobin and red blood cell indices may be normal despite severe hemorrhage.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Examples of possible conditions are provided within appropriate categories.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13890=[""].join("\n");
var outline_f13_36_13890=null;
var title_f13_36_13891="Plantar warts PI";
var content_f13_36_13891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Plantar warts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13891=[""].join("\n");
var outline_f13_36_13891=null;
var title_f13_36_13892="Uterine morcellation B";
var content_f13_36_13892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Uterine morcellation during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13892=[""].join("\n");
var outline_f13_36_13892=null;
var title_f13_36_13893="Vardenafil: Patient drug information";
var content_f13_36_13893=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vardenafil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     see \"Vardenafil: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levitra&reg;;",
"     </li>",
"     <li>",
"      Staxyn&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levitra&reg;;",
"     </li>",
"     <li>",
"      Staxyn&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat impotence.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not approved for use in women.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703120",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vardenafil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you use drugs called \"poppers\" like amyl nitrite and butyl nitrite.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703715",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been told not to have sex by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3435985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Staxyn&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701063",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to break down fructose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is more than one brand of this drug. One brand cannot safely be used for the other. Your doctor will tell you about any needed change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any eye problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease and are on dialysis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke within the last 6 months, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ulcer disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other drugs used to treat a change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loss of eyesight. This can be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change or loss of eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 60 minutes before sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"       After opening, place on your tongue and let melt. Do not take with water. Do not crush, break, or chew.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis. Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11233 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13893=[""].join("\n");
var outline_f13_36_13893=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233465\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855046\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022157\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022159\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022158\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022163\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022164\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022166\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022161\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022162\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022167\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022168\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=related_link\">",
"      Vardenafil: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_36_13894="Calculator: Rheumatoid arthritis Disease Activity Score (DAS-28)";
var content_f13_36_13894=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"RheumatoidArthritisDAS28_form\" name=\"RheumatoidArthritisDAS28_form\" onkeydown=\"clrResults();\" onkeypress=\"return validNumberField(event);\" onkeyup=\"RheumatoidArthritisDAS28_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Rheumatoid arthritis Disease Activity Score (DAS-28)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          DAS28 = ( 0.56 * sqr(TJC)) + (0.28 * sqr(SJC)) + ( 0.7 * ln(ESR)) + (0.014 * GH)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              ESR",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"ESR_param\" onblur=\"RheumatoidArthritisDAS28_fx(); minMaxCheck();\" onchange=\"RheumatoidArthritisDAS28_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"ESR_unit\" onchange=\"RheumatoidArthritisDAS28_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mm/hr\">",
"               mm/hr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              GH",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"GH_param\" onblur=\"RheumatoidArthritisDAS28_fx(); minMaxCheck();\" onchange=\"RheumatoidArthritisDAS28_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"GH_unit\" onchange=\"RheumatoidArthritisDAS28_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|#\">",
"               #",
"              </option>",
"              <option value=\"1|0|index\">",
"               index",
"              </option>",
"              <option value=\"1|0|none\">",
"               none",
"              </option>",
"              <option value=\"1|0|number\">",
"               number",
"              </option>",
"              <option value=\"1|0|points\">",
"               points",
"              </option>",
"              <option value=\"1|0|score\">",
"               score",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              DAS 28",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"DAS_28_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"DAS_28_unit\" onchange=\"RheumatoidArthritisDAS28_fx();\" style=\"width:105px;\">",
"               <option value=\"1|0|#\">",
"                #",
"               </option>",
"               <option value=\"1|0|index\">",
"                index",
"               </option>",
"               <option value=\"1|0|none\">",
"                none",
"               </option>",
"               <option value=\"1|0|number\">",
"                number",
"               </option>",
"               <option value=\"1|0|points\">",
"                points",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|score\">",
"                score",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"RheumatoidArthritisDAS28_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option selected=\"selected\">",
"               1",
"              </option>",
"              <option>",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"0\" cellpadding=\"5\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"80%\">",
"       <tr>",
"        <td align=\"center\" valign=\"top\">",
"         <table border=\"1\" cellpadding=\"10\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"center\" colspan=\"2\">",
"            <b>",
"             Tender Joint Count",
"            </b>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"left\" valign=\"top\">",
"            <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Shoulder",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Elbow",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Wrist",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"10\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" class=\"tipl\" height=\"20\" width=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"bottom\">",
"               Right hand",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" height=\"20\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\">",
"               <span class=\"medCalcFontTwo\">",
"                MCP 1-5",
"                <br/>",
"                IP 1, PIP 2-5",
"               </span>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"2\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip3\" height=\"30\">",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Knee",
"              </td>",
"             </tr>",
"            </table>",
"           </td>",
"           <td align=\"left\" valign=\"top\">",
"            <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Shoulder&nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Elbow&nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Wrist&nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"10\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"bottom\">",
"               Left hand",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tipr\" height=\"20\" width=\"20\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\">",
"               <span class=\"medCalcFontTwo\">",
"                MCP 1-5",
"                <br/>",
"                IP 1, PIP 2-5",
"               </span>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip3\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" colspan=\"2\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Knee&nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"            </table>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"2\">",
"            TJC &nbsp;",
"            <input name=\"TJC_param\" onfocus=\"blur();\" size=\"3\" type=\"text\"/>",
"            &nbsp;&nbsp;&nbsp;",
"            <input onclick=\"TJCAll();\" type=\"button\" value=\"Select All\"/>",
"            &nbsp;&nbsp;&nbsp;",
"            <input onclick=\"TJCClr();\" type=\"button\" value=\"Clear All\"/>",
"           </td>",
"          </tr>",
"         </table>",
"        </td>",
"        <td align=\"center\" valign=\"top\">",
"         <table border=\"1\" cellpadding=\"10\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"center\" colspan=\"2\">",
"            <b>",
"             Swollen Joint Count",
"            </b>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"left\" valign=\"top\">",
"            <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Shoulder",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Elbow",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Wrist",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"10\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" class=\"tipl\" height=\"20\" width=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"bottom\">",
"               Right hand",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" height=\"20\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\">",
"               <span class=\"medCalcFontTwo\">",
"                MCP 1-5",
"                <br/>",
"                IP 1, PIP 2-5",
"               </span>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"2\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip3\" height=\"30\">",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Knee",
"              </td>",
"             </tr>",
"            </table>",
"           </td>",
"           <td align=\"left\" valign=\"top\">",
"            <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Shoulder&nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Elbow&nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Wrist&nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"10\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"bottom\">",
"               Left hand",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tipr\" height=\"20\" width=\"20\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\">",
"               <span class=\"medCalcFontTwo\">",
"                MCP 1-5",
"                <br/>",
"                IP 1, PIP 2-5",
"               </span>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip3\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" colspan=\"2\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Knee&nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisDAS28_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"            </table>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"2\">",
"            SJC &nbsp;",
"            <input name=\"SJC_param\" onfocus=\"blur();\" size=\"3\" type=\"text\"/>",
"            &nbsp;&nbsp;&nbsp;",
"            <input onclick=\"SJCAll();\" type=\"button\" value=\"Select All\"/>",
"            &nbsp;&nbsp;&nbsp;",
"            <input onclick=\"SJCClr();\" type=\"button\" value=\"Clear All\"/>",
"           </td>",
"          </tr>",
"         </table>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         DAS 28 Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          DAS28 &lt;2.6:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Remission",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          DAS28 &gt;=2.6 and &lt;=3.2:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Low Disease Activity",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          DAS28 &gt;3.2 and &lt;=5.1:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Moderate Disease Activity",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_4\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          DAS28 &gt;5.1:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          High Disease Activity",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       In the hands, the joints that are evaluated include the first through fifth metacarpophalangeal joint, the interphalangeal joint of the thumb, and the second through fifth proximal interphalangeal joint.",
"      </li>",
"      <li>",
"       The",
"       <b>",
"        GH",
"       </b>",
"       or Global Health parameter represents the",
"patient's self assessment of disease activity on a 0-100 scale where 100 means maximal activity.",
"      </li>",
"      <li>",
"       A",
"       <b>",
"        DAS-28",
"       </b>",
"       reduction by 0.6 represents a moderate improvement.  A reduction more than 1.2 represents a major improvement.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Aletaha D, Ward MM, Machold KP, et. al. Remission and active disease in rheumatoid arthritis:  defining criteria for disease activity states.",
"        <i>",
"         Arthritis Rheum",
"        </i>",
"        . 2005 Sep;52(9):2625-36.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based  on judgment in clinical practice by rheumatologists.",
"        <i>",
"         J Rheumatol",
"        </i>",
"        . 1993 Mar;20(3):579-81.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Prevoo ML, van 't Hof MA, Kuper HH, et. al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.",
"        <i>",
"         Arthritis Rheum",
"        </i>",
"        . 1995 Jan;38(1):44-8.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Saag KG, Teng GG, Patkar NM, et. al. American College of Rheumatology 2008 recommendations for the use of nonbiologic  and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.",
"        <i>",
"         Arthritis Rheum",
"        </i>",
"        . 2008 Jun 15;59(6):762-84.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13894=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"function alertNaN(){",
"alert('This field is improperly formatted. You may only input the digits 0-9 and a decimal point.');  ",
"doCalc = false; ",
"clrResults();",
"}",
"",
"",
"function validNumberField(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"var val = field.value;",
"var charCode = event.charCode;",
"var key = String.fromCharCode(charCode);",
"",
"if(charCode == 0) {",
"return true;",
"}",
"",
"if(key == ' ') {",
"alert('Numeric field cannot contain spaces.');",
"return false;",
"}	",
"		",
"if(val.length == 0) {",
"if(key == '+') { return true; }",
"if(key == '-') { return true; }	",
"if(key == '.') { return true; }",
"}",
"		",
"if(key == '.') { return validFloat(val, key); }",
"",
"if(isNaN(parseInt(key))) {",
"alertNaN();",
"return false;",
"}",
"	",
"return validFloat(val, key);",
"}",
"return true;",
"}",
"",
"",
"function validFloat(val, key) {",
"var currentVal = parseFloat(val + key);",
"if(isNaN(val + key) || isNaN(currentVal)) {",
"alertNaN();",
"}",
"return true;",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function RheumatoidArthritisDAS28_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 2000);",
"",
"with(document.RheumatoidArthritisDAS28_form){",
"",
"",
"doCalc = true;",
"param_value = parseFloat(ESR_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = ESR_unit.options[ESR_unit.selectedIndex].value.split('|');",
"ESR = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(GH_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = GH_unit.options[GH_unit.selectedIndex].value.split('|');",
"GH = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"TJC = 0;",
"for (jcount = 0; jcount < 28; jcount++){",
"if(TJC_box[jcount].checked) TJC = TJC + 1;",
"}",
"TJC_param.value = TJC;",
"SJC = 0;",
"for (jcount = 0; jcount < 28; jcount++){",
"if(SJC_box[jcount].checked) SJC = SJC + 1;",
"}",
"SJC_param.value = SJC;",
"dp = decpts.options[decpts.selectedIndex].text;",
"DAS_28 =  ( 0.56 * sqr(TJC)) + (0.28 * sqr(SJC)) + ( 0.7 * ln(ESR)) + (0.014 * GH);",
"",
"unit_parts = DAS_28_unit.options[DAS_28_unit.selectedIndex].value.split('|');",
"if (doCalc) DAS_28_param.value = fixDP((DAS_28 - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"if (doCalc){",
"rrclr();",
"if (DAS_28 <2.6){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((DAS_28 >=2.6) && (DAS_28 <=3.2)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((DAS_28 >3.2) && (DAS_28 <=5.1)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if (DAS_28 >5.1){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.RheumatoidArthritisDAS28_form){",
"",
"if (ESR_param.value && isNaN(ESR_param.value)){ ESR_param.value = ''; alertNaN(); }",
"if (ESR_param.value && ESR < 1) {",
"ESR = 0;",
"ESR_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for ESR is 1 mm/hr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (ESR_param.value && ESR > 200) {",
"ESR_param.value = \"\";",
"clrResults();",
"ESR = 0;",
"doCalc = false;",
"alert(\"The maximum value for ESR is 200 mm/hr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (GH_param.value && isNaN(GH_param.value)){ GH_param.value = ''; alertNaN(); }",
"if (GH_param.value && GH < 0) {",
"GH = 0;",
"GH_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for GH is 0 #.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (GH_param.value && GH > 100) {",
"GH_param.value = \"\";",
"clrResults();",
"GH = 0;",
"doCalc = false;",
"alert(\"The maximum value for GH is 100 #.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.RheumatoidArthritisDAS28_form){",
"",
"DAS_28_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"function TJCClr() {",
"with(document.RheumatoidArthritisDAS28_form){",
"TJC = 0;",
"for (jcount = 0; jcount < 28; jcount++){",
"TJC_box[jcount].checked = false;",
"}",
"TJC_param.value = TJC;",
"RheumatoidArthritisDAS28_fx();",
"}}",
"",
"",
"function TJCAll() {",
"with(document.RheumatoidArthritisDAS28_form){",
"TJC = 28;",
"for (jcount = 0; jcount < 28; jcount++){",
"TJC_box[jcount].checked = true;",
"}",
"TJC_param.value = TJC;",
"RheumatoidArthritisDAS28_fx();",
"}}",
"",
"function SJCClr() {",
"with(document.RheumatoidArthritisDAS28_form){",
"SJC = 0;",
"for (jcount = 0; jcount < 28; jcount++){",
"SJC_box[jcount].checked = false;",
"}",
"SJC_param.value = SJC;",
"RheumatoidArthritisDAS28_fx();",
"}}",
"",
"",
"function SJCAll() {",
"with(document.RheumatoidArthritisDAS28_form){",
"SJC = 28;",
"for (jcount = 0; jcount < 28; jcount++){",
"SJC_box[jcount].checked = true;",
"}",
"SJC_param.value = SJC;",
"RheumatoidArthritisDAS28_fx();",
"}}",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f13_36_13894=null;
var title_f13_36_13895="Epidemiology, pathogenesis, and prevention of African trypanosomiasis";
var content_f13_36_13895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and prevention of African trypanosomiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13895/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13895/contributors\">",
"     Sanjeev Krishna, MA, BMChB, DPhil, FRCP, ScD, FMedSci",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13895/contributors\">",
"     August Stich, MD, MSc, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13895/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13895/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13895/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13895/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/36/13895/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by protozoan parasites transmitted via the bite of a tsetse fly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/1\">",
"     1",
"    </a>",
"    ]. There are two forms of the disease: an acute form occurring mainly in East Africa and caused by Trypanosoma brucei rhodesiense, and a more chronic form occurring mainly in West and Central Africa, caused by Trypanosoma brucei gambiense (",
"    <a class=\"graphic graphic_table graphicRef86457 \" href=\"UTD.htm?18/9/18588\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These two species have identical morphologic appearances and both are transmitted by tsetse flies of the genus Glossina. However, the clinical features of infection differ in presentation and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genome of Trypanosoma brucei brucei, a closely-related animal parasite that does not infect humans, has been fully delineated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/4\">",
"     4",
"    </a>",
"    ]. Serum resistance factors lyse animal trypanosomes (including T. evansi) and prevent infection in humans, unless there is a host genetic deficiency for these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, life cycle, and prevention of African trypanosomiasis will be reviewed here. The clinical manifestations, diagnosis, and treatment of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38681?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of African trypanosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two forms of human African trypanosomiasis (HAT): an acute form occurring mainly in East Africa and caused by Trypanosoma brucei rhodesiense, and a more chronic form occurring mainly in West and Central Africa, caused by Trypanosoma brucei gambiense [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/2\">",
"     2",
"    </a>",
"    ]. T. b. gambiense generally causes endemic disease with chronic manifestations, while T. b. rhodesiense is an acute epidemic disease (",
"    <a class=\"graphic graphic_table graphicRef85846 \" href=\"UTD.htm?20/16/20747\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the last century, there have been three severe epidemics of African trypanosomiasis: one between 1896 and 1906, mostly in Uganda and the Congo Basin; one in the 1920s in several Central African countries; and one that began in 1970, which is still in progress but declining. The 1920s epidemic was arrested using mobile teams that systematically screened millions of at-risk individuals. The disease practically disappeared between 1960 and 1965, and subsequently surveillance was relaxed. Civil wars, displacement of people, economic difficulties, and slackening in vector control measures subsequently allowed reemergence of disease in several foci.",
"   </p>",
"   <p>",
"    Sleeping sickness occurs in approximately 30 sub-Saharan African countries, within the distribution of the tsetse fly. There are about 60 million people at risk for infection (",
"    <a class=\"graphic graphic_figure graphicRef86653 \" href=\"UTD.htm?39/3/39986\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Countries particularly affected include the Democratic Republic of Congo, South Sudan, Angola, and the Central African Republic (all of which have T. b. gambiense disease), Uganda (which has both T. b. gambiense and T. b. rhodesiense disease), Tanzania, Malawi, and Zambia (which have T. b. rhodesiense disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/7-11\">",
"     7-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The difficulty in estimating the incidence and prevalence of African trypanosomiasis is exacerbated by the remoteness of affected regions and the focal nature of disease transmission (",
"    <a class=\"graphic graphic_figure graphicRef59127 \" href=\"UTD.htm?28/19/28979\">",
"     figure 2",
"    </a>",
"    ). In 1999, 45,000 cases of HAT were reported to the World Health Organization (WHO); at least 10 times as many cases are likely not reported, causing an estimated 100,000 deaths occur each year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The estimates have declined with implementation of concerted control measures; in 2010, approximately 7000 cases were reported to the WHO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many previously endemic countries have been disease free for more than a decade (including Ghana, the Gambia, and Kenya); several other countries report &lt;500 cases per year (including Gabon, United Republic of Tanzania, and Malawi). Most cases occur in the Democratic Republic of Congo (&gt;70 percent of cases; &gt;500 cases per year), followed by South Sudan, Angola, and the Central African Republic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/6,15\">",
"     6,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of HAT in a region often reflects war, civil unrest, and lack of a reliable presence of state authority. Therefore, nearly by definition, HAT as a public health problem occurs in areas where there is no research infrastructure; thus, many important questions of clinical and operational research remain unanswered.",
"   </p>",
"   <p>",
"    Travelers to game park areas near Lake Victoria are at risk of T. b. rhodesiense infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/17\">",
"     17",
"    </a>",
"    ]. One report described the acquisition of infection in two travelers from the United States who went on safari in Tanzania [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/18\">",
"     18",
"    </a>",
"    ]. Other reports have described clusters of infection among European tourists [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/19-21\">",
"     19-21",
"    </a>",
"    ], highlighting the potential for emergence of this disease in international travelers, particularly those traveling to the Tarangire and Serengeti, including the Masai Mara (previously not known to be an area at risk) and Lake Manyara National Parks. Other cases have been imported from Zambia and Zimbabwe. Given the rarity of imported HAT and the challenges associated with diagnosis, it must be actively excluded in travelers at risk. Cases of T. b. gambiense are most commonly found in immigrants or expatriate workers who have spent time in endemic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14020275\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans are the main reservoir for T. b. gambiense; this species can also be found in some animals, including domestic pigs. Wild game animals and cattle are the main reservoir of T. b. rhodesiense.",
"   </p>",
"   <p>",
"    During a blood meal, an infected tsetse fly injects trypomastigotes into the host skin tissue (",
"    <a class=\"graphic graphic_figure graphicRef85844 \" href=\"UTD.htm?38/19/39224\">",
"     figure 3",
"    </a>",
"    ). A painful chancre (local inflammatory reaction) can develop at the site of inoculation. The parasites enter regional lymphatics and then disseminate widely in the bloodstream, where the metacyclic trypomastigotes differentiate to long, slender forms that measure 15 to 35 mcm. These can be seen on blood smear examination (",
"    <a class=\"graphic graphic_picture graphicRef85845 \" href=\"UTD.htm?22/49/23317\">",
"     picture 1",
"    </a>",
"    ) and are characterized by a flagellum and a kinetoplast (an organelle associated with the mitochondrion containing extranuclear DNA). Trypomastigotes can pass through the walls of blood and lymphatic vessels into connective tissues and thereby enter the cerebrospinal fluid (CSF) and the brain.",
"   </p>",
"   <p>",
"    When ingested by a tsetse fly during a blood meal, trypomastigotes move to the midgut, transform into procyclic trypomastigotes with different developmental, morphologic, and metabolic characteristics, and undergo replication. After approximately three weeks, they migrate to the salivary gland, where they develop into epimastigotes and finally into new metacyclic trypomastigotes that are ready to be transmitted to another host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;HAT is transmitted to humans via the bite of a tsetse fly (Glossina spp). Tsetse flies tend to be found in warm, shaded areas and have an average life span of one to six months. Once infected with trypanosomes, they remain infective for life. Flies are attracted by large moving objects and are especially drawn to dark colors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/22\">",
"     22",
"    </a>",
"    ]. Tsetse flies are restricted to the African continent where they occur in 31 species and subspecies, though not all tsetse flies play a role in the transmission of sleeping sickness. T. b. gambiense is transmitted via tsetse flies mainly of the Glossina palpalis group, and T. b. rhodesiense is transmitted via tsetse flies mainly of the Glossina morsitans group. These flies are found in tropical Africa between 14&deg; north and 19&deg; south of the equator, which defines the geographic range for transmission of HAT (",
"    <a class=\"graphic graphic_figure graphicRef86653 \" href=\"UTD.htm?39/3/39986\">",
"     figure 1",
"    </a>",
"    ). The two vector groups have different biting habits that result in different epidemiologic features for Gambian and Rhodesian trypanosomiasis.",
"   </p>",
"   <p>",
"    The Glossina palpalis vector requires humidity and prefers dense riverine habitats in West and Central Africa. These flies are both zoophilic and anthropophilic but preferentially feed on humans, which are the main reservoir of infection. Humans are exposed to bites during bathing and washing in small rivers or pools of water in rural areas.",
"   </p>",
"   <p>",
"    The Glossina morsitans vector lives in drier and more open areas of woodlands and savannas in East Africa. These flies are mainly zoophilic and prefer to feed on wild animals such as antelope (bushbucks) or on domestic animals such as cattle and goats. Wild animals are the main reservoir for T. b. rhodesiense infection. These tsetse flies do not bite humans frequently, but farmers, hunters, or others who enter woodland areas and thickets where flies breed are at risk of incidental infection. In certain parts of East Africa, T. b. rhodesiense is transmitted by a riverine species of tsetse fly, and this transmission is associated with greater epidemic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other means of transmission are rare but include transmission via blood transfusion, laboratory inoculation, and congenital infection, which can result in abortion or perinatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/23\">",
"     23",
"    </a>",
"    ]. Urban transmission is rare but has been described in Libreville, Gabon, and Kinshasa, Democratic Republic of Congo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the life cycle of Trypanosoma brucei, there is modulation of the exposed surface antigens of the parasite. Metacyclic trypanosomes in the tsetse fly and bloodstream forms in mammalian and human hosts have proteins on their surface known as major variant surface glycoprotein (VSG). Each trypanosome is covered with approximately 10 million copies of a single VSG [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Innate immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innate immunity against T. brucei is due to the trypanolytic activity of apolipoprotein L-I (APOL1), which is bound to high-density lipoproteins in human serum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/26\">",
"     26",
"    </a>",
"    ]. This protein is taken up in the parasite by endocytosis and triggers osmotic swelling of the lysosomal compartment with subsequent cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/27\">",
"     27",
"    </a>",
"    ]. The importance of the APOL1 protein in innate immunity has been demonstrated by the onset of human disease when parasites have acquired resistance to APOL1 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/26\">",
"     26",
"    </a>",
"    ], or when patients have mutations in the APOL1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evasion of host defense",
"    </span>",
"    &nbsp;&mdash;&nbsp;T. brucei parasites can evade destruction by the mammalian host immune response in the bloodstream by periodically switching their VSG, a phenomenon known as antigenic variation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This results in characteristic waves of parasitemia during human African trypanosomiasis (HAT) infection. Trypanosomes express a different VSG during each successive wave of parasitemia and change their surface VSG each time the host begins to mount an effective immune response. In this way, the parasite is able to stay one step ahead of the host's immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/31\">",
"     31",
"    </a>",
"    ]. This process also leads to nonspecific activation of the host humoral immune response, which can induce false-positive antibody-based tests used to diagnose other infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other mechanisms enabling T. brucei parasites to survive despite host immune defenses include their ability to grow in the presence of high levels of interferon- (IFN) gamma and to avoid complement-mediated destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/32\">",
"     32",
"    </a>",
"    ]. One study identified two different genotypes of the parasite circulating simultaneously in the same patient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigenic variation leads to nonspecific polyclonal B cell activation during infection and IgM is produced in large quantities. Immune complexes form, and secondary hyperplasia of the reticuloendothelial system occurs, particularly involving the spleen and lymph nodes. This process may lead to downregulation of the immune system. Therefore, generalized suppression of humoral and cellular immune responses may be seen in advanced stages of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative contribution of immune complex deposition, inflammatory infiltrates, vascular infiltration, and direct parasite invasion to organ damage in African trypanosomiasis is uncertain; it is likely that the pathologenesis of HAT reflects a complex combination of these mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333238\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major tools to prevent transmission of infection are vector control and surveillance (with early treatment of identified cases). There is no vaccine available for human African trypanosomiasis (HAT); the parasite's ability to undergo antigenic switching makes vaccine development challenging, although there is some evidence that natural immunity develops following infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333245\">",
"    <span class=\"h2\">",
"     Vector control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional approaches include aerial insecticide spraying and reduction of wild animal populations in attempts to reduce tsetse populations in an area. Subsequently, vector control has focused on tsetse fly traps (",
"    <a class=\"graphic graphic_picture graphicRef86884 \" href=\"UTD.htm?26/41/27289\">",
"     picture 2",
"    </a>",
"    ) and insecticide treated screens. Insecticide impregnation must be repeated every three to four months, necessitating sustained programs in order for this approach to be effective. When epidemics occur and more rapid vector control is required, ground or aerial spraying of insecticides in tsetse breeding sites can be employed. Thus far insecticidal resistance has not been reported among tsetse flies. Removal of the woody vegetation that forms the usual habitat for the flies can also be helpful. Vector control is the primary prevention tool for T. b. rhodesiense. Some limited success with the release of irradiated sterile male flies has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/37\">",
"     37",
"    </a>",
"    ], but this approach is unlikely to be applied on a larger scale.",
"   </p>",
"   <p>",
"    African governments have implemented an initiative known as the Pan African Tsetse and Trypanosomiasis Eradication Campaign, which employs suppression methods to eradicate flies from areas of tsetse infestation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333252\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance aims to reduce the human reservoir of infection by identifying human cases and instituting early treatment during the asymptomatic phase of infection. This is helpful for controlling human disease as well as reducing T. b. gambiense transmission.",
"   </p>",
"   <p>",
"    Surveillance tools include screening for clinical lymphadenopathy and field use of the CATT (card agglutination test for T. b. gambiense trypanosomes). Individuals found to be CATT positive should undergo further investigation including lymph node aspiration and blood smear examination. Those with evidence of trypanosomal infection should be treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38681?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of African trypanosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal management of individuals who are CATT-positive and trypanosome-negative is uncertain. Some of these represent false positive results, while others represent individuals with asymptomatic infection and low numbers of circulating parasites. When available, more sensitive tests such as blood concentration techniques or polymerase chain reaction (PCR) might be useful to determine the best approach for these individuals. In the absence of additional diagnostic data, most individuals who are CATT-positive and trypanosome-negative need not be treated, provided there are no cerebrospinal fluid (CSF) abnormalities.",
"   </p>",
"   <p>",
"    Ideally, screening for T. b. gambiense should be undertaken twice a year in endemic communities; however, surveillance is performed among less than 10 percent of those at risk for HAT. Case detection is difficult and requires substantial human, technical, and material resources. The problem is especially challenging since the disease is rife in rural areas among poor people with little access to health facilities.",
"   </p>",
"   <p>",
"    Surveillance is not practical for control of T. b. rhodesiense infection because asymptomatic human infection is rare. Therefore, the only prevention tools consist of vector control and veterinary measures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13895/abstract/41\">",
"     41",
"    </a>",
"    ]. In the areas where T. b. rhodesiense infections occur, febrile diseases are frequently misdiagnosed as malaria. Healthcare workers must be trained to recognize trypanosomiasis in order to care for individual patients and to detect possible outbreaks.",
"   </p>",
"   <p>",
"    In public health terms, T. b. gambiense is the more important parasite. The regions with the highest prevalence and the largest populations at risk are in countries where political instability and poor infrastructure prevail. The resurgence of HAT in war-ridden areas in the late 1990s was a direct consequence of the political reality in parts of the African continent at the time. Numbers of reported cases are declining, although real control of HAT can be achieved only with combined and sustained efforts. With decreasing numbers of cases, public interest, political commitment, and sustainable funding may fade, which would likely lead to another epidemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333259\">",
"    <span class=\"h2\">",
"     Advice for travelers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers to endemic areas should be warned to avoid areas known to harbor tsetse flies, wear protective clothing, use insect repellents, and seek medical care early if symptoms develop. There is no role for chemoprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2334564\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by protozoan parasites transmitted via the bite of a tsetse fly. There are two forms of HAT: a chronic form occurring mainly in West and Central Africa caused by Trypanosoma brucei gambiense, and an acute form occurring mainly in East Africa and caused by Trypanosoma brucei rhodesiense. T. b. gambiense generally causes endemic disease with chronic manifestations, while T. b. rhodesiense is an acute epidemic disease (",
"      <a class=\"graphic graphic_table graphicRef85846 \" href=\"UTD.htm?20/16/20747\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleeping sickness occurs in approximately 30 sub-Saharan African countries, within the distribution of the tsetse fly. The occurrence of HAT in a region often reflects war, civil unrest, and lack of a reliable presence of state authority. There are about 60 million people at risk for infection (",
"      <a class=\"graphic graphic_figure graphicRef86653 \" href=\"UTD.htm?39/3/39986\">",
"       figure 1",
"      </a>",
"      ). Countries particularly affected include the Democratic Republic of Congo, South Sudan, Angola, and the Central African Republic (all of which have T. b. gambiense disease), Uganda (which has both T. b. gambiense and T. b. rhodesiense disease), and Tanzania (which has T. b. rhodesiense disease and exports the most cases). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Humans are the main reservoir for T. b. gambiense; this species can also be found in animals. Wild game animals are the main reservoir of T. b. rhodesiense. During a blood meal, an infected tsetse fly injects trypomastigotes into the host skin tissue (",
"      <a class=\"graphic graphic_figure graphicRef85844 \" href=\"UTD.htm?38/19/39224\">",
"       figure 3",
"      </a>",
"      ). A painful chancre (local inflammatory reaction) can develop at the site of inoculation. The parasites enter regional lymphatics and then disseminate widely in the bloodstream, where they differentiate to long, slender forms that can be seen on blood smear examination (",
"      <a class=\"graphic graphic_picture graphicRef85845 \" href=\"UTD.htm?22/49/23317\">",
"       picture 1",
"      </a>",
"      ). Trypomastigotes can pass into connective tissues and enter the cerebrospinal fluid (CSF) and the brain. (See",
"      <a class=\"local\" href=\"#H14020275\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T. brucei parasites can evade destruction by the mammalian host immune response by periodically switching their variant surface glycoprotein (VSG), a phenomenon known as antigenic variation. This results in characteristic waves of parasitemia during HAT infection. Trypanosomes express a different VSG during each successive wave of parasitemia and change their surface VSG each time the host begins to mount an effective immune response. In this way, the parasite is able to stay one step ahead of the host's humoral immune response. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no vaccine available for HAT. The two major tools to prevent transmission of infection are vector control and surveillance for T. b. gambiense infection, with early treatment of identified cases. The serologic test used most frequently for surveillance is the CATT (card agglutination test). Individuals with positive CATT should undergo lymph node aspiration and blood smear examination. Surveillance is not practical for control of T. b. rhodesiense infections. (See",
"      <a class=\"local\" href=\"#H2333238\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38681?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations, diagnosis, and treatment of African trypanosomiasis\", section on 'Antibody detection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H769228\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate Inc. would like to acknowledge Dr. Karin Leder and Dr. Peter Weller, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/1\">",
"      Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004; 113:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/2\">",
"      Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiases. Lancet 2003; 362:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/3\">",
"      Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/4\">",
"      Berriman M, Ghedin E, Hertz-Fowler C, et al. The genome of the African trypanosome Trypanosoma brucei. Science 2005; 309:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/5\">",
"      Pays E, Vanhollebeke B. Human innate immunity against African trypanosomes. Curr Opin Immunol 2009; 21:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/6\">",
"      Simarro PP, Cecchi G, Paone M, et al. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr 2010; 9:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/7\">",
"      Pepin J. Combination therapy for sleeping sickness: a wake-up call. J Infect Dis 2007; 195:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/8\">",
"      Smith DH, Pepin J, Stich AH. Human African trypanosomiasis: an emerging public health crisis. Br Med Bull 1998; 54:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/9\">",
"      Mhlanga JD. Sleeping sickness: perspectives in African trypanosomiasis. Sci Prog 1996; 79 ( Pt 3):183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/10\">",
"      Stich A, Abel PM, Krishna S. Human African trypanosomiasis. BMJ 2002; 325:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/11\">",
"      Barrett MP. The rise and fall of sleeping sickness. Lancet 2006; 367:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/12\">",
"      Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1998; 881:I.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/13\">",
"      Welburn SC, Odiit M. Recent developments in human African trypanosomiasis. Curr Opin Infect Dis 2002; 15:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/14\">",
"      Cattand P, Jannin J, Lucas P. Sleeping sickness surveillance: an essential step towards elimination. Trop Med Int Health 2001; 6:348.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Human African trypanosomiasis (sleeping sickness). Fact sheet 259. 2012. Available at: file://www.who.int/mediacentre/factsheets/fs259/en/ (Accessed on May 29, 2012).",
"    </li>",
"    <li>",
"     file://www.who.int/mediacentre/factsheets/fs259/en/ (Accessed on July 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/17\">",
"      Migchelsen SJ, B&uuml;scher P, Hoepelman AI, et al. Human African trypanosomiasis: a review of non-endemic cases in the past 20 years. Int J Infect Dis 2011; 15:e517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/18\">",
"      Sinha A, Grace C, Alston WK, et al. African trypanosomiasis in two travelers from the United States. Clin Infect Dis 1999; 29:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/19\">",
"      Ripamonti D, Massari M, Arici C, et al. African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers. Clin Infect Dis 2002; 34:E18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/20\">",
"      Moore DA, Edwards M, Escombe R, et al. African trypanosomiasis in travelers returning to the United Kingdom. Emerg Infect Dis 2002; 8:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/21\">",
"      Jelinek T, Bisoffi Z, Bonazzi L, et al. Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis 2002; 8:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/22\">",
"      Malvy D, Chappuis F. Sleeping sickness. Clin Microbiol Infect 2011; 17:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/23\">",
"      Lindner AK, Priotto G. The unknown risk of vertical transmission in sleeping sickness--a literature review. PLoS Negl Trop Dis 2010; 4:e783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/24\">",
"      Simon F, Mura M, Pag&egrave;s F, et al. Urban transmission of human African trypanosomiasis, Gabon. Emerg Infect Dis 2012; 18:165.",
"     </a>",
"    </li>",
"    <li>",
"     Pepin J, Donelson JE. African Trypanosomiasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 2nd ed, Guerrant R, Walker DH, Weller PF (Eds), Churchill Livingstone, Philadelphia 2006. Vol 2, p.1072.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/26\">",
"      Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003; 422:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/27\">",
"      P&eacute;rez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005; 309:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/28\">",
"      Vanhollebeke B, Truc P, Poelvoorde P, et al. Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. N Engl J Med 2006; 355:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/29\">",
"      Hajduk SL. Antigenic variation during the developmental cycle of Trypanosoma brucei. J Protozool 1984; 31:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/30\">",
"      Borst P, Rudenko G. Antigenic variation in African trypanosomes. Science 1994; 264:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/31\">",
"      Donelson JE. Antigenic variation and the African trypanosome genome. Acta Trop 2003; 85:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/32\">",
"      Donelson JE, Hill KL, El-Sayed NM. Multiple mechanisms of immune evasion by African trypanosomes. Mol Biochem Parasitol 1998; 91:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/33\">",
"      Truc P, Ravel S, Jamonneau V, et al. Genetic variability within Trypanosoma brucei gambiense: evidence for the circulation of different genotypes in human African trypanosomiasis patients in C&ocirc;te d'Ivoire. Trans R Soc Trop Med Hyg 2002; 96:52.",
"     </a>",
"    </li>",
"    <li>",
"     Pentreath VW, Kennedy PG. Pathogenesis of human African trypanosomiasis. In: The Trypanomiases, Mudlin I, Holmes PH, Miles MA.  (Eds), CABI Publishing, Reading, UK 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/35\">",
"      Chimelli L, Scaravilli F. Trypanosomiasis. Brain Pathol 1997; 7:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/36\">",
"      Khonde N, P&eacute;pin J, Niyonsenga T, et al. Epidemiological evidence for immunity following Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995; 89:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/37\">",
"      Vreysen MJ. Principles of area-wide integrated tsetse fly control using the sterile insect technique. Med Trop (Mars) 2001; 61:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/38\">",
"      Kabayo JP. Aiming to eliminate tsetse from Africa. Trends Parasitol 2002; 18:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/39\">",
"      Hursey BS. The programme against African trypanosomiasis: aims, objectives and achievements. Trends Parasitol 2001; 17:2.",
"     </a>",
"    </li>",
"    <li>",
"     Pan African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC). Available at: file://au.int/en/dp/rea/RO/PATTEC (Accessed on May 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13895/abstract/41\">",
"      Simarro PP, Diarra A, Ruiz Postigo JA, et al. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward. PLoS Negl Trop Dis 2011; 5:e1007.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5688 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13895=[""].join("\n");
var outline_f13_36_13895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2334564\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14020275\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Innate immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evasion of host defense",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2333238\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2333245\">",
"      Vector control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2333252\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2333259\">",
"      Advice for travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2334564\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H769228\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5688\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5688|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/3/39986\" title=\"figure 1\">",
"      HAT in endemic and nonendemic populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/19/28979\" title=\"figure 2\">",
"      Focal distribution of HAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/19/39224\" title=\"figure 3\">",
"      Life cycle African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5688|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/49/23317\" title=\"picture 1\">",
"      Blood smear African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/41/27289\" title=\"picture 2\">",
"      Maintaining tsetse trap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5688|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/9/18588\" title=\"table 1\">",
"      Treatment of HAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/16/20747\" title=\"table 2\">",
"      HAT species characteristics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38681?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_36_13896="Intraaortic balloon pump counterpulsation";
var content_f13_36_13896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intraaortic balloon pump counterpulsation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13896/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13896/contributors\">",
"     Roger J Laham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13896/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13896/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13896/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13896/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13896/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/36/13896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraaortic balloon pump counterpulsation (IABP) is one type of mechanical hemodynamic support, and it has emerged as the single most widely used circulatory assist device. It is used in a variety of clinical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiogenic shock (left ventricular failure or mechanical complications of an acute myocardial infarction)",
"     </li>",
"     <li>",
"      Intractable angina",
"     </li>",
"     <li>",
"      Low cardiac output after cardiopulmonary bypass",
"     </li>",
"     <li>",
"      Adjunctive therapy in high risk or complicated angioplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prophylaxis in patients with severe left main coronary arterial stenosis in whom surgery is pending [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intractable myocardial ischemia awaiting further therapy",
"     </li>",
"     <li>",
"      Refractory heart failure as a bridge to further therapy",
"     </li>",
"     <li>",
"      Intractable ventricular arrhythmias as a bridge to further therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The basic principles regarding use of the IABP are presented here. Its efficacy in different clinical conditions is discussed on the appropriate topic reviews. Use of other circulatory assist devices, the cardiopulmonary assist device and the left ventricular assist device, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98285519\">",
"    <span class=\"h1\">",
"     TECHNICAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intraaortic balloon counterpulsation system is composed of two principal parts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A flexible catheter with one lumen that allows for either distal",
"      <span class=\"nowrap\">",
"       aspiration/flushing",
"      </span>",
"      or pressure monitoring and a second that permits the periodic delivery and removal of helium gas to a closed balloon. The balloons are manufactured in sizes between 20 and 50 cc.",
"     </li>",
"     <li>",
"      A mobile console that contains the system for helium transfer as well as computer control of the inflation and deflation cycle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The catheter is inserted in most cases through a common femoral artery and advanced under fluoroscopic guidance such that the distal end is positioned in the proximal descending aorta, usually about one centimeter distal to the origin of the left subclavian artery. Alternative insertion sites, such as the right subclavian artery, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pumping is initiated and controlled by the console using input from both the aortic pressure and the electrocardiogram. Inflation occurs immediately after aortic valve closure and deflation just before aortic valve opening (",
"    <a class=\"graphic graphic_waveform graphicRef83420 \" href=\"UTD.htm?20/58/21418\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83948 \" href=\"UTD.htm?29/10/29861\">",
"     figure 1",
"    </a>",
"    ). Using software algorithms, current generation systems are capable of monitoring many aspects of both efficacy and safety, reducing the time required by health care personnel to directly supervise. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMODYNAMIC EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflation and deflation of the balloon has two major consequences:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood is displaced to the proximal aorta by inflation during diastole.",
"     </li>",
"     <li>",
"      Aortic volume (and thus afterload) is reduced during systole through a vacuum effect created by rapid balloon deflation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These effects may be quite variable, and they depend upon the volume of the balloon, its position in the aorta, heart rate, rhythm, the compliance of the aorta, and systemic resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/7\">",
"     7",
"    </a>",
"    ]. The higher the arterial elastance, which is determined in part by compliance, the greater the hemodynamic improvement from IABP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/8\">",
"     8",
"    </a>",
"    ]. Despite this variability, expected changes in the hemodynamic profile in the majority of patients with cardiogenic shock include (",
"    <a class=\"graphic graphic_figure graphicRef83421 \" href=\"UTD.htm?37/56/38786\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A decrease in systolic pressure by 20 percent",
"     </li>",
"     <li>",
"      An increase in aortic diastolic pressure by 30 percent, which may raise coronary blood flow to territory perfused by a vessel with a critical stenosis",
"     </li>",
"     <li>",
"      An increase in mean arterial pressure especially in patients with shock due to an acute mechanical abnormality such as mitral regurgitation (MR) or ventricular septal defect (VSD).",
"     </li>",
"     <li>",
"      A reduction of the heart rate by less than 20 percent",
"     </li>",
"     <li>",
"      A decrease in the mean pulmonary capillary wedge pressure by 20 percent",
"     </li>",
"     <li>",
"      An elevation in the cardiac output by 20 percent, especially in patients with MR, VSD, or a large territory of medically refractory ischemia that is improved by the addition of counterpulsation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, intraaortic balloon pumping reduces mean systemic impedance and developed systolic pressure, and causes a 14 percent decline in calculated peak left ventricular wall stress [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/10\">",
"     10",
"    </a>",
"    ]. The reductions in afterload and wall stress lead to a fall in myocardial oxygen consumption, which is one of the goals of treatment of patients with myocardial ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\", section on 'Pathophysiology of angina'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effects on coronary artery blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IABP has a variable effect on total coronary blood flow. Some studies have found little or no change in coronary blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], while others noted a significant augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased blood flow is most likely to occur in coronary vascular beds maximally dilated by ischemia, a setting in which autoregulation is at a maximal level and flow becomes pressure-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ]. As an example, autoregulation of the peripheral coronary bed tends to maintain flow across a stenotic area until the severity of the stenosis is sufficient to produce a distal perfusion pressure of 40 to 50 mmHg. At lower pressures, autoregulation is maximal and coronary flow to the territory affected by the stenosis cannot be maintained. Counterpulsation is able to enhance blood flow to these areas via an increase in perfusion pressure.",
"   </p>",
"   <p>",
"    Another determinant of the coronary blood flow response to IABP is the severity of the coronary stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. One report, for example, found no improvement in distal to critical stenoses (95 percent diameter narrowing) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/15\">",
"     15",
"    </a>",
"    ]. There was, however, a significant increase in flow after successful angioplasty (mean diameter narrowing 18 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consequent to the improvement in hemodynamic parameters described above, the IABP may be an effective temporary therapeutic option in patients with significant hemodynamic compromise resulting from myocardial ischemia.",
"   </p>",
"   <p>",
"    However, some patients with hemodynamic instability may require other percutaneous support due to IABP failure or as initial therapy. For example, an axial flow pump or a percutaneous left atrial-to-femoral arterial ventricular assist device may be appropriate for patients with low output states or shock when an IABP is deemed unlikely to provide adequate support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Refractory myocardial ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraaortic balloon pumping reduces electrocardiographic ST-segment abnormalities in patients with acute coronary syndromes, and is effective in the treatment of angina unresponsive to medical therapy that cannot be treated promptly with PCI or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, the availability of effective medical therapy and prompt revascularization has all but eliminated this indication. Rarely, patients with surgical disease and persistent ischemia do require IABP support pending surgery. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraaortic balloon counterpulsation alone is effective hemodynamically in patients with cardiogenic shock resulting from an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/9,19\">",
"     9,19",
"    </a>",
"    ], and it is useful as a bridge to definitive therapy. The use of IABP in patients in this setting is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H24#H24\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Intraaortic balloon pump'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     High-risk PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic intraaortic balloon pumping has been advocated to improve outcomes in both stable patients and patients with acute coronary syndromes undergoing high-risk or complicated percutaneous coronary intervention (PCI) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/3,4,20,21\">",
"     3,4,20,21",
"    </a>",
"    ]. Such recommendations have been based on the results of small, observational studies that were subject to selection bias and which were carried out before stenting and aggressive antiplatelet therapies were routine.",
"   </p>",
"   <p>",
"    However, the elective placement of an IABP was not found to improve outcomes in the BCIS-1 trial in which 301 high-risk patients were randomly assigned to either elective insertion of IABP before PCI or not [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/22\">",
"     22",
"    </a>",
"    ]. High risk was defined as severe left ventricular dysfunction (left ventricular ejection fraction &le;30 percent; mean = 24 percent) and complex, multivessel coronary artery disease. Rescue placement of an IABP was allowed in the no planned IABP group for procedural complications of prolonged hypotension, pulmonary edema, or refractory ventricular arrhythmias.",
"   </p>",
"   <p>",
"    There was no significant difference in the occurrence of the primary endpoint of major adverse cardiovascular and cerebral events (death, acute myocardial infarction, cerebrovascular event, or further revascularization) at 28 days (15.2 and 16.0 percent respectively; odds ratio 0.94, 95% CI 0.51-1.76). Cross-over from no IABP to IABP placement occurred in 12 percent. However, after a median follow-up of 51 months, all-cause mortality was lower among those who received an IABP (28 versus 39 percent; hazard ratio 0.66, 95% CI 0.40-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/23\">",
"     23",
"    </a>",
"    ]. The Kaplan-Meier curves appear to continue to diverge at five years.",
"   </p>",
"   <p>",
"    Based on the results of BCIS-1, we suggest not routinely placing an IABP electively before PCI in high-risk (as defined in BCIS-1) patients. However, placement of an IABP prior to PCI is potentially of benefit in those patients who are hemodynamically unstable before the procedure, or those who are judged highly likely to become unstable during the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary PCI for acute MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IABP is not routinely used in patients undergoing primary percutaneous coronary intervention. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link&amp;anchor=H1365940#H1365940\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Intraaortic balloon counterpulsation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14519700\">",
"    <span class=\"h2\">",
"     Refractory ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IABP can contribute to the management of medically refractory ventricular tachycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular fibrillation in selected patients. This includes those with severely impaired left ventricular function and those in whom the arrhythmia compromises hemodynamic status and for whom the IABP may provide time to implement appropriate therapy. As an example, one study of 21 patients found that the IABP suppressed the arrhythmia in 18; 13 of these patients were successfully weaned from the IABP, while in five the IABP was maintained until cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14519765\">",
"    <span class=\"h2\">",
"     Refractory heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IABP has been used as a bridge to the long-term management of refractory heart failure. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of refractory heart failure\", section on 'Mechanical circulatory support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other potential uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other possible indications for IABP include mechanical complications of acute myocardial infarction such as acute ventricular septal defect and mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/25\">",
"     25",
"    </a>",
"    ], inability to wean from cardiopulmonary bypass support [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/26\">",
"     26",
"    </a>",
"    ], and",
"    <span class=\"nowrap\">",
"     severe/critical",
"    </span>",
"    aortic stenosis in patients scheduled to under aortic valve replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=see_link&amp;anchor=H9#H9\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\", section on 'Low cardiac output'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41654?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical management of symptomatic aortic stenosis\", section on 'Patients awaiting valve replacement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"     \"Mechanical complications of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prophylactic placement of an IABP prior to CABG has been performed in patients with left main coronary artery stenosis, severely depressed left ventricular systolic function, diffuse coronary artery disease, and redo surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/5\">",
"     5",
"    </a>",
"    ]. A 2010 Cochrane systematic review of six randomized trials (five on-and one off-pump) of preoperative IABP placement concluded that IABP placement might be beneficial in high-risk patients based on the finding of a significantly lower rate of in-hospital death in patients treated with IABP compared to those not (odds ratio 0.18) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/27\">",
"     27",
"    </a>",
"    ]. However, the evidence was felt to be weak due to concerns for the quality, validity, and generalizability of the trials.",
"   </p>",
"   <p>",
"    The 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on bypass surgery concluded that prophylactic IABP placement prior to CABG is probably indicated in patients with evidence of ongoing ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reduced cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98284197\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on ST elevation MI made the following recommendations, which were not changed in the 2009 focused update, for the use of IABP in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/17,29\">",
"     17,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiogenic shock that is not quickly reversed with pharmacologic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute mitral regurgitation, particularly due to papillary muscle rupture, or ventricular septal rupture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"       \"Mechanical complications of acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent ischemic chest discomfort with signs of hemodynamic instability, poor left ventricular function, or a large area of myocardium at risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the last three settings, the use of an IABP was considered to be beneficial both for hemodynamic support and as a stabilizing measure for angiography and prompt revascularization.",
"   </p>",
"   <p>",
"    The evidence was considered less well established for the use of an IABP in patients with refractory pulmonary congestion but many such patients will have one of the above indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions are contraindications to IABP insertion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant (more than mild) aortic regurgitation since the degree of aortic regurgitation will be increased by counterpulsation (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"       \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=see_link\">",
"       \"Echocardiographic evaluation of the aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aortic dissection or clinically significant aortic aneurysm (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"       \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link\">",
"       \"Management of asymptomatic abdominal aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Uncontrolled sepsis",
"     </li>",
"     <li>",
"      Uncontrolled bleeding disorder",
"     </li>",
"     <li>",
"      Severe peripheral artery disease that cannot be pretreated with stenting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insertion can be carried out in patients with aorto-bifemoral bypass grafts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with the IABP may be divided into vascular and nonvascular events. In the above review of almost 17,000 patients who had an IABP inserted from 1996 to 2000, the incidence of any complication was 7 percent, while major complications (major acute limb ischemia, severe bleeding, balloon leak, death related directly to the IABP insertion or IABP failure) occurred in 2.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/2\">",
"     2",
"    </a>",
"    ]. The in-hospital mortality was 21 percent, one-half of which occurred while the IABP was in place. IABP-related mortality was only 0.5 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular complications (occurring in six to 25 percent of cases) remain the major risk associated with intraaortic balloon pumping [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The most common major complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limb (and visceral) ischemia",
"     </li>",
"     <li>",
"      Vascular laceration necessitating surgical repair",
"     </li>",
"     <li>",
"      Major hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important that the IABP be inserted into the common femoral artery rather than one of its branches (eg, the superficial or profunda femoral artery). Neither of the branches is generally large enough to permit insertion without producing arterial obstruction and limb ischemia. Improper insertion from a needle puncture which is too low is the most common cause of ischemic complications during IABP, and will often require removal of the IABP and contralateral insertion.",
"   </p>",
"   <p>",
"    Arterial dissection is most often due to improper advancement of the guidewire with subsequent insertion of the IABP into a false lumen. The balloon may function normally in this position. Dissection may be diagnosed by ultrasonography and requires immediate balloon removal.",
"   </p>",
"   <p>",
"    Less common vascular complications, due to IABP compromise of perfusion, include spinal cord ischemia and visceral ischemia (including renal ischemia). In one study of 63 cardiac surgical patients who underwent IABP placement and who received both chest radiography and a computerized tomographic (CT) imaging study, the balloon was correctly positioned in only 62 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/33\">",
"     33",
"    </a>",
"    ]. In 61 patients, compromise of at least one visceral artery was found by CT; this was attributable to use of a balloon with a length longer than optimal for the patient&rsquo;s anatomy in about 68 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/26,30-32,34-39\">",
"     26,30-32,34-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholesterol embolization is an infrequent occurrence that may result in limb loss [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/35\">",
"       35",
"      </a>",
"      ]. This complication should be suspected in patients with thrombocytopenia, livedo reticularis, eosinophilia, and, with renal atheroemboli, eosinophils in the urine sediment. Chronic anticoagulation may be detrimental in this setting, promoting further embolization [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/36\">",
"       36",
"      </a>",
"      ]. IABP should be removed in the presence of diagnosed or suspected cholesterol embolization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"       \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebrovascular accident is a rare complication of IABP, since the balloon is normally positioned distal to the left subclavian artery. Cerebral ischemia only occurs when the IABP has been placed too proximally or has accidentally migrated proximally, or the central balloon lumen has been flushed vigorously and dislodged a thrombus.",
"     </li>",
"     <li>",
"      Sepsis is uncommon unless counterpulsation continues for more than seven days. This observation suggests that infections can be minimized by meticulous attention to sterile technique, analogous to the care given to parenteral nutrition lines [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"       \"Prevention of intravascular catheter-related infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Balloon rupture is an uncommon event, and is generally related to the balloon pumping against a calcified plaque. Rupture may be followed by thrombus formation within the balloon, which may complicate removal [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/38\">",
"       38",
"      </a>",
"      ]. In order to prevent helium gas embolization from the IABP, the balloon console will withdraw helium from the balloon and shut down the system with an alarm when it detects a loss of pressure.",
"     </li>",
"     <li>",
"      Additional complications include a fall in platelet count, hemolysis, seromas, groin infection, and peripheral neuropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Factors increasing IABP complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors are associated with an increase in the probability of vascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/2,26,39-42\">",
"     2,26,39-42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Prolonged support",
"     </li>",
"     <li>",
"      Larger catheter size (&gt;9.5 French)",
"     </li>",
"     <li>",
"      Body surface area &lt;1.8 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Cardiac index &lt;2.2",
"      <span class=\"nowrap\">",
"       L/min/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The higher complication rate in women is most likely related to the size of the iliac and femoral arteries. Patients with diabetes and hypertension suffer more vascular complications due to an increased incidence of peripheral arterial disease.",
"   </p>",
"   <p>",
"    Clinical expertise is likely important. In an analysis from the National Registry of Myocardial Infarction-2 (NRMI-2) in which 12,771 patients with an acute MI complicated by cardiogenic shock underwent IABP placement, the mortality rate was significantly higher in hospitals with a low volume of IABP insertions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Factors decreasing IABP complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are associated with a decreased incidence of complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sheathless technique [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/26,39,44,45\">",
"       26,39,44,45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Smaller balloon size [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13896/abstract/26,39\">",
"       26,39",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14518232\">",
"    <span class=\"h2\">",
"     Routine care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following routine care measures likely decrease complication rates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A chest x-ray should be obtained after initial insertion and daily to document the position of the catheter tip, which should be at the level of bifurcation of left and right main bronchi.",
"     </li>",
"     <li>",
"      Documentation of the distal pulses should occur before, after, and three times every day.",
"     </li>",
"     <li>",
"      The pressure wave form should be evaluated by a practitioner knowledgeable with the use of the system twice daily.",
"     </li>",
"     <li>",
"      Daily measurement of the hematocrit, platelet count, and creatinine.",
"     </li>",
"     <li>",
"      Anticoagulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraaortic balloon pump (IABP) counterpulsation is the most widely used and simplest to deploy circulatory assist device used in hemodynamically unstable patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"       \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Expected changes in the hemodynamic profile in the majority of patients with cardiogenic shock include: a decrease in systolic pressure; an increase in diastolic pressure, which may raise coronary blood flow to territory perfused by a vessel with a critical stenosis; a reduction of the heart rate; a decrease in the mean pulmonary capillary wedge pressure; and an elevation in the cardiac output. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hemodynamic effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common and widely accepted indications for IABP include: hypotension (systolic blood pressure less than 90 mmHg or 30 mmHg below baseline mean arterial pressure) of cardiac origin that is not responsive to other interventions; cardiogenic shock that is not quickly reversed with pharmacologic therapy; and acute mitral regurgitation, particularly due to papillary muscle rupture, or ventricular septal rupture. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In patients scheduled to undergo revascularization:",
"     </li>",
"     <li>",
"      We suggest not routinely placing an IABP even in high-risk patients with planned percutaneous coronary intervention (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). High risk is defined as those with a left ventricular ejection fraction &le;30 percent and complex multivessel coronary artery disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'High-risk PCI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest placing an IABP in patients with recurrent ischemic chest discomfort who have signs of hemodynamic instability in whom revascularization with either percutaneous coronary intervention or coronary artery bypass surgery is planned (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Refractory myocardial ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contraindications to IABP insertion include: significant (more than mild) aortic regurgitation, abdominal aortic aneurysm or aortic dissection, uncontrolled sepsis, uncontrolled bleeding disorder, and severe untreated bilateral peripheral vascular disease that cannot be pretreated with stenting. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common and potentially life threatening complications include: limb and renal ischemia; vascular laceration necessitating surgical repair; major hemorrhage; and cerebrovascular accident. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/1\">",
"      Santa-Cruz RA, Cohen MG, Ohman EM. Aortic counterpulsation: a review of the hemodynamic effects and indications for use. Catheter Cardiovasc Interv 2006; 67:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/2\">",
"      Ferguson JJ 3rd, Cohen M, Freedman RJ Jr, et al. The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. J Am Coll Cardiol 2001; 38:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/3\">",
"      Ishihara M, Sato H, Tateishi H, et al. Intraaortic balloon pumping as the postangioplasty strategy in acute myocardial infarction. Am Heart J 1991; 122:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/4\">",
"      Lincoff AM, Popma JJ, Ellis SG, et al. Percutaneous support devices for high risk or complicated coronary angioplasty. J Am Coll Cardiol 1991; 17:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/5\">",
"      Rajai HR, Hartman CW, Innes BJ, et al. Prophylactic use of intra-aortic ballon pump in aortocoronary bypass for patients with left main coronary artery disease. Ann Surg 1978; 187:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/6\">",
"      Raman J, Loor G, London M, Jolly N. Subclavian artery access for ambulatory balloon pump insertion. Ann Thorac Surg 2010; 90:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/7\">",
"      Weber KT, Janicki JS. Intraaortic balloon counterpulsation. A review of physiological principles, clinical results, and device safety. Ann Thorac Surg 1974; 17:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/8\">",
"      Marchionni N, Fumagalli S, Baldereschi G, et al. Effective arterial elastance and the hemodynamic effects of intraaortic balloon counterpulsation in patients with coronary heart disease. Am Heart J 1998; 135:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/9\">",
"      Scheidt S, Wilner G, Mueller H, et al. Intra-aortic balloon counterpulsation in cardiogenic shock. Report of a co-operative clinical trial. N Engl J Med 1973; 288:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/10\">",
"      Urschel CW, Eber L, Forrester J, et al. Alteration of mechanical performance of the ventricle by intraaortic balloon counterpulsation. Am J Cardiol 1970; 25:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/11\">",
"      Port SC, Patel S, Schmidt DH. Effects of intraaortic balloon counterpulsation on myocardial blood flow in patients with severe coronary artery disease. J Am Coll Cardiol 1984; 3:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/12\">",
"      Williams DO, Korr KS, Gewirtz H, Most AS. The effect of intraaortic balloon counterpulsation on regional myocardial blood flow and oxygen consumption in the presence of coronary artery stenosis in patients with unstable angina. Circulation 1982; 66:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/13\">",
"      Mueller H, Ayres SM, Conklin EF, et al. The effects of intra-aortic counterpulsation on cardiac performance and metabolism in shock associated with acute myocardial infarction. J Clin Invest 1971; 50:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/14\">",
"      Kern MJ, Aguirre FV, Tatineni S, et al. Enhanced coronary blood flow velocity during intraaortic balloon counterpulsation in critically ill patients. J Am Coll Cardiol 1993; 21:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/15\">",
"      Kern MJ, Aguirre F, Bach R, et al. Augmentation of coronary blood flow by intra-aortic balloon pumping in patients after coronary angioplasty. Circulation 1993; 87:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/16\">",
"      Ishihara M, Sato H, Tateishi H, et al. Effects of intraaortic balloon pumping on coronary hemodynamics after coronary angioplasty in patients with acute myocardial infarction. Am Heart J 1992; 124:1133.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/18\">",
"      Weintraub RM, Voukydis PC, Aroesty JM, et al. Treatment of preinfarction angina with intraaortic balloon counterpulsation and surgery. Am J Cardiol 1974; 34:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/19\">",
"      Flaherty JT, Becker LC, Weiss JL, et al. Results of a randomized prospective trial of intraaortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarction. J Am Coll Cardiol 1985; 6:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/20\">",
"      Mishra S, Chu WW, Torguson R, et al. Role of prophylactic intra-aortic balloon pump in high-risk patients undergoing percutaneous coronary intervention. Am J Cardiol 2006; 98:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/21\">",
"      Brodie BR, Stuckey TD, Hansen C, Muncy D. Intra-aortic balloon counterpulsation before primary percutaneous transluminal coronary angioplasty reduces catheterization laboratory events in high-risk patients with acute myocardial infarction. Am J Cardiol 1999; 84:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/22\">",
"      Perera D, Stables R, Thomas M, et al. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. JAMA 2010; 304:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/23\">",
"      Perera D, Stables R, Clayton T, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation 2013; 127:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/24\">",
"      Fotopoulos GD, Mason MJ, Walker S, et al. Stabilisation of medically refractory ventricular arrhythmia by intra-aortic balloon counterpulsation. Heart 1999; 82:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/25\">",
"      Gold HK, Leinbach RC, Sanders CA, et al. Intraaortic balloon pumping for ventricular septal defect or mitral regurgitation complicating acute myocardial infarction. Circulation 1973; 47:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/26\">",
"      Eltchaninoff H, Dimas AP, Whitlow PL. Complications associated with percutaneous placement and use of intraaortic balloon counterpulsation. Am J Cardiol 1993; 71:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/27\">",
"      Theologou T, Bashir M, Rengarajan A, et al. Preoperative intra aortic balloon pumps in patients undergoing coronary artery bypass grafting. Cochrane Database Syst Rev 2011; :CD004472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/28\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/29\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/30\">",
"      Barnett MG, Swartz MT, Peterson GJ, et al. Vascular complications from intraaortic balloons: risk analysis. J Vasc Surg 1994; 19:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/31\">",
"      Funk M, Ford CF, Foell DW, et al. Frequency of long-term lower limb ischemia associated with intraaortic balloon pump use. Am J Cardiol 1992; 70:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/32\">",
"      Patel JJ, Kopisyansky C, Boston B, et al. Prospective evaluation of complications associated with percutaneous intraaortic balloon counterpulsation. Am J Cardiol 1995; 76:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/33\">",
"      Rastan AJ, Tillmann E, Subramanian S, et al. Visceral arterial compromise during intra-aortic balloon counterpulsation therapy. Circulation 2010; 122:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/34\">",
"      Anderson RD, Ohman EM, Holmes DR Jr, et al. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/35\">",
"      Alderman JD, Gabliani GI, McCabe CH, et al. Incidence and management of limb ischemia with percutaneous wire-guided intraaortic balloon catheters. J Am Coll Cardiol 1987; 9:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/36\">",
"      Hyman BT, Landas SK, Ashman RF, et al. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987; 82:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/37\">",
"      Aksnes J, Abdelnoor M, Berge V, Fjeld NB. Risk factors of septicemia and perioperative myocardial infarction in a cohort of patients supported with intra-aortic balloon pump (IABP) in the course of open heart surgery. Eur J Cardiothorac Surg 1993; 7:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/38\">",
"      Aru GM, King JT Jr, Hovaguimian H, et al. The entrapped balloon: report of a possibly serious complication. J Thorac Cardiovasc Surg 1986; 91:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/39\">",
"      Tatar H, Ci&ccedil;ek S, Demirkilic U, et al. Vascular complications of intraaortic balloon pumping: unsheathed versus sheathed insertion. Ann Thorac Surg 1993; 55:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/40\">",
"      Gottlieb SO, Brinker JA, Borkon AM, et al. Identification of patients at high risk for complications of intraaortic balloon counterpulsation: a multivariate risk factor analysis. Am J Cardiol 1984; 53:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/41\">",
"      Scholz KH, Ragab S, von zur M&uuml;hlen F, et al. Complications of intra-aortic balloon counterpulsation. The role of catheter size and duration of support in a multivariate analysis of risk. Eur Heart J 1998; 19:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/42\">",
"      Cohen M, Dawson MS, Kopistansky C, McBride R. Sex and other predictors of intra-aortic balloon counterpulsation-related complications: prospective study of 1119 consecutive patients. Am Heart J 2000; 139:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/43\">",
"      Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 2003; 108:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/44\">",
"      Erdogan HB, Goksedef D, Erentug V, et al. In which patients should sheathless IABP be used? An analysis of vascular complications in 1211 cases. J Card Surg 2006; 21:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13896/abstract/45\">",
"      Meharwal ZS, Trehan N. Vascular complications of intra-aortic balloon insertion in patients undergoing coronary reavscularization: analysis of 911 cases. Eur J Cardiothorac Surg 2002; 21:741.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1482 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13896=[""].join("\n");
var outline_f13_36_13896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98285519\">",
"      TECHNICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMODYNAMIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effects on coronary artery blood flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Refractory myocardial ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      High-risk PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary PCI for acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14519700\">",
"      Refractory ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14519765\">",
"      Refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other potential uses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98284197\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Factors increasing IABP complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Factors decreasing IABP complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14518232\">",
"      Routine care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1482\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1482|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/10/29861\" title=\"figure 1\">",
"      Intra-aortic balloon inflation and deflation timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/56/38786\" title=\"figure 2\">",
"      Intraaortic balloon pressure tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1482|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/58/21418\" title=\"waveform 1\">",
"      Timing of intraaortic balloon pump inflation and deflation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=related_link\">",
"      Echocardiographic evaluation of the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41654?source=related_link\">",
"      Medical management of symptomatic aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_36_13897="Treatment of ampullary adenomas";
var content_f13_36_13897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of ampullary adenomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13897/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13897/contributors\">",
"     John A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13897/contributors\">",
"     Gregory B Haber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13897/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13897/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/36/13897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign neoplasms of the ampulla of Vater are rare. They represent less than 10 percent of periampullary neoplasms, the majority of which are malignant tumors arising from the duodenum, ampulla, or pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The most common benign lesions are villous and tubulovillous adenomas; others include hemangiomas, leiomyomas, leiomyofibromas, lipomas, lymphangiomas, and neurogenic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although classified as benign, ampullary adenomas have the potential to undergo malignant transformation to ampullary carcinomas, similar to the adenoma-to-carcinoma sequence that occurs elsewhere in the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/1,5-13\">",
"     1,5-13",
"    </a>",
"    ]. As a result, their clinical significance extends beyond the need to treat any associated symptoms.",
"   </p>",
"   <p>",
"    Ampullary adenomas can occur sporadically or in the setting of familial polyposis syndromes, such as familial adenomatous polyposis (FAP) and its related conditions. Approximately 40 to 100 percent of patients with ampullary adenomas in the setting of FAP have coexisting duodenal adenomatous polyps, which are frequently numerous and also have malignant potential [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of ampullary adenomas has been estimated to be 0.04 to 0.12 percent in autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/5,19,20\">",
"     5,19,20",
"    </a>",
"    ]. However, they are being increasingly recognized premortem with the extensive availability of flexible endoscopy and the widespread application of screening and surveillance programs for high-risk patients, such as those with FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/7,14,16,18,21\">",
"     7,14,16,18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of ampullary adenomas will be reviewed here. The clinical manifestations and diagnosis of ampullary adenomas and carcinomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26950?source=see_link\">",
"     \"Clinical manifestations and diagnosis of ampullary adenomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with an ampullary adenoma have three options for definitive management: pancreaticoduodenectomy, surgical local excision, or endoscopic ampullectomy. They also have the option to forego excision and undergo close endoscopic surveillance.",
"   </p>",
"   <p>",
"    Radical surgical excision has traditionally been advocated for all ampullary adenomas. The rationale for this approach was based upon the need to relieve symptoms, the recognition that it is difficult to exclude a focus of carcinoma within the adenoma, and the malignant potential of the adenoma. However, with the development of less morbid local surgical and endoscopic procedures, the decision regarding treatment must be made on a case-by-case basis.",
"   </p>",
"   <p>",
"    Factors to consider in deciding on an endoscopic or surgical approach include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgery is preferred for high-grade dysplasia or carcinoma on preprocedural biopsies, for lymph node involvement on preprocedural imaging, and for larger adenomas",
"     </li>",
"     <li>",
"      Age and comorbid illnesses may affect fitness for surgery",
"     </li>",
"     <li>",
"      Local experience and expertise with the various procedures",
"     </li>",
"     <li>",
"      Patient preference",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The influence of these factors is discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sporadic ampullary adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of benign ampullary neoplasms or those containing intramucosal foci of dysplasia is unclear. While these lesions have traditionally been managed with surgery, including pancreaticoduodenectomy, less radical surgical approaches have been advocated. As an example, surgical ampullectomy has experienced resurgent interest as a potentially less morbid option, although most series have included only a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/8,11,18,22-38\">",
"     8,11,18,22-38",
"    </a>",
"    ]. More recently, endoscopic excision and thermal ablation have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. No controlled trials have compared these approaches directly. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Surgical approaches and outcomes'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Endoscopic approaches and outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some authors have suggested that endoscopic resection may be reasonable for tumors less than 4 to 4.5 cm in largest dimension with no evidence of intraductal growth or malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/40,42,43\">",
"     40,42,43",
"    </a>",
"    ]. However, one study found that adenomas with high-grade dysplasia or cancer were on average 1.8 and 2.0 cm, respectively, whereas those with low-grade dysplasia were 1.3 cm on average [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/44\">",
"     44",
"    </a>",
"    ]. These results led the authors of the study to suggest surgical management for adenomas that are more than 1.5 cm. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Initial assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similar results were noted in a second study in which benign ampullary masses had a median diameter of 1.3, whereas adenocarcinomas had a mean diameter of 2.0 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Familial polyposis syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The controversy regarding resection techniques is further complicated in patients with familial polyposis syndromes, such as familial adenomatous polyposis (FAP). These patients can have multiple upper intestinal adenomas; thus, complete excision of the ampullary adenoma does not eliminate the risk of upper gastrointestinal tract cancer. Fortunately, the risk of histologic progression of upper gastrointestinal tract adenomas in patients with FAP appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest studies to evaluate the issue of histologic progression included 114 patients undergoing surveillance endoscopy for FAP. They were followed for a mean of 51 months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/47\">",
"     47",
"    </a>",
"    ]. Duodenal polyps progressed in size in 26 percent, increased in number in 32 percent, and showed histologic progression in 11 percent. The histologic progression was mild, except in one patient who developed a periampullary cancer.",
"   </p>",
"   <p>",
"    These observations prompted some experts to advocate surveillance endoscopy with biopsies, rather than excision, for ampullary adenomas in patients with FAP as long as the polyp has a normal endoscopic appearance and is without dysplasia on biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/14\">",
"     14",
"    </a>",
"    ]. The benefit of this approach is that it avoids the risks of surgical or endoscopic excision or ablation in patients with no or minimal histologic progression.",
"   </p>",
"   <p>",
"    One problem with endoscopic surveillance is that endoscopic forceps biopsies may miss occult foci of carcinoma within ampullary adenomas. In a study of 33 patients with ampullary adenomas (though not necessarily with FAP), 29 had biopsies of the adenoma prior to either endoscopic resection or surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/44\">",
"     44",
"    </a>",
"    ]. Carcinoma was found at the time of resection in 5 of the 10 patients with high-grade dysplasia on biopsy, and 3 of the 19 patients with low-grade dysplasia on biopsy. This lack of sensitivity and concordance between forceps biopsies and surgical excision pathology is supported by other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of these issues, the management of patients with FAP and ampullary adenomas is decided on a case-by-case basis, taking into consideration the patient's general health and medical comorbidities, life expectancy, technical amenability to endoscopic excision or ablation, and the patient's wishes and risk tolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ampullary carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreaticoduodenectomy (\"Whipple\" or \"Kausch-Whipple\" procedure) or pylorus-preserving pancreaticoduodenectomy is the treatment of choice for frank carcinoma, which many experts consider to include lesions demonstrating adenoma with high-grade dysplasia or foci of carcinoma in situ on pre-excisional biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/18,22,44,50-52\">",
"     18,22,44,50-52",
"    </a>",
"    ]. However, small series have demonstrated technical success in endoscopic excision of focal, low-grade, early-stage T1 ampullary adenocarcinoma (",
"    <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible role of adjuvant therapy for ampullary carcinoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3674?source=see_link&amp;anchor=H19#H19\">",
"     \"Ampullary carcinoma: Treatment and prognosis\", section on 'Adjuvant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SURGICAL APPROACHES AND OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete excision remains the only method to eliminate the risk of histologic progression and exclude foci of carcinoma within the adenoma, but carries with it significant morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pancreaticoduodenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreaticoduodenectomy is considered to be the definitive approach for achieving curative resection of ampullary adenomas. A major advantage compared to less aggressive approaches is that it eliminates the risk of local recurrence in patients who do not have familial adenomatous polyposis (FAP) or who harbor occult adenocarcinoma. It also eliminates the need for surveillance endoscopy in patients with sporadic adenomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43721?source=see_link\">",
"     \"Pancreaticoduodenectomy (Whipple procedure): Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of a radical regional resection, such as pancreaticoduodenectomy, recurrence rates for local ampullary adenomas (ie, adenomas that are not found to harbor carcinoma) approach zero.",
"   </p>",
"   <p>",
"    The major disadvantages of this approach are largely related to the higher postoperative morbidity and mortality rates compared to local therapies. Data from multiple series of pancreaticoduodenectomy performed for benign and malignant ampullary tumors demonstrated an operative mortality rate of 0 to 10 percent and operative morbidity of 25 to 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/18,25,32,35,37,41,50-52,56-60\">",
"     18,25,32,35,37,41,50-52,56-60",
"    </a>",
"    ]. Perioperative mortality rates were lowest (less than 4 percent) in centers with a high procedure volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Perioperative morbidity and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Local surgical excision (ampullectomy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to a high rate of tumor recurrence, local surgical excision initially failed to achieve wide acceptance. More recently, interest has been renewed due to a greater appreciation of the morbidity and mortality associated with radical resection and a better understanding of the natural history of ampullary adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Choice of treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of technical variations of surgical ampullectomy have evolved. Most entail mobilization of the duodenum and longitudinal duodenotomy, followed either by simple excision of the ampullary neoplasm or an extended excision, involving the ampulla and also adjacent duodenal and ductal tissue. The latter approach typically requires operative reconstruction of the biliary and pancreatic ducts using a sphincteroplasty technique [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/29,34,61,62\">",
"     29,34,61,62",
"    </a>",
"    ]. A laparoscopic variant has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials comparing local excision and pancreaticoduodenectomy have not been performed. The available data come from small, heterogeneous studies whose results may reflect selection bias, since patients with smaller neoplasms may have been more likely to undergo local resection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, almost without exception, the pancreaticoduodenectomy results have been reported with ampullary neoplasms grouped together simply as \"ampullary tumors,\" without a distinction being made between ampullary adenomas and ampullary carcinomas.",
"   </p>",
"   <p>",
"    The available data suggest that local resection is associated with lower morbidity and perioperative mortality compared to radical excision. This was demonstrated in a series of 38 patients who had undergone ampullary resection or pancreaticoduodenectomy for benign and malignant ampullary neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/64\">",
"     64",
"    </a>",
"    ]. Compared to pancreaticoduodenectomy, ampullary resection was associated with significantly shorter operating room time (169 versus 268 minutes), less blood loss (192 versus 727 mL), shorter hospital length of stay (10 versus 25 days), and lower overall morbidity (29 versus 78 percent).",
"   </p>",
"   <p>",
"    The decreased morbidity and perioperative mortality must be balanced against a higher recurrence rate and the potential for inadequate excisional margins, which may be a particular problem if an occult carcinoma is found in the operative specimen. Recurrence rates for local surgical excision range from 0 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/3,8,11,18,29,32,34,64,65\">",
"     3,8,11,18,29,32,34,64,65",
"    </a>",
"    ] and 35 to 60 percent of ampullary adenomas harbor small foci of adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/10,44,64-67\">",
"     10,44,64-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the higher risk of recurrence, patients treated with local resection should undergo surveillance endoscopy. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC APPROACHES AND OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Endoscopic excision and ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acceptable morbidity, mortality, and recurrence rates associated with local surgical excision prompted efforts to develop an analogous endoscopic procedure that was even less invasive and morbid. The resulting intervention, known as endoscopic ampullectomy or endoscopic papillectomy, was first described in the late 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/39,41,68,69\">",
"     39,41,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of endoscopic excision remains controversial and it is generally performed only in referral centers with expertise in interventional endoscopy. However, at least one series from a referral center suggests that endoscopic excision has similar efficacy compared with surgical ampullectomy with lower morbidity rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of endoscopy in ampullary and duodenal adenomas was reviewed in a guideline statement published by the American Society for Gastrointestinal Endoscopy in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/71\">",
"     71",
"    </a>",
"    ]. The following discussion is largely consistent with the guideline recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in patients being considered for endoscopic excision is a diagnostic endoscopy to look for signs of malignancy. These include induration, ulceration, and submucosal tumor extension. If there is evidence of malignancy, patients should be referred for surgical resection. Adenoma ingrowth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolapse of the biliary or pancreatic ducts do not necessarily imply malignancy, but make endoscopic excision more difficult (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Endoscopic outcomes'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    At the index procedure when the adenoma is recognized, biopsies are taken to determine if carcinoma or dysplasia is present. Endoscopic cholangiopancreatography (ERCP) is usually performed to exclude associated stones or strictures and to assess for extension of the adenoma into the biliary or pancreatic ducts.",
"   </p>",
"   <p>",
"    In cases of suspected malignancy, endoscopic ultrasound",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraductal ultrasound may be performed to assess the depth of involvement, the extent of the lesion, and, with endoscopic ultrasound, the periampullary lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Patients with lesions that do not extend beyond the muscularis propria and without nodal involvement may be candidates for endoscopic excision. In clinical practice, however, intraductal ultrasound is rarely performed, in part because there is little evidence to demonstrate that it offers a significant advantage over EUS alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Endoscopic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In deciding how best to remove an ampullary adenoma, the endoscopist must clearly note the margins of the lesion (which is sometimes difficult if it is located on the edge of a diverticulum) and determine whether it is feasible to snare the entire lesion en bloc (ie, in one piece). En bloc resection is the preferred method, since it increases the likelihood of complete removal, especially if the adenoma is abutting the biliary and pancreatic orifices.",
"   </p>",
"   <p>",
"    Endoscopic ampullectomy is typically performed with the standard monopolar diathermic snare used in colonoscopic polypectomy. The snare should be relatively soft and flexible to allow manipulation across the elevator of a duodenoscope. We routinely groom the snare to create a gentle curve at the tip. This facilitates passage of the snare through the right-angle turn in the accessory channel of the scope and across the elevator. We also use the larger channel therapeutic duodenoscope to allow easier passage of both the snare and thermal ablation probes. The larger channel also permits aspiration of insufflated air and argon gas when a snare or probe is present in the channel.",
"   </p>",
"   <p>",
"    The goal of endoscopic resection is to achieve complete excision of the ampullary neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/40,75,76\">",
"     40,75,76",
"    </a>",
"    ]. En bloc resection using the standard snare technique may not be technically feasible in the presence of one or more of the following: large tumor size, limited endoscopic accessibility, or sessile nature of the tumor, including laterally-spreading extra-papillary extension. In these cases, piecemeal resection may be undertaken, frequently with adjuvant ablative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Ablative therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Retrieval of the entire resected specimen is essential for complete evaluation for foci of adenocarcinoma. Retrieval should be performed immediately after resection since, due to insufflation and peristalsis, there is a tendency for the excised specimen to migrate distally in the duodenum and be lost. The snare that was used for the excision or a retrieval net is ideal for this purpose. The specimen should NOT be aspirated through the accessory channel of the duodenoscope into a trap, since this could lead to fragmentation of the specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sphincterotomy and stent placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive techniques, including biliary or pancreatic sphincterotomy and biliary or pancreatic stent or drain placement, may enhance technical success [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/40,42,78-80\">",
"     40,42,78-80",
"    </a>",
"    ] and decrease complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/42,53,78,79\">",
"     42,53,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether pancreatic or biliary sphincterotomy is undertaken prior to ampullectomy is variable, depending upon the endoscopist's preference. A biliary sphincterotomy may facilitate complete excision of the adenomatous tissue if it is situated partly in the biliary orifice. A pancreatic or biliary sphincterotomy may also facilitate placement of a stent.",
"   </p>",
"   <p>",
"    Placement of a prophylactic pancreatic stent decreases the risk of post-ERCP pancreatitis following ampullectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/53,81,82\">",
"     53,81,82",
"    </a>",
"    ]. In a randomized controlled trial of 19 patients, pancreatitis developed in three of the nine patients who did not receive stents and in none of the patients who did, a difference that was statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/81\">",
"     81",
"    </a>",
"    ]. Although the number of patients was very small, the benefit of stenting was similar to that seen in a meta-analysis that demonstrated the efficacy of prophylactic pancreatic stenting to prevent post-ERCP pancreatitis in which ERCP was performed for a variety of indications (5.8 versus 15.5 percent without stenting) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the size or irregularity of the margins favors piecemeal removal, placement of a pancreatic stent prior to the resection may protect the orifice from thermal injury from the snare. With an en bloc resection, the stent cannot be placed beforehand, since it would prevent en bloc removal. Unfortunately, stent placement following ampullectomy can be technically challenging. One group described a procedural modification allowing for stent placement prior to ampullectomy, with retrieval of the ampullectomy specimen via perpendicular needle-knife incision of the snared ampullary neoplasm, citing greater ease of pancreatic stent placement prior to rather than following ampullectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stent is generally removed two or three weeks later, at which time any suspicious-appearing residual polypoid tissue can be removed to ensure complete excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Submucosal injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local saline injection may increase technical success and decrease complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/42,78\">",
"     42,78",
"    </a>",
"    ]. The injection prevents a deeper burn into the duodenal wall, similar to a saline lift for colonoscopic polypectomy. It can also help to optimize the orientation of papillary mound relative to the endoscope to best achieve precise and complete excision.",
"   </p>",
"   <p>",
"    The injection is typically carried out with saline, which may be combined with epinephrine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    . The addition of epinephrine may help minimize bleeding and prolong the time that the mucosa is lifted. Methylene blue may be added to enhance endoscopic visualization of the margins of the adenoma.",
"   </p>",
"   <p>",
"    There are potential problems with submucosal injection, especially with smaller lesions. Since the center of the ampullary lesion is tethered down by the biliary and pancreatic ducts, it may not lift. In addition, the surrounding normal mucosa, which does lift, may \"mushroom\" around the adenoma and partially bury its central aspect, preventing good snare placement and compromising complete excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ablative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;With en bloc resection, removal of residual marginal tissue is usually minimal and relatively simple. By contrast, with piecemeal resection, the tissue around the duct orifices may be difficult to excise entirely. When this occurs, fulguration using thermal modalities may be employed including monopolar coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/39,78\">",
"     39,78",
"    </a>",
"    ], bipolar coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/78\">",
"     78",
"    </a>",
"    ], Nd:YAG laser [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/41,68,78\">",
"     41,68,78",
"    </a>",
"    ], photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/68\">",
"     68",
"    </a>",
"    ], and argon plasma coagulation (APC) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/42,78\">",
"     42,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We often use the APC probe, generally the 7 Fr diameter device. We use a setting of 50 to 60 watts and pay careful attention to aggressive tissue destruction around the biliary and pancreatic orifices. We perform a biliary sphincterotomy prior to fulguration to lay open the lower end of the bile duct, and place a pancreatic stent before thermally coagulating around the pancreatic orifice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Endoscopic outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review estimated that success rates for endoscopic removal of ampullary adenomas range from 46 to 92 percent, while recurrence rates range from 0 to 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study in the review focused on 103 patients and found a success rate of 80 percent, which included patients who were subsequently successfully treated endoscopically for recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/75\">",
"     75",
"    </a>",
"    ]. Predictors of success on multivariate analysis included age greater than 48 years, lesion size of 24 mm or less, male sex, and absence of a genetic predisposition (eg, familial adenomatous polyposis, which may be associated with a high rate of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/78\">",
"     78",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Another report of 106 patients found that intraductal adenoma growth was associated with less favorable outcomes compared to adenomas without intraductal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/84\">",
"     84",
"    </a>",
"    ]. Endoscopic resection was significantly less likely to be curative (46 versus 83 percent) and significantly more patients required surgery for incomplete adenoma removal (37 versus 12 percent). Use of a balloon-tipped catheter to expose intraductally extending adenoma and allow complete endoscopic excision has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications after ampullectomy include pancreatitis (8 to 15 percent), perforation (0 to 4 percent), bleeding (2 to 13 percent), cholangitis (0 to 2 percent), and papillary stenosis (0 to 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/9,40,42,43,68,75,86-90\">",
"     9,40,42,43,68,75,86-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In eight series published between 1989 and 2001, the overall complication rate was 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/2,39,40,68,78,80,91\">",
"     2,39,40,68,78,80,91",
"    </a>",
"    ]. Seventy percent of the complications were due to pancreatitis, which was mild to moderate in severity in almost all cases, and only one patient developed severe pancreatitis. By comparison, the complication rate for local surgical excision appears to be higher, but the data are limited. In one study, 4 of 18 patients (29 percent) who underwent local surgical resection experienced complications (gastric outlet obstruction, pancreatitis cholangitis, and common bile duct stricture) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following surveillance regimen has been recommended: initial surveillance examination one to six months after the initial procedure, followed by repeat examinations with a duodenoscope every 3 to 12 months for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/71\">",
"     71",
"    </a>",
"    ]. Periodic examinations are required thereafter and are guided by the initial histology (ie, high-grade dysplasia or not), the presence of FAP, and the age and operability of the patient, should surgery be subsequently indicated. While there are no firm recommendations with regard to the subsequent follow-up, in the absence of FAP, it has been suggested that ampullary adenomas be treated similar to flat colonic polyps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FAP patients require regular surveillance for examination of the duodenum for other polyps, as well as to monitor the major and minor papillae for recurrent adenoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with sporadic ampullary adenomas, screening colonoscopy should be undertaken to exclude colonic polyps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Endoscopic palliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic drainage of ductal obstruction in ampullary tumors via papillotomy or transpapillary stent placement has been a widely accepted technique that provides effective symptomatic relief in patients with obstruction of the biliary or pancreatic ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13897/abstract/92-98\">",
"     92-98",
"    </a>",
"    ]. Endoscopic drainage may be considered in patients who are not candidates for surgical or endoscopic resection, or who decline these procedures.",
"   </p>",
"   <p>",
"    Obstruction extending proximal to the papilla may require placement of a biliary or pancreatic stent, with or without concomitant sphincterotomy. Common bile duct stones, sometimes encountered in association with ampullary adenomas, can be removed with a Dormia basket or extraction balloon catheter following sphincterotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COX-2 INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclooxygenase-2 (COX-2) inhibitors reduce colonic polyps in patients with familial adenomatous polyposis. Their efficacy in reducing duodenal and ampullary adenomas in these patients has not been well studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link&amp;anchor=H12142671#H12142671\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\", section on 'Chemoprevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link&amp;anchor=H9#H9\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\", section on 'COX-2 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ampullary adenomas occur sporadically and in the setting of familial polyposis syndromes. In both cases, they are associated with a risk of progression to adenocarcinoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment options include pancreaticoduodenectomy, surgical ampullectomy, endoscopic resection, and surveillance without resection.",
"     </li>",
"     <li>",
"      The choice of treatment needs to be individualized, taking into account histologic features of the adenoma, the patient's ability to tolerate surgery, local expertise, and patient preferences. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Choice of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radical surgery (pancreaticoduodenectomy) has the advantage of a low recurrence rate, but at the expense of higher morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pancreaticoduodenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Local surgical excision (surgical ampullectomy) has the advantages of lower morbidity, essentially no mortality, and possibly a decreased hospital length of stay compared to radical surgery. However, it has a higher recurrence rate and requires postoperative endoscopic surveillance. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Local surgical excision (ampullectomy)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopic resection has lower morbidity and mortality than surgical approaches. Disadvantages include limited availability of experienced operators, procedural complexity sometimes requiring adjunctive modalities such as fulguration, the need for multiple procedures to achieve complete excision, recurrence rates approaching 30 percent, and, as with local surgical excision, the need for postprocedure endoscopic surveillance. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Endoscopic excision and ablation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients, we suggest endoscopic resection for ampullary adenomas if it can be performed by an interventional endoscopist experienced in ampullectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with evidence of malignancy within the adenoma on imaging or endoscopy, we suggest pancreaticoduodenectomy rather than limited surgery or endoscopic resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ampullary carcinoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Initial assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients undergoing endoscopic excision, we recommend prophylactic stenting of the pancreatic duct (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Sphincterotomy and stent placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopic surveillance is required for patients undergoing local surgical excision or endoscopic resection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Local surgical excision (ampullectomy)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with intraductal tumor growth, we suggest surgical excision (either pancreaticoduodenectomy or local surgical excision) rather than endoscopic resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Endoscopic excision and ablation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/1\">",
"      Park SH, Kim YI, Park YH, et al. Clinicopathologic correlation of p53 protein overexpression in adenoma and carcinoma of the ampulla of Vater. World J Surg 2000; 24:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/2\">",
"      Park SW, Song SY, Chung JB, et al. Endoscopic snare resection for tumors of the ampulla of Vater. Yonsei Med J 2000; 41:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/3\">",
"      Treitschke F, Beger HG. Local resection of benign periampullary tumors. Ann Oncol 1999; 10 Suppl 4:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/4\">",
"      Allgaier HP, Schwacha H, Kleinschmidt M, et al. Ampullary hamartoma: A rare cause of biliary obstruction. Digestion 1999; 60:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/5\">",
"      Sato T, Konishi K, Kimura H, et al. Adenoma and tiny carcinoma in adenoma of the papilla of Vater--p53 and PCNA. Hepatogastroenterology 1999; 46:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/6\">",
"      Sellner FJ, Riegler FM, Machacek E. Implications of histological grade of tumour for the prognosis of radically resected periampullary adenocarcinoma. Eur J Surg 1999; 165:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/7\">",
"      Stolte M, Pscherer C. Adenoma-carcinoma sequence in the papilla of Vater. Scand J Gastroenterol 1996; 31:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/8\">",
"      Asbun HJ, Rossi RL, Munson JL. Local resection for ampullary tumors. Is there a place for it? Arch Surg 1993; 128:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/9\">",
"      Seifert E, Schulte F, Stolte M. Adenoma and carcinoma of the duodenum and papilla of Vater: a clinicopathologic study. Am J Gastroenterol 1992; 87:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/10\">",
"      Yamaguchi K, Enjoji M. Adenoma of the ampulla of Vater: putative precancerous lesion. Gut 1991; 32:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/11\">",
"      Ryan DP, Schapiro RH, Warshaw AL. Villous tumors of the duodenum. Ann Surg 1986; 203:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/12\">",
"      Kozuka S, Tsubone M, Yamaguchi A, Hachisuka K. Adenomatous residue in cancerous papilla of Vater. Gut 1981; 22:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/13\">",
"      Perzin KH, Bridge MF. Adenomas of the small intestine: a clinicopathologic review of 51 cases and a study of their relationship to carcinoma. Cancer 1981; 48:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/14\">",
"      Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998; 90:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/15\">",
"      Heiskanen I, Kellokumpu I, J&auml;rvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 1999; 31:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/16\">",
"      Offerhaus GJ, Giardiello FM, Krush AJ, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992; 102:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/17\">",
"      Vasen HF, B&uuml;low S, Myrh&oslash;j T, et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut 1997; 40:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/18\">",
"      Galandiuk S, Hermann RE, Jagelman DG, et al. Villous tumors of the duodenum. Ann Surg 1988; 207:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/19\">",
"      Shapiro PF, Lifvendahl RA. Tumors of the Extrahepatic Bile-ducts. Ann Surg 1931; 94:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/20\">",
"      BAKER HL, CALDWELL DW. Lesions of the ampulla of Vater. Surgery 1947; 21:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/21\">",
"      van Stolk R, Sivak MV Jr, Petrini JL, et al. Endoscopic management of upper gastrointestinal polyps and periampullary lesions in familial adenomatous polyposis and Gardner's syndrome. Endoscopy 1987; 19 Suppl 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/22\">",
"      Beger HG, Treitschke F, Gansauge F, et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg 1999; 134:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/23\">",
"      Chappuis CW, Divincenti FC, Cohn I Jr. Villous tumors of the duodenum. Ann Surg 1989; 209:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/24\">",
"      Sharp KW, Brandes JL. Local resection of tumors of the ampulla of Vater. Am Surg 1990; 56:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/25\">",
"      Sand JA, Nordback IH. Transduodenal excision of benign adenoma of the papilla of Vater. Eur J Surg 1995; 161:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/26\">",
"      Komorowski RA, Cohen EB. Villous tumors of the duodenum: a clinicopathologic study. Cancer 1981; 47:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/27\">",
"      Gray G, Browder W. Villous tumors of the ampulla of Vater: local resection versus pancreatoduodenectomy. South Med J 1989; 82:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/28\">",
"      Rosenberg J, Welch JP, Pyrtek LJ, et al. Benign villous adenomas of the ampulla of Vater. Cancer 1986; 58:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/29\">",
"      Farouk M, Niotis M, Branum GD, et al. Indications for and the technique of local resection of tumors of the papilla of Vater. Arch Surg 1991; 126:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/30\">",
"      CATTELL RB, BRAASCH JW, KAHN F. Polypoid epithelial tumors of the bile ducts. N Engl J Med 1962; 266:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/31\">",
"      Iwama T, Tomita H, Kawachi Y, et al. Indications for local excision of ampullary lesions associated with familial adenomatous polyposis. J Am Coll Surg 1994; 179:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/32\">",
"      Cahen DL, Fockens P, de Wit LT, et al. Local resection or pancreaticoduodenectomy for villous adenoma of the ampulla of Vater diagnosed before operation. Br J Surg 1997; 84:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/33\">",
"      Chijiiwa K, Yamashita H, Kuroki S. Wide ampullectomy for patients with villous adenoma of duodenal papilla and follow-up results of pancreaticobiliary tract. Int Surg 1994; 79:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/34\">",
"      Branum GD, Pappas TN, Meyers WC. The management of tumors of the ampulla of Vater by local resection. Ann Surg 1996; 224:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/35\">",
"      Alstrup N, Burcharth F, Hauge C, Horn T. Transduodenal excision of tumours of the ampulla of Vater. Eur J Surg 1996; 162:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/36\">",
"      Rattner DW, Fernandez-del Castillo C, Brugge WR, Warshaw AL. Defining the criteria for local resection of ampullary neoplasms. Arch Surg 1996; 131:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/37\">",
"      Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg 2010; 14:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/38\">",
"      Kemp CD, Russell RT, Sharp KW. Resection of benign duodenal neoplasms. Am Surg 2007; 73:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/39\">",
"      Shemesh E, Nass S, Czerniak A. Endoscopic sphincterotomy and endoscopic fulguration in the management of adenoma of the papilla of Vater. Surg Gynecol Obstet 1989; 169:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/40\">",
"      Binmoeller KF, Boaventura S, Ramsperger K, Soehendra N. Endoscopic snare excision of benign adenomas of the papilla of Vater. Gastrointest Endosc 1993; 39:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/41\">",
"      Lambert R, Ponchon T, Chavaillon A, Berger F. Laser treatment of tumors of the papilla of Vater. Endoscopy 1988; 20 Suppl 1:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/42\">",
"      Desilets DJ, Dy RM, Ku PM, et al. Endoscopic management of tumors of the major duodenal papilla: Refined techniques to improve outcome and avoid complications. Gastrointest Endosc 2001; 54:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/43\">",
"      Cheng CL, Sherman S, Fogel EL, et al. Endoscopic snare papillectomy for tumors of the duodenal papillae. Gastrointest Endosc 2004; 60:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/44\">",
"      Kim JH, Kim JH, Han JH, et al. Is endoscopic papillectomy safe for ampullary adenomas with high-grade dysplasia? Ann Surg Oncol 2009; 16:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/45\">",
"      Hornick JR, Johnston FM, Simon PO, et al. A single-institution review of 157 patients presenting with benign and malignant tumors of the ampulla of Vater: management and outcomes. Surgery 2011; 150:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/46\">",
"      Matsumoto T, Iida M, Nakamura S, et al. Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance. Am J Gastroenterol 2000; 95:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/47\">",
"      Burke CA, Beck GJ, Church JM, van Stolk RU. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc 1999; 49:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/48\">",
"      Bellizzi AM, Kahaleh M, Stelow EB. The assessment of specimens procured by endoscopic ampullectomy. Am J Clin Pathol 2009; 132:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/49\">",
"      Grobmyer SR, Stasik CN, Draganov P, et al. Contemporary results with ampullectomy for 29 \"benign\" neoplasms of the ampulla. J Am Coll Surg 2008; 206:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/50\">",
"      Talamini MA, Moesinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg 1997; 225:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/51\">",
"      Allema JH, Reinders ME, van Gulik TM, et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery 1995; 117:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/52\">",
"      Chareton B, Coiffic J, Landen S, et al. Diagnosis and therapy for ampullary tumors: 63 cases. World J Surg 1996; 20:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/53\">",
"      Yamao T, Isomoto H, Kohno S, et al. Endoscopic snare papillectomy with biliary and pancreatic stent placement for tumors of the major duodenal papilla. Surg Endosc 2010; 24:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/54\">",
"      Ito K, Fujita N, Noda Y, et al. Impact of technical modification of endoscopic papillectomy for ampullary neoplasm on the occurrence of complications. Dig Endosc 2012; 24:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/55\">",
"      Yoon SM, Kim MH, Kim MJ, et al. Focal early stage cancer in ampullary adenoma: surgery or endoscopic papillectomy? Gastrointest Endosc 2007; 66:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/56\">",
"      Jordan PH Jr, Ayala G, Rosenberg WR, Kinner BM. Treatment of ampullary villous adenomas that may harbor carcinoma. J Gastrointest Surg 2002; 6:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/57\">",
"      Tran TC, Vitale GC. Ampullary tumors: endoscopic versus operative management. Surg Innov 2004; 11:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/58\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/59\">",
"      Roberts RH, Krige JE, Bornman PC, Terblanche J. Pancreaticoduodenectomy of ampullary carcinoma. Am Surg 1999; 65:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/60\">",
"      Sperti C, Pasquali C, Piccoli A, et al. Radical resection for ampullary carcinoma: long-term results. Br J Surg 1994; 81:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/61\">",
"      Gertsch P, Matthews JB, Lerut J, et al. The technique of papilloduodenectomy. Surg Gynecol Obstet 1990; 170:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/62\">",
"      Beger HG, Staib L, Schoenberg MH. Ampullectomy for adenoma of the papilla and ampulla of Vater. Langenbecks Arch Surg 1998; 383:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/63\">",
"      Ahn KS, Han HS, Yoon YS, et al. Laparoscopic transduodenal ampullectomy for benign ampullary tumors. J Laparoendosc Adv Surg Tech A 2010; 20:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/64\">",
"      Clary BM, Tyler DS, Dematos P, et al. Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. Surgery 2000; 127:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/65\">",
"      Posner S, Colletti L, Knol J, et al. Safety and long-term efficacy of transduodenal excision for tumors of the ampulla of Vater. Surgery 2000; 128:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/66\">",
"      Yamaguchi K, Enjoji M. Carcinoma of the ampulla of vater. A clinicopathologic study and pathologic staging of 109 cases of carcinoma and 5 cases of adenoma. Cancer 1987; 59:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/67\">",
"      Takashima M, Ueki T, Nagai E, et al. Carcinoma of the ampulla of Vater associated with or without adenoma: a clinicopathologic analysis of 198 cases with reference to p53 and Ki-67 immunohistochemical expressions. Mod Pathol 2000; 13:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/68\">",
"      Ponchon T, Berger F, Chavaillon A, et al. Contribution of endoscopy to diagnosis and treatment of tumors of the ampulla of Vater. Cancer 1989; 64:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/69\">",
"      Norton ID, Gostout CJ, Baron TH, et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 2002; 56:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/70\">",
"      Ceppa EP, Burbridge RA, Rialon KL, et al. Endoscopic versus surgical ampullectomy: an algorithm to treat disease of the ampulla of Vater. Ann Surg 2013; 257:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/71\">",
"      Standards of Practice Committee, Adler DG, Qureshi W, et al. The role of endoscopy in ampullary and duodenal adenomas. Gastrointest Endosc 2006; 64:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/72\">",
"      Rivadeneira DE, Pochapin M, Grobmyer SR, et al. Comparison of linear array endoscopic ultrasound and helical computed tomography for the staging of periampullary malignancies. Ann Surg Oncol 2003; 10:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/73\">",
"      Ito K, Fujita N, Noda Y, et al. Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US: a prospective and histopathologically controlled study. Gastrointest Endosc 2007; 66:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/74\">",
"      Chen CH, Yang CC, Yeh YH, et al. Reappraisal of endosonography of ampullary tumors: correlation with transabdominal sonography, CT, and MRI. J Clin Ultrasound 2009; 37:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/75\">",
"      Catalano MF, Linder JD, Chak A, et al. Endoscopic management of adenoma of the major duodenal papilla. Gastrointest Endosc 2004; 59:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/76\">",
"      Han J, Kim MH. Endoscopic papillectomy for adenomas of the major duodenal papilla (with video). Gastrointest Endosc 2006; 63:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/77\">",
"      Hopper AD, Bourke MJ, Williams SJ, Swan MP. Giant laterally spreading tumors of the papilla: endoscopic features, resection technique, and outcome (with videos). Gastrointest Endosc 2010; 71:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/78\">",
"      Martin JA, Haber GB. Ampullary adenoma: clinical manifestations, diagnosis, and treatment. Gastrointest Endosc Clin N Am 2003; 13:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/79\">",
"      Bertoni G, Sassatelli R, Nigrisoli E, Bedogni G. Endoscopic snare papillectomy in patients with familial adenomatous polyposis and ampullary adenoma. Endoscopy 1997; 29:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/80\">",
"      Norton ID, Geller A, Petersen BT, et al. Endoscopic surveillance and ablative therapy for periampullary adenomas. Am J Gastroenterol 2001; 96:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/81\">",
"      Harewood GC, Pochron NL, Gostout CJ. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. Gastrointest Endosc 2005; 62:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/82\">",
"      Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/83\">",
"      Hwang JC, Kim JH, Lim SG, et al. Endoscopic resection of ampullary adenoma after a new insulated plastic pancreatic stent placement: a pilot study. J Gastroenterol Hepatol 2010; 25:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/84\">",
"      Bohnacker S, Seitz U, Nguyen D, et al. Endoscopic resection of benign tumors of the duodenal papilla without and with intraductal growth. Gastrointest Endosc 2005; 62:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/85\">",
"      Kim JH, Moon JH, Choi HJ, et al. Endoscopic snare papillectomy by using a balloon catheter for an unexposed ampullary adenoma with intraductal extension (with videos). Gastrointest Endosc 2009; 69:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/86\">",
"      Vogt M, Jakobs R, Benz C, et al. Endoscopic therapy of adenomas of the papilla of Vater. A retrospective analysis with long-term follow-up. Dig Liver Dis 2000; 32:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/87\">",
"      Charton JP, Deinert K, Schumacher B, Neuhaus H. Endoscopic resection for neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004; 11:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/88\">",
"      Patel R, Davitte J, Varadarajulu S, Wilcox CM. Endoscopic resection of ampullary adenomas: complications and outcomes. Dig Dis Sci 2011; 56:3235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/89\">",
"      Nguyen N, Shah JN, Binmoeller KF. Outcomes of endoscopic papillectomy in elderly patients with ampullary adenoma or early carcinoma. Endoscopy 2010; 42:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/90\">",
"      Irani S, Arai A, Ayub K, et al. Papillectomy for ampullary neoplasm: results of a single referral center over a 10-year period. Gastrointest Endosc 2009; 70:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/91\">",
"      Hoyuela C, Cugat E, Veloso E, Marco C. Treatment options for villous adenoma of the ampulla of Vater. HPB Surg 2000; 11:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/92\">",
"      Huibregtse K, Tytgat GN. Carcinoma of the ampulla of Vater: the endoscopic approach. Endoscopy 1988; 20 Suppl 1:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/93\">",
"      Seyrig JA, Liguory C, Meduri B, et al. [Endoscopy in tumors of the Oddi region. Diagnostic and therapeutic possibilities]. Gastroenterol Clin Biol 1985; 9:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/94\">",
"      Huibregtse K, Tytgat GN. Palliative treatment of obstructive jaundice by transpapillary introduction of large bore bile duct endoprosthesis. Gut 1982; 23:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/95\">",
"      R&ouml;sch W. Endoscopic sphincterotomy in carcinoma of the ampulla of Vater. Gastrointest Endosc 1982; 28:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/96\">",
"      Vallon AG, Shorvon PJ, Cotton PB. Duodenoscopic sphincterotomy for tumours of the papilla of Vater (abstract). Gut 1982; 23:A456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/97\">",
"      Toussaint J, De Toeuf J, Dunham F, Cremer M. [Periampullary tumors: clinical study and results of palliative or preoperative treatment by endoscopic sphincterotomy (author's transl)]. Acta Gastroenterol Belg 1981; 44:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13897/abstract/98\">",
"      Alderson D, Lavelle MI, Venables CW. Endoscopic sphincterotomy before pancreaticoduodenectomy for ampullary carcinoma. Br Med J (Clin Res Ed) 1981; 282:1109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 649 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-18180375D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13897=[""].join("\n");
var outline_f13_36_13897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sporadic ampullary adenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Familial polyposis syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ampullary carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SURGICAL APPROACHES AND OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Local surgical excision (ampullectomy)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ENDOSCOPIC APPROACHES AND OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Endoscopic excision and ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Society guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Endoscopic resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sphincterotomy and stent placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Submucosal injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ablative therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Endoscopic outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Endoscopic palliation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COX-2 INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/649|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/13/40156\" title=\"table 1\">",
"      TNM staging ampullary CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=related_link\">",
"      Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3674?source=related_link\">",
"      Ampullary carcinoma: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26950?source=related_link\">",
"      Clinical manifestations and diagnosis of ampullary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43721?source=related_link\">",
"      Pancreaticoduodenectomy (Whipple procedure): Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=related_link\">",
"      Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_36_13898="Risk of sudden cardiac death in athletes";
var content_f13_36_13898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk of sudden cardiac death in athletes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13898/contributors\">",
"     Antonio Pelliccia, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13898/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13898/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13898/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13898/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/36/13898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/36/13898/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/36/13898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death (SCD) associated with athletic activity is a rare but devastating event. Victims are usually young and apparently healthy, but many have underlying cardiovascular disease that is not diagnosed until after the event. As a result, there is great interest in detecting such abnormalities early, and then defining appropriate activity restrictions for affected individuals to minimize the risk of SCD.",
"   </p>",
"   <p>",
"    The majority of SCD events in athletes are due to malignant arrhythmias, usually ventricular tachycardia (VT) or ventricular fibrillation (VF). In the small number of susceptible individuals with certain underlying cardiac disorders, athletics can increase the likelihood of these events in two ways: prolonged physical training induces changes in cardiac structure (eg, chamber dilation, myocyte death, and fibrosis) that create arrhythmic substrate; and, the immediate physiologic demands of intense athletics can trigger malignant arrhythmias and SCD.",
"   </p>",
"   <p>",
"    The potential for SCD associated with athletic activity generates two questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How should individuals be evaluated prior to initiating athletic activity?",
"     </li>",
"     <li>",
"      What restrictions should be placed upon individuals with known cardiovascular disease?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Answers to these questions are complicated and controversial, and vary based upon three factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The age of the individual",
"     </li>",
"     <li>",
"      The type of underlying heart disease",
"     </li>",
"     <li>",
"      The nature of the activity (ie, competitive versus recreational athletics).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although definitions vary, \"young\" often refers to high school and college athletes, but applies in general to individuals under age 35 in whom SCD is usually due to congenital heart disease. Older, or \"masters\", athletes include individuals over age 35, in whom SCD is most commonly due to coronary heart disease (CHD).",
"   </p>",
"   <p>",
"    Competitive athletics include organized team or individual sports in which there is regular competition, placing a premium on achievement. This definition implies that individuals will engage in high levels of exertion, and may not have the opportunity or the judgment to limit their activity. This most frequently applies to high school, college, or professional sports.",
"   </p>",
"   <p>",
"    In contrast, recreational sports do not generally require systematic training and do not involve the same pressures to excel. Activity levels may still be vigorous, and the distinction from competitive athletics is not always clear. However, defining recreational athletics separately permits the development of guidelines for noncompetitive athletes with cardiovascular disease.",
"   </p>",
"   <p>",
"    Because many of the causative cardiovascular abnormalities are potentially detectable with screening tests, there is great interest in the development of screening protocols to detect underlying heart disease in athletes. However, several logistical obstacles have precluded implementation of standardized preparticipation screening protocols:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The number of people eligible",
"     </li>",
"     <li>",
"      The number of diseases to be considered, each with distinct diagnostic criteria and optimal testing modalities",
"     </li>",
"     <li>",
"      The impact of false-positive screening test results, which will be common when screening for rare diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these obstacles, organizations in the United States and in Europe have developed recommended approaches to preparticipation screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31318?source=see_link&amp;anchor=H4#H4\">",
"     \"Screening to prevent sudden cardiac death in athletes\", section on 'Major society guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the major etiologies of SCD in athletes, recommendations for participation in sports in the presence of various cardiac abnormalities, and recommendations for preparticipation screening of athletes. The broader range of arrhythmias and conduction disturbances common in athletes is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4184?source=see_link\">",
"     \"Electrocardiographic abnormalities and conduction disturbances in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10177261\">",
"    <span class=\"h1\">",
"     BALANCE OF RISKS AND BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The balance between the risks and benefits of athletic activity depends upon several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence and nature of cardiac disease",
"     </li>",
"     <li>",
"      Baseline fitness level",
"     </li>",
"     <li>",
"      The nature and intensity of athletic activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with a congenital disorder, either structural or arrhythmic (eg, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), the risk associated with athletic activity requires some restriction on athletic activity. Such restrictions are discussed in detail below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Hypertrophic cardiomyopathy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Arrhythmogenic right ventricular cardiomyopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, for most other individuals, including those with stable CHD, the overall benefits of regular exercise outweigh the risks. A prudent and gradually progressive exercise program is appropriate in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in selected patients, preparticipation screening with echocardiography or stress testing is appropriate. These issues are reviewed below and discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Coronary heart disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RECREATIONAL ATHLETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature on SCD during exertion has largely focused on competitive athletics. However, recreational activity limitations are also important in individuals with one of the cardiovascular diseases commonly associated with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, patients with known genetic disorders that predispose to SCD (eg, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, Marfan syndrome, long QT syndrome) should avoid recreational activities with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Burst\" exertion, involving rapid acceleration and deceleration, as is common in sprints, basketball, tennis, and soccer. Activities with stable energy expenditure, such as jogging, biking on level terrain, and lap swimming are preferred.",
"     </li>",
"     <li>",
"      Extreme environmental conditions (temperature, humidity, and altitude) that impact blood volume and electrolytes.",
"     </li>",
"     <li>",
"      Systematic and progressive training focused on achieving higher levels of conditioning and excellence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with unusual or high-risk clinical features may require greater restriction. These features include a history of syncope or presyncope, prior cardiac surgery, prior arrhythmic episodes, or an implantable cardioverter-defibrillator (ICD).",
"   </p>",
"   <p>",
"    Activity restrictions and exercise programs in patients with other types of heart disease (eg, CHD, valve disease, cardiomyopathies) generally involve older patients and lower levels of exertion. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with an ICD or pacemaker should not engage in sports with a danger of bodily collisions that may damage the device. Patients with an ICD should be limited to low intensity activities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link&amp;anchor=H26#H26\">",
"     \"Arrhythmia in athletes\", section on 'Implantable cardioverter-defibrillators and pacemakers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10176503\">",
"    <span class=\"h1\">",
"     COMPETITIVE ATHLETES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence of sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of SCD among competitive athletes is actually quite low, estimated to be between 1 per 50,000 athletes to 1 per 300,000 athletes over a 10 to 20 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Data are imprecise since they are derived from retrospective analyses, and incidence varies depending upon the intensity of exercise, the athletic population considered, and the time period of observation. (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of the problem and the challenges inherent in screening are illustrated in reports of arrhythmic events associated with major endurance sporting events [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. The largest such study examined the prevalence of SCD in 215,413 marathon runners participating in a Marine Corps or a civilian marathon over a 19 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/5\">",
"     5",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SCD occurred in four individuals during or immediately following the marathon, an incidence of approximately 1 in 50,000. This is substantially lower than the annual risk of premature death in the general population.",
"     </li>",
"     <li>",
"      None of the four subjects had prior cardiac symptoms.",
"     </li>",
"     <li>",
"      Two of the four had completed several previous marathons.",
"     </li>",
"     <li>",
"      Three of the four had coronary artery disease on autopsy, although none had a previous infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the incidence of SCD in marathon runners is very low, and in this population, it appears unlikely that even a carefully taken medical history or routine screening with an electrocardiogram (ECG) or echocardiogram would have revealed potential risk.",
"   </p>",
"   <p>",
"    Although the incidence of SCD among marathon runners is low (one death per 215,000 hours), it is higher than for other types of exercise, such as noncompetitive jogging (one death per 396,000 hours), cross-country skiing (one death per 607,000 hours), or general, noncompetitive exercise (one death per 375,000 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Etiology of sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to the etiology of SCD are discussed in detail separately. The following discussion summarizes those issues that are relevant to evaluating athletes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Structural heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCD in athletes often occurs in the presence of structural heart disease, although the underlying disorder is often undetected until the presenting arrhythmic event. Structural heart disease can increase the risk for SCD by one or more of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventricular tachyarrhythmias, which are commonly due to reentrant arrhythmias that develop in abnormal myocardium",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      areas of fibrotic replacement of myocardial tissue.",
"     </li>",
"     <li>",
"      Bradyarrhythmia or asystole due to extension of the pathologic process into the conduction system, causing complete heart block without a reliable escape focus.",
"     </li>",
"     <li>",
"      Syncope which, in addition to arrhythmic causes, may result from cyanosis during exercise in the setting of certain congenital lesions with right-to-left shunts.",
"     </li>",
"     <li>",
"      Dissection of the great vessels, as in patients with Marfan syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the majority of conditions discussed below, ventricular tachyarrhythmias are the most common cause of SCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Young athletes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large series have evaluated SCD in athletes less than 35 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/3,13-16\">",
"     3,13-16",
"    </a>",
"    ]. Structural heart disease was present in most cases, but the distribution of underlying diseases varied with geographic location.",
"   </p>",
"   <p>",
"    A registry from the United States documented the etiologies of SCD among 1435 young competitive athletes in whom cardiovascular disease was evident post-mortem [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/16\">",
"     16",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertrophic cardiomyopathy (HCM) &ndash; 36 percent, with possible HCM in another 8 percent",
"     </li>",
"     <li>",
"      Anomalous origin of a coronary artery &ndash; 17 percent",
"     </li>",
"     <li>",
"      Myocarditis &ndash; 6 percent",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy &ndash; 4 percent",
"     </li>",
"     <li>",
"      Mitral valve prolapse &ndash; 4 percent",
"     </li>",
"     <li>",
"      Aortic stenosis &ndash; 3 percent",
"     </li>",
"     <li>",
"      Tunneled coronary artery &ndash; 3 percent",
"     </li>",
"     <li>",
"      Coronary atherosclerosis &ndash; 3 percent",
"     </li>",
"     <li>",
"      Ion channelopathies &ndash; 3 percent",
"     </li>",
"     <li>",
"      Idiopathic dilated cardiomyopathy &ndash; 2 percent",
"     </li>",
"     <li>",
"      Ruptured aortic aneurysm &ndash; 2 percent",
"     </li>",
"     <li>",
"      Other congenital heart disease &ndash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A different distribution was noted in a series of 49 athletes under age 35 with SCD from northern Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy &ndash; 22 percent",
"     </li>",
"     <li>",
"      Coronary atherosclerosis &ndash; 18 percent",
"     </li>",
"     <li>",
"      Anomalous origin of a coronary artery &ndash; 12 percent",
"     </li>",
"     <li>",
"      Mitral valve prolapse &ndash; 10 percent",
"     </li>",
"     <li>",
"      Myocarditis &ndash; 6 percent",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy &ndash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third series included data on over 6 million military recruits in the United States (mean age 19, range 17 to 35) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/15\">",
"     15",
"    </a>",
"    ]. There were 126 nontraumatic sudden deaths, of which 108 (86 percent) were related to exercise. Autopsies were performed in all cases. Of the 64 deaths due to an identifiable cardiac abnormality, the most common were anomalous coronary origin (33 percent), myocarditis (20 percent), coronary atherosclerosis (16 percent), and hypertrophic cardiomyopathy (13 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Athletes aged 35 years or older",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to these series in young subjects, among those over the age of 35 (so-called masters athletes), coronary artery disease is the predominant cause of SCD during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Coronary heart disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Absence of structural heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCD during athletics also occurs in the absence of structural heart disease. A number of inherited arrhythmia syndromes predispose individuals to SCD, and the heart is usually structurally normal in these patients. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long QT syndrome",
"     </li>",
"     <li>",
"      Brugada syndrome",
"     </li>",
"     <li>",
"      Catecholaminergic polymorphic ventricular tachycardia (CPVT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These inherited syndromes, like congenital structural abnormalities, may sometimes be detected by screening tests.",
"   </p>",
"   <p>",
"    In addition, in individuals with structurally normal hearts, arrhythmic events may be precipitated by trauma or occur as",
"    <span class=\"nowrap\">",
"     sporadic/idiopathic",
"    </span>",
"    phenomena, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Commotio cordis, in which SCD results from being struck in the precordium with a projectile object such as a baseball, hockey puck, or fist",
"     </li>",
"     <li>",
"      Idiopathic ventricular fibrillation, also called primary electrical disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general topic of SCD in the absence of structural heart disease and several of these specific conditions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=see_link\">",
"     \"Commotio cordis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, several case reports describe SCD in young athletes who had no previously known heart disease but were taking androgens for performance enhancement; cardiac hypertrophy or myocarditis were found at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. It is not possible to establish causality in these sporadic cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of androgens and other hormones to enhance athletic performance\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Structural abnormalities associated with SCD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a relatively common disease, occurring in 0.16 to 0.29 percent of individuals in the general population (one in 350 to 625) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In the United States, HCM has been among the most common cardiac abnormalities found in athletes with SCD, and occurs disproportionately in African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, HCM was relatively rare in a smaller series from Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/14\">",
"     14",
"    </a>",
"    ]. In most athletes with SCD due to HCM, the diagnosis was not previously established. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Etiology of sudden death'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the screening and evaluation of athletes, a unique challenge involves distinguishing left ventricular hypertrophy (LVH) due to HCM from physiologic increases in left ventricular (LV) wall thickness, cavity size and mass that develop in response to intensive endurance training (ie, \"athlete's heart\"). A 12-lead electrocardiogram, echocardiography, and, on occasion, functional exercise testing all play a role in distinguishing HCM from athlete's heart (",
"    <a class=\"graphic graphic_figure graphicRef87658 \" href=\"UTD.htm?33/3/33855\">",
"     figure 2",
"    </a>",
"    ). Detailed discussions of the diagnosis of HCM and making the distinction between HCM and athlete&rsquo;s heart are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H18608369#H18608369\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Diagnostic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H1613344#H1613344\">",
"     \"Definition and classification of the cardiomyopathies\", section on 'Athlete's heart'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H2599233#H2599233\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Criteria to distinguish HCM from athlete's heart'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with HCM, stratification can identify patients at high and relatively low risk for SCD (",
"    <a class=\"graphic graphic_table graphicRef74083 \" href=\"UTD.htm?36/53/37724\">",
"     table 1",
"    </a>",
"    ); however, even patients with no risk factors are at some risk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Activity restriction has been recommended for HCM patients based upon expert opinion since data are limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Competitive athletes &ndash; As delineated by the 2005 36th Bethesda Conference on Eligibility Recommendations for Competitive Athletes with Cardiovascular Abnormalities, athletes with a probable or unequivocal clinical diagnosis of HCM should not participate in most competitive sports with the possible exception of those that are low intensity (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This recommendation is independent of age, gender, and phenotypic appearance, and does not differ for those athletes with or without symptoms, LV outflow obstruction, prior treatment with drugs, or major interventions including surgery, alcohol septal ablation, pacemaker, or implantable cardioverter-defibrillator.",
"      <br/>",
"      <br/>",
"      Similar recommendations regarding competitive sports participation were also made in a 2005 consensus document from the Study Group of Sports Cardiology of the European Society of Cardiology [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recreational athletics &ndash; A 2004 AHA scientific statement delineated guidelines for recreational athletics in patients with certain genetic cardiovascular disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients with HCM should not participate in most high-intensity noncompetitive sports, including basketball, ice hockey, sprinting, and singles tennis. In addition, the risks associated with impaired consciousness (ie, syncope or presyncope) should be considered with regards to activities with the potential for trauma (eg, weightlifting with free weights, horseback riding) or certain water activities (eg, scuba diving or snorkeling).",
"      <br/>",
"      <br/>",
"      Some moderate-intensity and many low-intensity recreational activities are generally considered to be safe when performed in moderation, including biking, doubles tennis, swimming laps, golf, and skating. Lifting weights with weight-training machines may be safe in some HCM patients, but intense static (isometric) activity may induce a Valsalva maneuver and exacerbate an LV outflow tract gradient.",
"      <br/>",
"      <br/>",
"      The guidelines also recommend that HCM patients be discouraged from any exertion that provokes limiting dyspnea or systematic training during which they extend themselves beyond the physical limits of their underlying disease and the average aerobic state expected for their age.",
"      <br/>",
"      <br/>",
"      Guidelines on physical activities were also provided in a 2006 consensus paper of the Study Group of Sports Cardiology of the European Society of Cardiology [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinically silent gene carriers &ndash; The natural history is not well-defined in individuals with a genetic diagnosis of HCM, but no symptoms and no hypertrophy (as opposed to those with hypertrophy but no symptoms). At present, no compelling data are available that would preclude these patients from competitive sports, particularly in the absence of a family history of sudden death. Major caution, however, is suggested by European recommendations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Congenital coronary artery abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In three series cited above, an anomalous origin of a coronary artery was found in 12 to 33 percent of young athletes with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The most common anomalies associated with SCD are the origin of the left main coronary artery from the right sinus of Valsalva and the origin of the right coronary artery from the left coronary sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Etiology of sudden death'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital and pediatric coronary artery abnormalities\", section on 'Variations of coronary artery origin from the aorta'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High-risk coronary anomalies are those in which the anomalous coronary artery makes an acute bend and courses between the pulmonary artery and aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]. The presumed mechanism of SCD involves ischemia secondary to an exaggeration of a sharp angle in the aberrant origin that occurs with exercise, especially as the artery traverses an expanded aorta and pulmonary arterial trunk.",
"   </p>",
"   <p>",
"    Patients with congenital coronary anomalies may present with anginal chest pain, syncope, or presyncope, especially with exercise. Unfortunately, SCD is often the first clinical symptom. This was illustrated in a report of 18 patients with an anomalous coronary artery origin, only six of whom had a preceding history of angina",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/30\">",
"     30",
"    </a>",
"    ]. In another series of autopsy results on 27 patients with an anomalous coronary artery, 55 percent had no clinical manifestations during life or with testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/32\">",
"     32",
"    </a>",
"    ]. In the remaining patients, premonitory symptoms occurred only shortly before SCD.",
"   </p>",
"   <p>",
"    Physical examination and diagnostic studies are usually unrevealing in the absence of myocardial infarction or symptoms of ongoing ischemia. When anomalous origin of a coronary artery is suspected, noninvasive magnetic resonance coronary angiography (MRCA) is increasingly used to define anomalous coronary anatomy. Coronary angiography by computed tomography (CTCA) is a noninvasive alternative to MRCA. Coronary angiography had been the historical gold standard for the evaluation of the origin and course of the coronary arteries, and is still recommended when other studies are not diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital and pediatric coronary artery abnormalities\", section on 'Variations of coronary artery origin from the aorta'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005 36th Bethesda Conference recommends that an athlete with any uncorrected anomalous coronary artery origin, regardless of the presence or absence of symptoms, be excluded from all competitive sports [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/33\">",
"     33",
"    </a>",
"    ]. These patients may consider appropriate management, which in certain cases includes surgical correction with coronary reimplantation or bypass grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/30\">",
"     30",
"    </a>",
"    ]. Participation in all sports three months after successful operation may be considered on an individual basis for an athlete without prior infarction, ischemia, ventricular or tachyarrhythmia, or left ventricular dysfunction during maximal exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Athletes with previously infarcted myocardium need to follow appropriate guidelines for clearance and observation, which primarily depend upon the degree of left ventricular dysfunction and exercise-associated arrhythmias. In such patients, the approach is similar to that in patients with atherosclerotic coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Coronary heart disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Arrhythmogenic right ventricular cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an entity involving fibrofatty infiltration of the right ventricular (RV) myocardium, predominantly the free wall. Tachyarrhythmias and SCD are not as frequent in patients with ARVC compared to those with a dilated cardiomyopathy or a previous infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/14,35\">",
"     14,35",
"    </a>",
"    ]. In a cohort of patients with ARVC, followed for over 10 years, the mortality rate was 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetics, clinical features, diagnosis and management of ARVC are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ARVC is a significantly more common cause of SCD in case series from northern Italy than in those from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Etiology of sudden death'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical presentation of patients with ARVC, particularly the athlete, includes exercise-induced palpitations, presyncope,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    syncope, consistent with the catecholamine-sensitive nature of many of the associated tachyarrhythmias as well as the wall stretch observed in the right heart in response to the increased venous return occurring with exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The electrocardiogram can help in screening the athlete for possible ARVC. ECG findings, primarily localized to the right precordial leads, include a QRS duration in V1 of more than 110 msec, an epsilon wave due to delayed activation across the right ventricular myocardium in leads V1 or V2, and T wave inversion in the right precordial leads (",
"    <a class=\"graphic graphic_waveform graphicRef60781 \" href=\"UTD.htm?41/5/42078\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/35,38\">",
"     35,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the risk of disease progression and the association between exercise and the induction of ventricular tachyarrhythmias, patients with ARVC should not participate in most competitive sports [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/25,39\">",
"     25,39",
"    </a>",
"    ]. Any activity, competitive or not, that causes symptoms of palpitations, presyncope, or syncope should be avoided.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Competitive athletes &ndash; The 2005 36th Bethesda Conference recommends that an athlete with ARVC should",
"      <strong>",
"       NOT",
"      </strong>",
"      participate in most competitive sports, with the possible exception of those of low intensity (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recreational athletes &ndash; A 2004 AHA scientific statement delineated guidelines for recreational athletics in patients with certain genetic cardiovascular disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients with ARVC should not participate in most high-intensity noncompetitive sports, including basketball, ice hockey, sprinting, and singles tennis. In addition, the risks associated with impaired consciousness (ie, syncope or presyncope) should be considered with regards to activities with the potential for trauma (eg, weight-training with free weights, horseback riding) or certain water activities (eg, scuba diving or snorkeling).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with ARVC should also avoid or approach with caution most moderate-intensity activities, including biking and doubles tennis. However, they may participate in many low-intensity recreational activities, including golf, skating, and weightlifting (with weight-training machines).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Marfan syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marfan syndrome is one of the most common inherited disorders of connective tissue; it is an autosomal dominant condition with a reported incidence of 1 in 10,000 to 20,000 individuals. It is characterized by arachnodactyly, tall stature, pectus excavatum, kyphoscoliosis, and lenticular dislocation. The genetics, diagnosis, and management of Marfan syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link\">",
"     \"Management of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignant arrhythmias are not common in Marfan syndrome, but the cardiovascular manifestations include aortic dissection, which can lead to sudden death.",
"   </p>",
"   <p>",
"    For competitive athletes, the 2005 36th Bethesda Conference recommended the following approach for an athlete with Marfan syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with Marfan syndrome can participate in low and moderate",
"      <span class=\"nowrap\">",
"       static/low",
"      </span>",
"      dynamic competitive sports (classes IA and IIA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) if they do not have one or more of the following: aortic root dilatation, moderate-to-severe mitral regurgitation, or family history of dissection or sudden death in a Marfan relative. It is recommended that these athletes have an echocardiographic measurement of aortic root dimension repeated every six months, for close surveillance of aortic enlargement.",
"     </li>",
"     <li>",
"      Athletes with unequivocal aortic root dilatation, prior surgical aortic root reconstruction, chronic dissection of aorta or other artery, moderate-to-severe mitral regurgitation, or family history of dissection or sudden death can participate only in low-intensity competitive sports (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes with Marfan syndrome, familial aortic aneurysm or dissection, or congenital bicuspid aortic valve with any degree of ascending aortic enlargement should not participate in sports that involve the potential for bodily collision (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For recreational athletes, the 2004 AHA scientific statement delineated guidelines for recreational athletics in patients with certain genetic cardiovascular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with Marfan syndrome should not participate in most high-intensity noncompetitive sports, including basketball, ice hockey, and sprinting.",
"   </p>",
"   <p>",
"    The risk of intense static (isometric) exertion can be associated with increased wall stress, therefore, activities such as weight training with either free weights or weight machines should be avoided.",
"   </p>",
"   <p>",
"    Some moderate-intensity and many low-intensity recreational activities are generally considered to be safe, including stationary biking, hiking, doubles tennis, swimming laps, golf, and skating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the autopsy series described above, myocarditis was present in 6 to 7 percent of cases of SCD in competitive athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/13,14\">",
"     13,14",
"    </a>",
"    ] and 20 percent of military recruits [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Etiology of sudden death'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of myocarditis is most often suggested by clinical findings of heart failure in an otherwise healthy young person, ECG signs (usually diffuse repolarization abnormalities),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    global or regional wall motion abnormalities on cardiac imaging. Active myocarditis is associated with atrial and ventricular tachyarrhythmias, bradyarrhythmias, and SCD. Healed myocarditis leading to a dilated cardiomyopathy or persistent segmental abnormalities increases the risk for SCD, and this risk may be proportional to the degree of cardiac dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005 36th Bethesda Conference recommended the following approach for a competitive athlete with myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with probable or definite evidence of myocarditis should be withdrawn from all competitive sports and undergo a prudent convalescent period of about six months following the onset of clinical manifestations.",
"     </li>",
"     <li>",
"      Athletes may return to training and competition after this period of time if LV function, wall motion, and cardiac dimensions return to normal (based on echocardiographic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radionuclide studies at rest and with exercise), clinically relevant arrhythmias such as frequent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complex repetitive forms of ventricular or supraventricular ectopic activity are absent on ambulatory Holter monitoring and graded exercise testing, serum markers of inflammation and heart failure have normalized, and the 12-lead ECG has normalized. Persistence of relatively minor ECG alterations such as some ST-T changes are not the basis for restriction from competition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Mitral valve prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve prolapse (MVP) occurs frequently in the general population, implying that a relatively large number of athletes will have this usually benign finding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link\">",
"     \"Definition and diagnosis of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship of MVP, tachyarrhythmias, and SCD is controversial. In patients with isolated MVP in the absence of mitral regurgitation (MR) or advanced mitral apparatus pathology, the risk of SCD has been estimated at approximately 2 per 10,000 per year, a rate which is about ten-fold less than the annual risk of SCD from all causes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, patients with MVP and significant mitral valve pathology or MR are at significantly increased risk for SCD. For example, one study calculated the annual SCD mortality rate to be 0.9 to 1.9 percent, a significant increase compared either to patients who have isolated MVP without MR or to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005 36th Bethesda Conference and the 2001 ESC task force recommended that a competitive athlete with MVP can participate in all competitive sports and high dynamic training unless there are features placing the individual at high risk for sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of syncope associated with documented arrhythmia",
"     </li>",
"     <li>",
"      A family history of MVP and SCD",
"     </li>",
"     <li>",
"      Documented supraventricular tachycardias or complex ventricular ectopy",
"     </li>",
"     <li>",
"      Moderate to severe associated mitral valve regurgitation",
"     </li>",
"     <li>",
"      A prior embolic event",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If any of these is present, activity should be restricted to low intensity competitive sports (class IA) (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the potential for worsening of mitral regurgitation and rupture of myxomatous chordae due to the greatly increased systemic vascular resistance occurring with isometric exercise, sports with vigorous isometric components (eg, weight lifting) should be avoided when MVP is associated with marked valvular abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Congenital heart diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of congenital abnormalities in the athlete is 0.2 percent. Recommendations for athletic activity in patients with congenital heart disease depend upon the nature of the abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/33\">",
"     33",
"    </a>",
"    ]. A common theme, however, is a prohibition of sports in those who have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant pulmonary hypertension",
"     </li>",
"     <li>",
"      Cyanosis with an arterial saturation &lt;80 percent",
"     </li>",
"     <li>",
"      Symptomatic arrhythmias",
"     </li>",
"     <li>",
"      Symptomatic ventricular dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Inherited arrhythmia syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several inherited arrhythmia syndromes are associated with SCD in athletes. In addition, a number of generally benign rhythm abnormalities and conduction disorders commonly develop in athletes. These more common disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4184?source=see_link\">",
"     \"Electrocardiographic abnormalities and conduction disturbances in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Congenital long QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long QT syndrome (LQTS), diagnosed on the basis of a prolonged corrected QT interval on the ECG, has been associated with a significant risk for SCD. The clinical features and management of LQTS are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link\">",
"     \"Diagnosis of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link\">",
"     \"Prognosis and management of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of ion channel mutations have been linked to LQTS, with varied effects on cardiac electrical behavior and arrhythmic risk. Exercise appears to increase the risk of SCD in some of these LQTS subtypes. As an example, LQTS 1, 2, and 3 account for over 90 percent of cases of congenital long QT syndrome (LQTS). Arrhythmic events triggered by exercise are much more common in LQTS 1 (62 versus 13 percent in types 2 and 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/42\">",
"     42",
"    </a>",
"    ], an effect that may be related to exaggerated prolongation of the QT interval during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link&amp;anchor=H18#H18\">",
"     \"Genetics of congenital and acquired long QT syndrome\", section on 'Variability of clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For competitive athletes, the 2005 36th Bethesda Conference recommended the following approach for an athlete with long QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of SCD or a suspected LQTS-precipitated syncopal episode should be limited to low-intensity competitive sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Asymptomatic patients with QTc prolongation (&ge;470 msec in men, &ge;480 msec in women) should be limited to low-intensity competitive sports.",
"     </li>",
"     <li>",
"      Asymptomatic patients with genetically proven LQTS type 3 may have this restriction liberalized. On the other hand, European recommendations are more restrictive, suggesting that individuals with definite diagnosis of LQTS should avoid competitive sport activities [",
"      <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For recreational athletes, the 2004 AHA scientific statement delineated guidelines for recreational athletics in patients with certain genetic cardiovascular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with LQTS should not participate in most high-intensity noncompetitive sports, including basketball, ice hockey, sprinting, and singles tennis. In addition, the risks associated with impaired consciousness (ie, syncope or presyncope) should be considered with regards to activities with the potential for trauma (eg, weightlifting with free weights, horseback riding) or certain water activities (eg, scuba diving or snorkeling).",
"   </p>",
"   <p>",
"    Since the 2004 AHA statement and the 2005 Bethesda conference, additional data have been published that suggest a low rate of cardiac events among athletes with LQTS who have chosen to resume activity. Among 130 patients (out of a total cohort of 353 patients) with LQTS who remained active in competitive athletics and were followed for an average of 5.5 years, there were no cardiac events among 70 genotype",
"    <span class=\"nowrap\">",
"     positive/phenotype",
"    </span>",
"    negative patients and only one event (appropriate ICD shock) among 60 genotype",
"    <span class=\"nowrap\">",
"     positive/phenotype",
"    </span>",
"    positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/45\">",
"     45",
"    </a>",
"    ]. While our experts continue to recommend restricted athletic participation in accordance with the Bethesda Conference recommendations, these cohort data are reassuring that continued athletic participation in patients with genotype positive LQTS is relatively safe.",
"   </p>",
"   <p>",
"    Some moderate-intensity and many low-intensity recreational activities are generally considered to be safe, including biking, doubles tennis, golf, skating and weightlifting (with weight-training machines). LQT1 has been associated with SCD while swimming or diving. Unless a patient is genetically proven to have a subtype other than LQT 1, recreational swimming should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Brugada syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Brugada syndrome is characterized by the electrocardiographic findings of right bundle branch block (RBBB) and ST-segment elevation in leads V1 to V3 (",
"    <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"UTD.htm?8/35/8762\">",
"     waveform 2",
"    </a>",
"    ), and an increased risk of sudden death. Arrhythmic events generally occur between the ages 22 and 65 and are more common at night than in the day and during sleep than while awake [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. SCD in Brugada patients is usually not related to exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For competitive athletes, the 2005 36th Bethesda Conference recommended the following approach for an athlete with Brugada syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although a clear association between exercise and sudden death has not been established, because of the potential impact of hyperthermia and enhanced parasympathetic activity induced by athletic training, restriction to participation in low-intensity sports seems advisable (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For recreational athletes, the 2004 AHA scientific statement delineated guidelines for recreational athletics in patients with certain genetic cardiovascular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with Brugada syndrome should avoid or participate cautiously in most high-intensity noncompetitive sports, including basketball, ice hockey, sprinting, and singles tennis. In addition, the risks associated with impaired consciousness (ie, syncope or presyncope) should be considered with regards to activities with the potential for trauma (eg, weightlifting with free weights, horseback riding) or certain water activities (eg, scuba diving or snorkeling).",
"   </p>",
"   <p>",
"    In contrast to other congenital abnormalities, however, most moderate- and low-intensity recreational sports are considered safe, except for those that would incur significant risk with impaired consciousness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Catecholaminergic polymorphic VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catecholaminergic polymorphic VT (CPVT) occurs in the absence of structural heart disease or known associated syndromes. The disorder typically begins in childhood or adolescence, and affected patients may have a family history of juvenile sudden death or stress-induced syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/49\">",
"     49",
"    </a>",
"    ]. The disorder has been linked to mutations in the cardiac ryanodine receptor and calsequestrin 2 genes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H3#H3\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Catecholaminergic polymorphic VT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients typically present with life-threatening VT or VF occurring during emotional or physical stress, with syncope often being the first manifestation of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/49\">",
"     49",
"    </a>",
"    ]. Arrhythmic events during swimming, previously considered to be specific for LQTS type 1, have also been described with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/50\">",
"     50",
"    </a>",
"    ]. The VT may have a polymorphic appearance or may be a bidirectional VT that resembles the arrhythmia associated with digitalis toxicity.",
"   </p>",
"   <p>",
"    For competitive athletes, the 2005 36th Bethesda Conference recommended the following approach for an athlete with CPVT [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic patients have a poor prognosis unless treated with an implantable cardioverter-defibrillator (ICD), and all such patients are restricted from competitive sports with the possible exception of minimal contact, class IA activities (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      As with LQT1, patients with CPVT should be restricted from competitive swimming.",
"     </li>",
"     <li>",
"      Individuals who are detected as part of familial screening, who have no prior history of symptoms, but do have documented exercise- or isoproterenol-induced VT should refrain from all competitive sports except possible class IA activities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For recreational athletes, the 2004 AHA scientific statement delineated guidelines for recreational athletics in patients with certain genetic cardiovascular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/2\">",
"     2",
"    </a>",
"    ]. Due to potential for catecholamine release in most forms of exercise, this panel recommended that patients with CPVT should be cautioned against virtually all forms of vigorous physical activity.",
"   </p>",
"   <p>",
"    Among individuals with a genetic diagnosis of CPVT, but none of the clinical features (asymptomatic, no inducible VT), the natural history is not well-defined. A less restrictive approach may be taken in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients over age 35, the most frequent cause of exercise-related SCD is CHD. Ventricular arrhythmias can originate from myocardial scar (from prior myocardial infarctions), or from acute ischemia. In addition, ischemia during exertion can result either from fixed, chronic coronary stenoses that preclude increased myocardial oxygen delivery during exercise (ie, demand ischemia), or from an acute coronary syndrome. Autopsy examination of adults with exercise-related SCD usually reveals advanced CHD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an acute coronary lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/17,51\">",
"     17,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data that directly relate the presence and severity of CHD to the risk of participating in competitive athletics. However, it is likely that the risk of a cardiac event during exercise increases with the presence of increasingly severe CAD, LV dysfunction and ventricular arrhythmias, as well as with the intensity of the competitive sport and the individual's effort. As a result, risk assessment should involve a full evaluation of cardiac status.",
"   </p>",
"   <p>",
"    Prior to initiating systematic training or competition, athletes with previously documented CAD should have an assessment of LV function using echocardiography or radionuclide scanning. Exercise testing with perfusion imaging or echocardiography should be done, both to assess exercise capacity and to determine the extent of ischemia. Whenever possible, such testing should be performed while the patient is taking prescribed medications and should approximate the cardiovascular and metabolic demands of the planned athletic activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=see_link\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the basis of the above testing, subjects can be risk stratified into those with a minimally increased or markedly increased risk.",
"   </p>",
"   <p>",
"    Athletes with CHD are at minimally increased risk if all of the following are true:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV ejection fraction (LVEF) &ge;50 percent.",
"     </li>",
"     <li>",
"      Normal exercise tolerance for age.",
"     </li>",
"     <li>",
"      No inducible ischemia with exercise testing.",
"     </li>",
"     <li>",
"      No sustained or nonsustained VT during exercise testing.",
"     </li>",
"     <li>",
"      No hemodynamically significant coronary artery stenoses if angiography is performed. Patients who have had successful revascularization of prior stenoses are also considered to be at low risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Athletes with CHD are at substantially increased risk if any of the above features are abnormal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h4\">",
"     Competitive athletes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the 2005 36th Bethesda Conference on athletes and cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/36/13898/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes with a minimally increased risk can participate in low dynamic and",
"      <span class=\"nowrap\">",
"       low/moderate",
"      </span>",
"      static competitive sports (classes IA and IIA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) but should avoid intensely competitive sports.",
"     </li>",
"     <li>",
"      Selected athletes with mildly increased risk may be permitted to compete in sports of higher levels of intensity when their overall clinical profile suggests very low exercise risk. This is particularly true for athletes in whom the only indication that coronary atherosclerosis is present is from an EBCT performed for screening purposes, and in which the total coronary calcium score is relatively low (ie, &lt;15). All athletes should understand that the risk of a cardiac event with exertion is probably increased once coronary atherosclerosis of any severity is present.",
"     </li>",
"     <li>",
"      Athletes with mildly increased risk engaging in competitive sports should undergo re-evaluation of their risk stratification at least annually.",
"     </li>",
"     <li>",
"      Athletes in the substantially increased risk category should generally be restricted to low-intensity competitive sports (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Athletes should be informed of the nature of prodromal symptoms (such as chest, arm, jaw and shoulder discomfort, unusual dyspnea) and should be instructed to cease their sports activity promptly and to contact their clinician if symptoms appear. Clinicians should be aware that competitive athletes may minimize symptoms that occur during exertion.",
"     </li>",
"     <li>",
"      Those with a recent MI or myocardial revascularization should cease their athletic training and competition until recovery is deemed complete. This interval varies among patient groups and depends upon the severity of the cardiovascular event and the success of revascularization. Such patients may benefit from cardiac rehabilitation during the recovery period. No firm guidelines exist for how long patients should avoid vigorous exercise training, but in general, patients post-stent placement for stable CAD symptoms should avoid vigorous exercise training for competition for approximately four weeks. Patients undergoing stent placement for unstable disease should wait at least this long. Following coronary bypass surgery, patients should avoid vigorous training until their incisions can tolerate vigorous activity.",
"     </li>",
"     <li>",
"      All athletes with atherosclerotic CAD should have their atherosclerotic risk factors aggressively treated as studies suggest that comprehensive risk reduction is likely to stabilize coronary lesions and may reduce the risk of exercise-related events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h4\">",
"     Recreational athletes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for recreational sports and exercise for patients with CHD are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10177151\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden cardiac death (SCD) associated with athletic activity is a rare but devastating event. The majority of SCD events in athletes are due to malignant arrhythmias, usually ventricular tachycardia (VT) or ventricular fibrillation (VF). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The balance between the risks and benefits of athletic activity depends upon several factors, including the presence and nature of cardiac disease, baseline fitness level in the individual, and the nature and intensity of athletic activity. Although there are some exceptions, for most individuals, the overall benefits of regular exercise outweigh the risks. (See",
"      <a class=\"local\" href=\"#H10177261\">",
"       'Balance of risks and benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The literature on SCD during exertion has largely focused on competitive athletics. However, recreational activity limitations are also important in individuals with one of the cardiovascular diseases commonly associated with SCD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Recreational athletes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of SCD among competitive athletes is actually quite low, estimated to be between 1 per 50,000 athletes to 1 per 300,000 athletes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Incidence of sudden death'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potential etiologies of SCD include structural heart disease, inherited arrhythmias syndromes, and coronary heart disease; the exact distribution of etiologies varies according to age and geography, among other variables. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Etiology of sudden death'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"       \"Pathophysiology and etiology of sudden cardiac arrest\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some level of activity restriction (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) is recommended for nearly all individuals with underlying heart disease. The precise restrictions vary depending on the underlying disease process and other comorbidities. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Structural abnormalities associated with SCD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Inherited arrhythmia syndromes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H128307277\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to thank Drs. David Bharucha, Roger Marinchak, and William McKenna, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/1\">",
"      Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation 2007; 115:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/2\">",
"      Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/3\">",
"      Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996; 276:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/4\">",
"      Van Camp SP, Bloor CM, Mueller FO, et al. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc 1995; 27:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/5\">",
"      Maron BJ, Poliac LC, Roberts WO. Risk for sudden cardiac death associated with marathon running. J Am Coll Cardiol 1996; 28:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/6\">",
"      Phillips M, Robinowitz M, Higgins JR, et al. Sudden cardiac death in Air Force recruits. A 20-year review. JAMA 1986; 256:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/7\">",
"      Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/8\">",
"      Belonje A, Nangrahary M, de Swart H, Umans V. Major adverse cardiac events during endurance sports. Am J Cardiol 2007; 99:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/9\">",
"      Hillis WS, McIntyre PD, Maclean J, et al. ABC of sports medicine. Sudden death in sport. BMJ 1994; 309:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/10\">",
"      Thompson PD, Funk EJ, Carleton RA, Sturner WQ. Incidence of death during jogging in Rhode Island from 1975 through 1980. JAMA 1982; 247:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/11\">",
"      . The cardiovascular risks of physical activity. Acta Med Scand 1986; 711:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/12\">",
"      Gibbons LW, Cooper KH, Meyer BM, Ellison RC. The acute cardiac risk of strenuous exercise. JAMA 1980; 244:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/13\">",
"      Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/14\">",
"      Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/15\">",
"      Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med 2004; 141:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/16\">",
"      Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2007; 115:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/17\">",
"      Waller BF, Roberts WC. Sudden death while running in conditioned runners aged 40 years or over. Am J Cardiol 1980; 45:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/18\">",
"      Virmani R, Robinowitz M, McAllister HA Jr. Nontraumatic death in joggers. A series of 30 patients at autopsy. Am J Med 1982; 72:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/19\">",
"      Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death--a case report and review of the literature. Int J Legal Med 1998; 111:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/20\">",
"      Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust 1993; 158:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/21\">",
"      Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/22\">",
"      Maron BJ, Mathenge R, Casey SA, et al. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 1999; 33:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/23\">",
"      Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/24\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:e783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/25\">",
"      Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005; 45:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/26\">",
"      Pelliccia A, Fagard R, Bj&oslash;rnstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/27\">",
"      Heidb&uuml;chel H, Corrado D, Biffi A, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil 2006; 13:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/28\">",
"      Taylor AJ, Rogan KM, Virmani R. Sudden cardiac death associated with isolated congenital coronary artery anomalies. J Am Coll Cardiol 1992; 20:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/29\">",
"      Liberthson RR. Sudden death from cardiac causes in children and young adults. N Engl J Med 1996; 334:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/30\">",
"      Liberthson RR, Dinsmore RE, Fallon JT. Aberrant coronary artery origin from the aorta. Report of 18 patients, review of literature and delineation of natural history and management. Circulation 1979; 59:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/31\">",
"      Taylor AJ, Byers JP, Cheitlin MD, Virmani R. Anomalous right or left coronary artery from the contralateral coronary sinus: \"high-risk\" abnormalities in the initial coronary artery course and heterogeneous clinical outcomes. Am Heart J 1997; 133:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/32\">",
"      Basso C, Maron BJ, Corrado D, Thiene G. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol 2000; 35:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/33\">",
"      Graham TP Jr, Driscoll DJ, Gersony WM, et al. Task Force 2: congenital heart disease. J Am Coll Cardiol 2005; 45:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/34\">",
"      Thompson PD, Balady GJ, Chaitman BR, et al. Task Force 6: coronary artery disease. J Am Coll Cardiol 2005; 45:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/35\">",
"      Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988; 318:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/36\">",
"      Blomstr&ouml;m-Lundqvist C, Sabel KG, Olsson SB. A long term follow up of 15 patients with arrhythmogenic right ventricular dysplasia. Br Heart J 1987; 58:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/37\">",
"      Douglas PS, O'Toole ML, Hiller WD, Reichek N. Different effects of prolonged exercise on the right and left ventricles. J Am Coll Cardiol 1990; 15:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/38\">",
"      Nava A, Canciani B, Buja G, et al. Electrovectorcardiographic study of negative T waves on precordial leads in arrhythmogenic right ventricular dysplasia: relationship with right ventricular volumes. J Electrocardiol 1988; 21:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/39\">",
"      Nava A, Bauce B, Basso C, et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000; 36:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/40\">",
"      Kligfield P, Levy D, Devereux RB, Savage DD. Arrhythmias and sudden death in mitral valve prolapse. Am Heart J 1987; 113:1298.",
"     </a>",
"    </li>",
"    <li>",
"     Kligfield P, Devereaux RB. Is the patient with mitral valve prolapse at high risk for sudden death identifiable?. In: Dilemmas in clinical cardiology, Cheitlin MD (Ed), FA Davis, Philadelphia 1990. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/42\">",
"      Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/43\">",
"      Takenaka K, Ai T, Shimizu W, et al. Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation 2003; 107:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/44\">",
"      Zipes DP, Ackerman MJ, Estes NA 3rd, et al. Task Force 7: arrhythmias. J Am Coll Cardiol 2005; 45:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/45\">",
"      Johnson JN, Ackerman MJ. Return to play? Athletes with congenital long QT syndrome. Br J Sports Med 2013; 47:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/46\">",
"      Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/47\">",
"      Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999; 20:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/48\">",
"      Corrado D, Basso C, Buja G, et al. Right bundle branch block, right precordial st-segment elevation, and sudden death in young people. Circulation 2001; 103:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/49\">",
"      Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/50\">",
"      Choi G, Kopplin LJ, Tester DJ, et al. Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes. Circulation 2004; 110:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/36/13898/abstract/51\">",
"      Thompson PD, Stern MP, Williams P, et al. Death during jogging or running. A study of 18 cases. JAMA 1979; 242:1265.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 986 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-75F91836D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13898=[""].join("\n");
var outline_f13_36_13898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10177151\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10177261\">",
"      BALANCE OF RISKS AND BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RECREATIONAL ATHLETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10176503\">",
"      COMPETITIVE ATHLETES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence of sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Etiology of sudden death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Young athletes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Athletes aged 35 years or older",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Absence of structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Structural abnormalities associated with SCD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Congenital coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Myocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Congenital heart diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Inherited arrhythmia syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Catecholaminergic polymorphic VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Competitive athletes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Recreational athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10177151\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H128307277\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/986|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 1\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/3/33855\" title=\"figure 2\">",
"      Pathologic LVH vs Physiologic LVH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/986|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/53/37724\" title=\"table 1\">",
"      ESC risk stratification HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/986|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/5/42078\" title=\"waveform 1\">",
"      12-lead ECG epsilon wave and T wave inversions in ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/35/8762\" title=\"waveform 2\">",
"      ECG Brugada syndrome type I pattern",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=related_link\">",
"      Commotio cordis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=related_link\">",
"      Efficacy of cardiac rehabilitation in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4184?source=related_link\">",
"      Electrocardiographic abnormalities and conduction disturbances in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=related_link\">",
"      Management of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31318?source=related_link\">",
"      Screening to prevent sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=related_link\">",
"      Use of androgens and other hormones to enhance athletic performance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_36_13899="Survival DPAM versus muc cancer";
var content_f13_36_13899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparative survival of appendiceal cancer according to histology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Subset",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median survival, months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year survival, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        10-year survival, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated peritoneal adenomucinosis (DPAM)",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        112.4",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucinous carcinomatosis",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DPAM: disseminated peritoneal adenomucinosis.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ronnett BM, Yan H, Kurman RJ, et al. Patients with Pseudomyxoma Peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001; 92:85.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13899=[""].join("\n");
var outline_f13_36_13899=null;
var title_f13_36_13900="Guidelines pacemaker type";
var content_f13_36_13900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for choice of pacemaker generator in selected indications for pacing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of pacemaker",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sinus node dysfunction",
"       </td>",
"       <td class=\"subtitle1\">",
"        AV block",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neurally-mediated syncope or carotid sinus hypersensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single-chamber atrial",
"       </td>",
"       <td>",
"        No suspected abnormality of AV conduction and not at increased risk for future AV block",
"        <br/>",
"        <br/>",
"        Maintenance of AV synchrony during pacing desired",
"        <br/>",
"        <br/>",
"        Rate response available if desired",
"       </td>",
"       <td>",
"        Not appropriate",
"       </td>",
"       <td>",
"        Not appropriate (unless AV block systematically excluded)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single-chamber ventricular",
"       </td>",
"       <td>",
"        Maintenance of AV synchrony during pacing not necessary",
"        <br/>",
"        <br/>",
"        Rate response available if desired",
"       </td>",
"       <td>",
"        Chronic atrial fibrillation or other atrial tachyarrhythmia or maintenance of AV synchrony during pacing not necessary",
"        <br/>",
"        <br/>",
"        Rate response available if desired",
"       </td>",
"       <td>",
"        Chronic atrial fibrillation or other atrial tachyarrhythmia",
"        <br/>",
"        <br/>",
"        Rate response available if desired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dual-chamber",
"       </td>",
"       <td>",
"        AV synchrony during pacing desired",
"        <br/>",
"        <br/>",
"        Suspected abnormality of AV conduction or increased risk for future AV block",
"        <br/>",
"        <br/>",
"        Rate response available if desired",
"       </td>",
"       <td>",
"        AV synchrony during pacing desired",
"        <br/>",
"        <br/>",
"        Atrial pacing desired",
"        <br/>",
"        <br/>",
"        Rate response available if desired",
"       </td>",
"       <td>",
"        Sinus mechanism present",
"        <br/>",
"        <br/>",
"        Rate response available if desired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single-lead, atrial-sensing ventricular",
"       </td>",
"       <td>",
"        Not appropriate",
"       </td>",
"       <td>",
"        Normal sinus node function and no need for atrial pacing",
"        <br/>",
"        <br/>",
"        Desire to limit number of pacemaker leads",
"       </td>",
"       <td>",
"        Not appropriate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gregoratos G, Cheitlin MD, Conill A, et al. Circulation 1998; 97:1325.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13900=[""].join("\n");
var outline_f13_36_13900=null;
var title_f13_36_13901="Arrhythmias alcoholic CMP";
var content_f13_36_13901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Freedom from sustained VT, VF or SCD in ACM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This report compared 119 patients with idiopathic dilated cardiomyopathy (IDCM) and 75 patients with alcoholic cardiomyopathy (ACM). Among those with ACM, 47 abstained from alcohol consumption and 28 continued to drink. Major arrhythmic events were evaluated including sustained ventricular tachycardia (VT), ventricular fibrillation (VF), and sudden cardiac death (SCD), and the event-free survival for each group of patients was determined. The red line indicates patients with ACM and alcohol abstinence, the green line indicates IDCM, and the blue line indicates patients with ACM without abstinence. Compared to patients with ACM and alcohol abstinence, the relative risk of events was 8.0 for patients with ACM without abstinence and 7.3 for patients with IDCM.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fauchier L. Alcoholic cardiomyopathy and ventricular arrhythmias. Chest 2003; 123:1320. Copyright &copy; 2003 American College of Chest Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13901=[""].join("\n");
var outline_f13_36_13901=null;
var title_f13_36_13902="Rx symptomatic chron severe MR";
var content_f13_36_13902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: Management strategy for symptomatic patients with chronic severe mitral regurgitation (MR)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 346px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic dimension.",
"     <br>",
"      <br>",
"       The 2012 European Society of Cardiology (ESC) valvular heart disease guidelines recommend a similar management strategy. The key difference&nbsp;is that the ESC guidelines classify symptomatic patients by LVEF &gt;30 percent only (without any LVESD criterion). In addition, the ESC guidelines recommend valve surgery in patients with an LVEF &le;30 percent only if&nbsp;they are refractory to medical therapy and durable valve repair is likely and there is low comorbidity. Patients with LVEF &le; 30 percent&nbsp;who have refractory heart failure and who are not eligible for durable repair should receive extended HF treatment. Task Force Members, Vahanian A, Alfieri O, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33:2451.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13902=[""].join("\n");
var outline_f13_36_13902=null;
var title_f13_36_13903="Pocket magnet for removal of nasal magnets";
var content_f13_36_13903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pocket magnet for removal of nasal magnets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A&nbsp;pocket magnetic pick-up as pictured here can be used to remove disc magnets that have attached across the nasal septum. The magnets are used as backing for flashing earrings (silver cylinders above)&nbsp;and other jewelry.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Starke L. Easy removal of nasal magnets. Pediatr Emerg Care 2005; 21:598. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_36_13903=[""].join("\n");
var outline_f13_36_13903=null;
